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Abstract 
Botulinum neurotoxin type A (BoNT/A) is a SNAP-25-cleaving protease produced by the 
bacterium C. botulinum that blocks synaptic transmission at the neuromuscular junction. 
Inhalation of 1 g can be lethal while lower doses can result in a paralysis that lasts for several 
months. However, this terrifying potency and persistence has converted it into a valuable drug 
in many muscle and neurological disorders. Paradoxically, BoNT/A induces nerve regeneration 
and BoNT/E, a BoNT/A homolog, has a much shorter persistence despite many mechanistic 
similarities.  
Tools for the comparative study of BoNT/A and BoNT/E were produced but shown to be 
ineffective for purposes of this thesis.  
By using a catalytically inactive mutant of BoNT/A (BoNT/A(0)), I showed that the toxin 
enters neurons through multiple mechanisms before entering the endocytic pathway. 
BoNT/A(0) escaped lysosomal degradation but was degraded by the proteasome. Furthermore, 
a fraction of BoNT/A was static at the early endosome and another fraction was exocytosed 
and was able to re-enter neurons as a full-length toxin. 
In addition, this research shows that neurite outgrowth induced by BoNT/A(0) is restricted to 
axonal outgrowth in vitro and is mediated by activation of the small GTPase Rac1 through the 
binding domain of BoNT/A (HCC/A). HCC/A also induced the formation of filopodia 
presynaptic vesicle release and neurogenesis.  
This thesis provides a model for the trafficking of full-length BoNT/A prior to any catalytic 
action and reformulates BoNT/A receptor binding domain as a neurotrophic factor. 
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1 
Chapter 1 Introduction 
2 
Neurons 
Neurons are highly specialised cells that, together with glia (astrocytes, Schwann cells, 
oligodendrocytes and microglia), constitute the cellular basis of the nervous system, which 
controls conscious and unconscious actions from the human body (Purves et al., 2012). 
Neurons communicate via specialised structures called synapses and, as detailed below, 
Botulinum Neurotoxin A (BoNT/A), the focus of this thesis, acts by silencing synapses 
(Montecucco and Schiavo, 1994). 
Neurites 
Neurons are divided into axons and somatodendritic compartments (i.e. soma plus dendrites) 
(see Figure 1-1) (Purves et al., 2012). 
Figure 1-1. The neuron.  
Schematic depiction of a neuron, with the somatodendritic compartment in blue and the 
axon in yellow. Squares represent magnifications of dendritic spines and axonal 
presynaptic buttons. 
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The soma (cell body) is the point where neurites emerge and the centre of activity of the neuron. 
It contains the nucleus, integrates electrical information and produces most of the proteins to 
be used throughout the neuron (Purves et al., 2012).  
Axons 
Axons are processes which emerge from the cell soma (Figure 1-1) and propagate electrical 
information from it (Purves et al., 2012). Information is carried in the form of action potentials, 
consisting of a rapid, transient depolarisation of the membrane, followed by a repolarisation 
and an over-polarisation and a recovery of the basal potential. Depolarisation of a proximal 
segment of the axon triggers the generation of an action potential (AP) until it reaches the 
presynaptic button (Hodgkin and Huxley, 1952).
In the presynaptic button, the electrical signal of the AP is converted to a chemical signal in 
the form of neurotransmitters. Neurotransmitters are stored within the presynaptic button in 
vesicles which, on activation, fuse to the presynaptic membrane and release their contact into 
the synaptic cleft to bind their receptors at the post-synaptic surface (Purves et al., 2012).  This 
process is described in section 1.1.2.1. 
Despite of being the smallest organelle in a cell and its apparent simple structure, synaptic 
vesicles are coated by a complex array of proteins responsible for many of the actions of the 
vesicle (Südhof, 1995). For instance, a proton pump located at the membrane acidifies the 
organelle; the Vesicular Acetylcholine transporter (VAChT) is responsible for the uptake of 
neurotransmitter of vesicles at the neuromuscular junction (Usdin et al., 1995), using the 
gradient generated by a proton pump (Beyenbach and Wieczorek, 2006). In addition, vesicle 
N-Ethylmaleidimide Sensitive Factor (NSF) Receptors (v-SNAREs) facilitate vesicle docking 
and release of neurotransmitters by interacting with target-SNARE (t-SNARE) proteins located 
at the cell membrane (Südhof, 2013). This is described in section 1.2.1.2.  
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Dendrites 
Dendrites are branched protrusions which receive synaptic stimulus (see section 1.1.2) and 
propagate it to the soma. They are the main synaptic input of the neuron, they are responsible 
for spatiotemporal integration of the signals received (Stuart and Spruston, 2015), although the 
complexity of their organisation is variable across different neuron types (Purves et al., 2012).  
Dendrites present protrusions within them, which according to their morphology and possible 
functional correlates, these are named as filopodia, thin spines, stubby spines and mushroom 
spines (Figure 1-2). In general, excitatory synapses (e.g. using glutamate) are located on spines 
whereas inhibitory synapses (e.g. using -Aminobutyric Acid, GABA) occur on the dendritic 
shaft (Mody and Pierce, 2004; Chen et al., 2012). 
Filopodia are elongated protrusions that explore the environment in search of contacts to form 
new synapses (Varnum-Finney et al., 1994; Yoshihara et al., 2009; Heckman et al., 2013). 
Once a filopodium detects a suitable place to form a synapse, it can be converted into a 
functional dendritic spine by acquiring the machinery necessary to remodel its shape and form 
Figure 1-2. Types of dendritic protrusions.
According to structural differences, dendritic protrusions are distinguished into filopodia 
and dendritic spines (thin, stubby and mushroom). 
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the postsynapse (Niell et al., 2004; Yoshihara et al., 2009). Thin, stubby and mushroom spines 
have excitatory synaptic activity and are thought to represent different stages of maturation, 
although this is not certain yet. 
The postsynaptic density (PSD) is the area of a spine where proteins necessary synaptic 
transmission, including receptors, adaptor proteins, signalling molecules or scaffolding 
proteins, are clustered (Kennedy, 1997). 
Synapses 
Synapses can be considered the minimal functional unit of communication in the nervous 
system (Purves et al., 2012) and comprise of the components outlined briefly above (section 
1.1.1).  
Types of neuronal connexions 
There are broadly two main types of synapses: electrical synapses and chemical synapses.  
Electrical synapse 
Electrical synapses are specialised cell-to-cell connexions in which electrical pulses are 
transmitted from a presynaptic neuron to a postsynaptic neuron through ion channels 
connecting both cells without neurotransmitter release (for a review, see Hormuzdi et al., 
2004). 
Chemical synapses 
Chemical synapses occur between neurons and also analogous structures occur between 
neurons and other cell types, notably muscle cells where it is called the neuromuscular junction 
(NMJ).  
In chemical synapses, the presynaptic terminal is responsible for the release of 
neurotransmitters contained in synaptic vesicles to stimulate a postsynaptic cell (see Figure 
1-3). Release of the vesicle content is achieved when action potential-generated depolarisation 
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leads to the opening of calcium channels. Calcium ions flux into the presynaptic button and 
trigger the fusion of the vesicle with the cell membrane (for the specific mechanism, see section 
1.2.1.1). Then, neurotransmitter diffuses into the synaptic cleft and reaches the postsynaptic 
membrane (Purves et al., 2012). At the membrane of the postsynaptic cell, metabotropic 
(coupled to signalling molecules) and ionotropic (ligand-gated ion channels) receptors are 
responsible for detecting the neurotransmitter and delivering their stimulus to the postsynaptic 
cell (Kennedy, 1997). After neurotransmitter release, presynaptic vesicles are re-filled with 
neurotransmitter and recycled (Südhof, 1995). In neurons, this elicits changes in membrane 
potential and integration of the information by the cell (see section 1.1.1.2). For a schematic, 
see Figure 1-3. 
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Neuromuscular junction 
Muscle cells (myocytes) can also receive information from neurons through neurotransmitter 
release at the NMJ. In mammals, NMJs use the neurotransmitter acetylcholine (ACh) (Sandow 
Figure 1-3. A chemical synapse.  
An electrical stimulus triggers neurotransmitter release from a docked vesicle. This is re-
internalised and loaded again with neurotransmitter and docked for repetitive cycles of 
neurotransmitter release. This recycling pool can be supported by vesicles in reserve pools. 
When neurotransmitter is released, it activates receptors located at the post-synaptic 
membrane, allowing signal transduction. 
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et al., 1952). Nicotinic ACh Receptors (nAChRs) present on the postsynaptic membrane of 
myocytes are ligand-gated ion channels whose activation stimulates myocyte excitation and 
contraction (Sandow et al., 1952; Landau, 1978). Consistent and synchronous contraction is 
achieved through motor units and motor pools. Motor units are the combination of a single 
motor neuron and the muscle cells it innervates, whereas motor pools refers to the combination 
of motor units of a muscle (Enoka, 1995). 
Synaptic plasticity 
Synaptic plasticity is the process by which synapses in the Central Nervous System (CNS) 
potentiate or depress their activity. Generally, two main types of plasticity are considered. The 
first is called Hebbian plasticity and includes Short- and Long-Term Potentiation (STD, LTD), 
and Short and Long-Term Depression (STD, LTD). These respond with an increase (STP and 
LTP) of activity to positive inputs and with a decrease of activity (STD and LTD) to negative 
inputs (Fioravante and Regehr, 2011; Andersen et al., 2017). 
On the other hand, homeostatic plasticity is the form of plasticity where a circuit responds to 
negative inputs with a compensatory increase of activity (Li et al., 2018). The mechanism 
underlying this process is called synaptic scaling (Turrigiano, 2008).  
For these two categories, changes can be mediated via multiple factors, including altering the 
amount of neurotransmitter release (Stevens and Wesseling, 1999), the number of receptors at 
the PSD (Gerrow and Triller, 2010) or receptor subunit composition (Henley and Wilkinson, 
2016). These can also produce structural changes in the synapse (Nishiyama et al., 2015). All 
these mechanisms are shown in Figure 1-4. 
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In vitro study of neuronal cell biology 
In vitro culture of neuronal cells is a very powerful model that allows simplification of the 
brain complexity and facilitates the study of fundamental cellular processes. There is a vast 
literature using primary neuronal culture for the investigation of synaptic formation and 
function, also in the field of neurotoxins (Herreros et al., 2001; Deinhardt et al., 2006; Harper 
et al., 2011; Restani et al., 2012b; Wang et al., 2015). In recent years other in vitro models have 
also emerged to facilitate the study of specific questions. For instance, Neural Stem Cells 
(NSCs) are obtained from immature brains and retained in a proliferative stage until a stimulus 
that triggers differentiation is received (Dwyer et al., 2016). Immortalised cell lines are also a 
Figure 1-4. Synaptic plasticity.
Synaptic plasticity is an adaptation of the synapse to a stimulus. For instance, at the 
presynapse, this can be achieved by modifying the number of synaptic vesicles available. At 
the postsynapse, this can be done by altering the composition or expression of receptors at the 
surface, either by diffusion or endocytosis/exocytosis. Structural changes are also common on 
dendritic spines. 
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valuable and extensively used tool (Fernández-Salas et al., 2004b; Couesnon et al., 2009; Tsai 
et al., 2010; Chen and Barbieri, 2011; Jacky et al., 2013). However, differences between 
neurons and these cells must be considered when translating results as they constitute different 
models.
Vesicle trafficking 
At chemical synapses and at the NMJ, the release of neurotransmitter requires appropriate 
vesicle dynamics (Südhof, 1995). Vesicle trafficking can be split into three main events: 
exocytosis, endocytosis and vesicle transport within the cell. BoNT/A blocks exocytosis and 
also uses endocytosis and vesicle transport for its own benefit (Montecucco and Schiavo, 
1994). 
Exocytosis of synaptic vesicles 
Triggering of synaptic release by calcium 
Voltage-sensitive calcium channels exist at the presynaptic terminal (Bartschat and Blaustein, 
1985; Caterall, 2000). When an action potential reaches the presynaptic terminal the membrane 
depolarisation opens calcium channels allowing the influx of calcium ions (Nachsen, 1985). 
Calcium and the release of synaptic vesicles are coupled by synaptotagmins, which act as 
calcium sensors and transmit this signal to the SNARE complex to fuse the vesicle with the 
cell membrane (Lai et al., 2011; Lai et al., 2014).  
The SNARE complex 
The SNARE complex is essential for the release of synaptic vesicles. This complex is formed 
by proteins which share a conserved domain of 60 amino acids approximately, known as the 
SNARE motif (Weimbs et al., 1997; Wesolowski and Paumet, 2010).  
In neurons, the SNARE complex is formed by four -helices in three different proteins (Fukuda 
et al., 2000; Xiao et al., 2001; Chen et al., 2002). Syntaxin is a transmembrane t-SNARE (i.e. 
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located at the membrane of the cell) consisting of a single -helix (Bennett et al., 1992; Terrian 
and White, 1997; Fukuda et al., 2000). Vesicle-Associated Membrane Protein (VAMP), also 
known as synaptobrevin, is a t-SNARE (i.e. located at the membrane of the vesicle) and also 
consisting of a single -helix inserted in the membrane (Tribmle et al., 1988; Terrian and 
White, 1997; Fukuda et al., 2000). Synaptosomal-Associated Protein 25 (SNAP-25) is a soluble 
t-SNARE with two -helices which locate at the membrane through palmitoylation and 
interaction with syntaxin (Hess et al., 1992; Terrian and White, 1997; Fukuda et al., 2000).  
Formation of the complex starts when syntaxin is free to interact with other SNARE proteins 
(Figure 1-5) in a process regulated by Mammalian uncoordinated-18 (Munc-18) (Burkhardt et 
al., 2008). Formation of the bundle is a spontaneous process and it is sufficient to bring 
membranes together by zipping four -helices (Chen and Scheller, 2001).  
Figure 1-5. Synaptic vesicle release.  
Schematic showing the main components of synaptic vesicle release. Proton pumps acidify 
the vesicle allowing neurotransmitter loading. Docking of the vesicle is coupled with SNARE 
complex formation, controlled by Synaptotagmin and Munc-18. Fusion of the membranes 
opens a pore that releases the neurotransmitter and neutralises the acid pH of the vesicle 
(shades of pink). 
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A single SNARE complex is sufficient to fuse both membranes. However, a zippering force 
provided by multiple complexes is necessary to maintain the pore open and expand it, allowing 
effective neurotransmitter release, which is achieved by the formation of a ring composed of 
multiple SNARE complexes around the fusion pore (Shi et al., 2012). Correspondingly, the 
probability of synaptic vesicle release is dependent on the number of SNARE complexes per 
vesicle (Acuna et al., 2014). 
Since the formation of the SNARE complex is a thermodynamically spontaneous process, its 
disassembly is not. The disassembly reaction requires Adenosine Triphosphate (ATP) 
hydrolysis by NSF together with cofactors Soluble NSF Attachment Proteins (SNAP-
and (Söllner et al., 1993; Littleton et al., 2001). This triggers conformational changes 
in the SNARE proteins to unzip the complex allowing the component SNARE proteins to be 
reused in further cycles of vesicle release. 
Synaptic vesicle pools 
Synaptic vesicles in presynaptic terminals are not a homogeneous population (Fernández-
Alfonso et al., 2006; Burrone et al., 2006; Crawford and Kavalali, 2015). Rather, they constitute 
pools that have traditionally been called the Ready Releasable Pool (RRP) and the Reserve 
Pool (RP). The RRP is the pool whose synaptic vesicles are docked and ready to be very rapidly 
when a stimulus is received (Schikorski et al., 2014). The RP is the pool whose vesicles feed 
the RRP when these are not sufficient to transmit stronger stimuli (see Figure 1-3) (Denker et 
al., 2011). However, many of the molecular characteristics remain unclear and there is growing 
evidence to support the idea that these pools are heterogeneous within themselves (reviewed 
by Neher, 2015). 
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Endocytosis  
Mechanisms of endocytosis 
Types of endocytosis are classified according to different criteria, including the machinery 
employed and structure (Figure 1-6). A major classification is between dynamin-dependent 
and dynamin-independent endocytosis (Takey et al., 2005; Mayor, 2014). Dynamin is a 
Guanosine Triphosphate (GTP) hydrolase (GTPase) which forms a ring around a membrane 
invagination and constricts it. This constriction results in the separation of an independent 
vesicle (De Camilli, 1995). For an illustration, see Figure 1-6. 
Figure 1-6. Types of endocytosis.  
Schematic showing different types of endocytosis distinguishing between dynamin-dependent 
endocytosis (including clathrin-mediated and clathrin-independent processes such as caveolae 
or endophilin-mediated endocytosis), and mechanisms dynamin-independent endocytosis
such as bulk endocytosis and macropinocytosis 
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Dynamin-dependent endocytic processes can be subdivided clathrin-mediated (CME) 
endocytosis and clathrin-independent endocytosis (CIE) (Mayor, 2014). Clathrin is a coating 
protein with a triskelion shape that forms a polyhedron around the vesicle and is linked to the 
vesicle and intracellular machinery through adaptors (Fotin et al., 2004; Maldonado-Báez and 
Wendland, 2006; Boucrot et al., 2010). Examples of clathrin-independent but dynamin-
dependent endocytosis are caveolae and endophilin-mediated endocytosis (EME) (Henley et 
al., 1998; Boucrot et al., 2015). Caveolae are invaginations not coated by clathrin and 
dependent on cholesterol-rich lipid rafts and mostly dependent on a family of scaffolding 
proteins named caveolins (Rothberg et al., 1992; Henley et al., 1998). These rafts are membrane 
microdomains enriched in lipids such as sphingomyelin, phosphatidylinositol and cholesterol 
and can also act as signalling platforms (Simons and Toomre, 2000; Kinoshita and Kato, 2008). 
On the other hand, Endophilin physically binds to the membrane and bends it forming 
invaginations (Bai et al., 2010; Boucrot et al., 2015). 
As a clarifying note, CME is often categorised as receptor-mediated endocytosis due to the 
importance of the study of endocytosis of transferrin and its receptor (Harding et al., 1983; 
Vieira et al., 1996; Sakakibara et al., 2004, Boucrot et al., 2010). However, other receptors (e.g. 
Fibroblast Growth Factor (FGF) Receptor 3 (Fgfr3) or Interleukin-2 (IL-2) Receptor (IL-2R)) 
which are endocytosed without the use of clathrin (Haugsten et al., 2011; Lamaze et al., 2011); 
Glebov et al., 2015). Moreover, EME can also mediate some forms of receptor-mediated 
endocytosis (Boucrot et al., 2015). 
Dynamin-independent endocytosis underpins a variety of processes which generate atypical 
vesicles. Macropinocytosis is a form of pinocytosis (endocytosis of fluids) in which 
lamellipodia protrude from the cell to be then close, forming a large vesicle that follows the 
endocytic pathway (Bloomfield and Kay, 2016; see Figure 1-6). On the other hand, bulk 
endocytosis is characterised by the large volume of the membrane endocytosed and it is used 
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by cells when the volume of membrane input increases and needs balancing (Clayton and 
Cousin, 2009). Their mechanisms are less well understood than those mediating dynamin-
dependent endocytosis. 
Endocytosis at the synapse 
Endocytosis at the pre-synapse 
Initially, it was thought that synaptic vesicle recycling was predominately CME (Heuser et al., 
1979). Later, it was shown that CIE forms also contribute to this process (Jockusch et al., 2005; 
Watanabe et al., 2013). It now seems that all the processes mentioned in section 1.2.2.1 
contribute to vesicle recycling and endocytosis of synaptic vesicles is currently classified in 
three different categories according to their kinetics, namely slow, fast and ultrafast 
endocytosis (reviewed at Smith et al., 2008 and Watanabe and Boucrot, 2017). 
Slow endocytosis works with a scale of tens of seconds (von Gersdorff and Matthews, 1994) 
and is thought to be mainly CME-dependent (Jockusch et al., 2005). In addition, CME 
constitutes the major endocytic mechanism under resting conditions (Bitsikas et al., 2014).  
However, the speed of membrane retrieval by CME is insufficient to compensate for the 
increase in membrane influx derived from stimulation of synaptic vesicle exocytosis. 
Therefore, endocytosis after synaptic vesicle exocytosis is supported by fast and ultrafast 
endocytosis (Watanabe and Boucrot, 2017). 
Fast endocytosis works with a scale of seconds (von Gersdorff and Matthews, 1994) and is 
mediated by macropinocytosis, activity-dependent bulk endocytosis, and EME (Watanabe and 
Boucrot, 2017). Bulk endocytosis is particularly important under high stimulation, as the rate 
of vesicle exocytosis increases, which needs to be compensated by mechanism that enables 
removal of greater membrane volumes (Clayton and Cousin, 2009). Ultrafast endocytosis acts 
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at the millisecond scale and its endocytosis appears to be mediated by endophilin (Watanabe 
et al., 2013; Watanabe et al., 2018).   
Finally, a model called kiss-and-run represents a form of neurotransmitter release in which full 
endocytosis and exocytosis do not occur (Fesce et al., 1994). Instead, membrane fusion is 
minimal (few nanometers) and the synaptic vesicle pore is transient being closed rapidly after 
fusion with the participation of a loose SNARE complex (Wen et al., 2017).  
Endocytosis at the post-synapse 
As described for the presynapse, several forms of endocytosis occur at the post-synapse. For 
instance, clathrin-mediated, dynamin-dependent endocytosis mediates the well-studied 
internalisation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
(AMPARs), one of the major glutamatergic receptors in neurons (Carroll et al., 1999; Man et 
al., 2000; Fiuza et al., 2017), although it can also be dynamin-independent (Glebov et al., 2015). 
Caveolae (dynamin-dependent, clathrin-independent) are responsible for the internalisation of 
the Cannabinoid type 1 receptor (CB1) (Wu et al., 2008) together with clathrin-dependent 
endocytosis (Hsieh et al., 1999). Similarly, dopamine receptors 1 and 2 (D1 and D2) undergo 
both dynamin-dependent and independent endocytosis (Vickery and von Zastrow, 1999).  
Endocytic vesicle trafficking 
Endosomal pathway leading to lysosomal degradation 
After a vesicle has been endocytosed, it typically enters the endosomal pathway and undergoes 
progressive acidification by the action of proton pumps (Forgac et al., 1982; McNeil et al., 
1983). For a graphic summary, see Figure 1-7. Vesicles in the endosomal pathway normally 
traffic to the lightly acidic early endosome (Mayor et al., 1993; Overly et al., 1995; Presley et 
al., 1997).  
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Endosomes undergo several changes, including formation of intra-luminal vesicles (generating 
multivesicular bodies (MVB)), acidification, relocation to perinuclear positions and acquisition 
of lysosomal hydrolases (reviewed by Huotari and Helenius, 2011). This process is governed 
by Rat sarcoma (Ras)-related protein in brain 5 (Rab5) and 7 (Rab7), small GTPases which 
control endosome formation and maturation (de Hoop et al., 1994; Rink et al, 2005; Vonderheit 
and Helenius, 2005, Poteryaev et al., 2010).  
Then, they can fuse with lysosomes (Luzio et al., 2000) or autophagosomes, double-membrane 
organelles capturing cytosol components or organelles, and progress their maturation to form 
lysosomes (Liou et al., 1997; Berg et al., 1998). In lysosomes, contents are degraded (De Duve 
and Wattiaux, 1966). 
In neurons, this maturation tipically occurs coupled to the transport of the vesicle from the 
axonal end towards the neuronal body (Kristensson et al., 1971; LaVail and LaVail, 1972). 
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Recycling from the endosomal pathway 
Endocytosed proteins can be recycled after they have entered the endosomal pathway through 
different pathways. However, in neurons, a population of synaptic vesicles can recycle without 
the necessity of trafficking into the early endosome, therefore existing recycling mechanisms 
at the synaptic vesicle level (Heuser and Reese, 1973; Logiudice et al., 2009). Here are a few 
relevant examples of recycling from the endosomal pathway. 
A prototypic mechanism is the one controlled by adenosine diphosphate (ADP)-rybosylation 
factor 6 (Arf6), which mediates recycling of clathrin-coated vesicles, as shown by transferrin 
receptor trafficking (van Dam et al., 2002; Dai et al., 2004; Li et al., 2007). Arf6-mediated 
recycling selects vesicles at the endosome and these are recycled directly to the cell membrane 
Figure 1-7. The endosomal pathway.  
An endocytosed vesicle containing, for example previously surface expressed receptor(s), is 
incorporated into an early endosome, which mature forming multivesicular bodies (MVB).
These can fuse and mature finally into lysosomes. Shades of red indicate acidity. 
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(Prigent et al., 2003). In neurons, this mechanism is responsible for the maintenance of the RRP 
(Tagliatti et al., 2016).  
Another mechanism also depending on small GTPases is the system formed by Rab4 and 
Rab11, which also retrieves content from endosomes. In this case, the cargo, such as receptors, 
can be targeted to a vacuolar domain in the early endosome, from where it be carried to a late 
endosome. Alternatively, cargoes can be targeted to tubular domains, from where it will be 
recycled to the membrane.  
Third, the retromer -a protein complex- targets proteins to the tubular domains of the endosome 
and directs them towards the Trans Golgi Network to be secreted (reviewed by Burd and 
Cullen, 2014). Relating this to synaptic function, the retromer has been shown to be particularly 
relevant, as AMPARs and N-methyl-D-aspartate (NMDA) Receptors (NMDARs, a major 
group of glutamatergic receptors) are retromer cargoes and the retromer ensures functional 
expression of both receptors at the PSD (Choy et al., 2014). 
The last excamples is the release of exosomes, which is the result of the fusion between MVB 
and the plasma membrane, constituting a mechanism of recycling where not only the vesicle 
cargo is exocytosed, but also the vesicle itself (Denzer et al., 2000). 
Figure 1-8 includes this information and the information shown in Figure 1-7. 
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Figure 1-8. Recycling within the endosomal pathway.  
After an endocytosed vesicle reaches an early endosome, two mechanisms can direct it towards 
the membrane. The two most studied are Arf6-dependent recycling, which recycles it directly 
to the membrane and the retromer, which directs it to the Trans Golgi Network to undergo 




Diversity of Clostridial toxins 
The genus Clostridium is a group of bacteria composed by a majority of non-pathogenic 
bacteria, while others can cause clinically important pathologies, including C. difficile, C. 
perfringens, C. tetani, and C. botulinum (Woodford and Livermore, 2009; Samul et al., 2013). 
These bacteria express potent toxins which comprise a range of heterogeneous proteins with 
different targets (Aktories, 1994; Montecucco and Schiavo, 1994; Sakaguchi et al., 2015; Di 
Bella et al., 2016; Takehara et al., 2017). However, many of them have a binary structure with 
clearly differentiated delivery mechanism to gain entry into the target cell and a catalytic 
domain that acts intracellularly. 
Neurotoxic proteases 
Clostridial neurotoxins (CNT) are homologous proteins and at least eight have been identified 
as being produced by C. botulinum and are named Botulinum Neurotoxin A (BoNT/A) to /G; 
and one by C. tetani, named Tetanus Neurotoxin (TeNT) (Eisel et al., 1986; Halpern et al., 
1989; Montecucco and Schiavo, 1994; Lacy and Stevens, 1999; Montecucco and Rasotto, 
2015). BoNTs and TeNT are the molecular cause of botulism and tetanus respectively, diseases 
that can be lethal unless life support in form of food and ventilation is given for periods 
spanning up to several months (Sobel, 2005; Hassel et al., 2013). Nonetheless, they have been 
used for a multiple of different purposes, commented in sections 1.4.2 and 1.4.3. 
Within the CNT family, different BoNTs are referred as serotoxins due to their different 
reactivity to antisera (Montecucco, 2015). However, these correspond ultimately to proteins 
synthetised by homologue genes with common structure (Lacy and Stevens, 1999; Brunt et al., 
2018). Genetic arragements between these genes can also generate hybrids, such as the toxin 
named BoNT/DC, a hybrid between BoNT/D and the C-terminal domain of BoNT/C (Moriishi 
et al., 1996). In 2014, a new serotype of BoNT (BoNT/H) was proposed (Barash and Arnon, 
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2014). Later, it was suggested that BoNT/H was a hybrid between BoNT/A and BoNT/F 
serotypes and named BoNT/FA (Johnson et al., 2014; Maslanka et al., 2016). In 2017, BoNT/X 
was reported (Zhang et al., 2017) and seen to cleave several VAMPs (Masuyer et al., 2018). 
Finally, TeNT is phylogenetically closer to other BoNTs such as BoNT/A or B than to BoNT/C 
or /D (Zhang et al., 2017) despite having a slightly different mechanism of pathogenicity 
(Hassel et al., 2013). Therefore, these are together classified as CNTs. 
CNTs present similar characteristics and a common mode of action: 
1. They are produced by bacteria of the genus Clostridium. 
2. They are synthetised as ~150 kDa proteins with two chains connected by a disulfide 
bridge (see section 1.3.2). 
3. They are self-sufficient to enter neurons and block their synaptic transmission (see 
section 1.6.1). 
4. They act by cleaving SNARE proteins at the presynaptic terminal (see section 1.7.2). 
However, other bacteria from the genus (C. butyricum and C. baratti) can also express BoNT 
as plasmids encoding for BoNTs are susceptible of genetic transfer (McCroskey et al., 1986; 
Hauser et al., 1995; Nawrocki et al., 2018). Interestingly, a strain of Weisella oryzare has been 
reported to possess a functional gene for a BoNT-like protease capable of cleaving VAMP2, 
thus being named BoNT/Wo (Mansfield et al., 2015; Zornetta et al., 2016). Moreover, a strain 
of Enterococcus faecium (a bacterium commonly found in humans) has been recently shown 
to carry a gene encoding for a BoNT-like functional protease named BoNT/En (initially named 




Clostridial bacteria produce many other toxins with binary structures composed of an 
intracellularly delivered enzymatic component and a delivery component formed by modules 
dedicated to endocytosis and channel formation and translocation (Sakaguchi et al., 2015; Di 
Bella et al., 2016; Takehara et al., 2017). For example, C. difficile can cause gut infections 
mainly due to its prolific growth and the production of two toxins. C. difficile toxin A (TcdA) 
acts as a glycosylase on small GTPases and is delivered by C. difficile toxin B (TcdB) (Di Bella 
et al., 2016). C. perfringens causes food poisoning and produces a cytotoxic ADP rybosylase 
named iota toxin which ADP-ribosylates actin (Sakurai et al., 2009). Finally, In addition to 
BoNT/C, C. botulinum strain C also produces C2 toxin, and the non-binary C3 toxin, which 
are ADP-ribosylases acting on actin and small GTPases of the intoxicated host (Aktories, 1994; 
Sakaguchi et al., 2015). 
Functional and structural overview of clostridial neurotoxins 
CNTs are expressed by a single gene as a protein with two chains. The N-terminal chain is a 
50 kDa zinc-dependent protease which acts as the catalytic domain, and is called light chain 
(LC) (Schiavo et al., 1992a; Schiavo et al., 1992b; Montecucco and Schiavo, 1994; Lacy and 
Stevens, 1999). The C-terminal 100 kDa chain, called heavy chain (HC), has two domains. Its 
N-terminal domain (HCN) corresponds to a pore-forming domain and its C-terminal domain 
(HCC) corresponds to a receptor binding domain (DasGupta and Sugiyama, 1972; Montecucco 
and Schiavo, 1994). LC and HCs are translated as a single polypeptide (BoNT or TeNT) that 
is subsequently processed to generate functional toxins (Montecucco and Schiavo, 1994). This 
modification consists in a cleavage of the peptide bond linking LC and HC, which are kept 
bound by non-covalent interactions and a disulfide bond, whose functional significance is 
detailed in section 1.6.2.5. This structure is shown in Figure 1-9.  
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The extraordinary efficacy of these toxins (with lethal doses in the nanogram range) is the result 
of several properties that act in combination to optimise their intoxication. Their mode of action 
can be summarised as follows: 
1. Membrane binding, internalisation and traffic through the endosome pathway. 
2. Channel formation and LC delivery. 
3. LC cleavage of SNARE proteins. 
Figure 1-9. Structure of BoNT/A. 
A) 3D structure of BoNT/A (PDB: 3BTA), highlighting the different domains of 
clostridial neurotoxins. Light chain (LC/A) is in blue, and the heavy chain (HC) in 
yellow (HCN/A) and orange (HCC/A).  
B) Diagram showing the structure of clostridial neurotoxins with the same colour scheme.
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Nomenclature of clostridial neurotoxins and their components 
There is a widespread confusion regarding the name of the toxins and their abbreviations, 
particularly for CNTs and BoNT/A. Indeed, different abbreviations have been used by 
individual groups and inconsistent abbreviations exist even within single papers. This has been 
promoted by the multidisciplinary nature of BoNT research or the structure of the toxin itself 
and the aim of this section is provide a rational overview of the literature. 
Full length toxin 
BoNT is the most used abbreviation given to botulinum neurotoxin, with serotypes and 
subtypes, if specified, written after a slash. For example, this would generate the abbreviation 
BoNT/A and BoNT/A1, the most used subtype, which refers to BoNT serotype A (Montecucco 
and Schiavo, 1994; Fischer et al., 2007a; Verderio et al., 2007; Harper et al., 2011; Wang et 
al., 2015; Harper et al., 2016; Fan et al., 2017; Jang et al., 2018). Confusingly, however, it has 
also been named A1NTX (Torii et al., 2011), as well as NT (Schmid et al., 1993), BT-A 
(Dressler and Eleopra, 2006), BoTA (Park et al., 2016), BoTx (Kristensson et al., 1998; Ray et 
al., 1993), Botx (Donovan and Middlebrook, 1986), BoTX (Franz et al., 2018), BTxA 
(Schengrund et al., 1992), BTXA (Roh et al., 2013), BTX-A (Drinovac et al., 2014; Møller et 
al., 2011) and BoNTA (Wang et al., 2011). Yet more, BT and BT-B have been used to name 
BoNT/B (Dressler and Eleopra, 2006). Similarly, confusion can arise from the fact that 
BoNT/C1 has been used in the literature (Foran et al., 1996; Lawrence et al., 2014) not as an 
indicator of the subtype 1 of BoNT/C but to distinguish it from botulinum toxins C2 and C3 
(see section 1.3.1.2). 
Despite their similarities, tetanus neurotoxin is not produced by C. botulinum bacteria, and 
therefore, its abbreviation corresponds to TeNT (Deinhardt et al., 2006; Restani et al., 2012a). 
However, it has also been referred to as TeTx (Cubí et al., 2013) and TTX (Fishman et al., 
1999). 
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In addition, commercial names for BoNTs include Botox, renamed onabotulinumtoxinA; 
Xeomin, renamed IncobotulinumtoxinA; or Dysport, renamed abobotulinumtoxinA, 
corresponding to different pharmaceutical formulations of the toxin. BoNT/B is branded as 
Myobloc, renamed rimabotulinumtoxinB (Jancovic, 2017). The most widely used 
nomenclature, i.e. BoNT/A as an abbreviation for BoNT serotype A is used throughout this 
thesis. 
Light Chain 
For the light chain, similarly, there is no consensus on the nomenclature. As I did with BoNT/A, 
I will use the abbreviation LC/A, with a slash, to designate the light chain of serotype A, for 
example. This form has been already used by many groups (Chen and Barbieri, 2006; Chen 
and Barbieri, 2011; Scheps et al., 2017; Pellett et al., 2018a). Nonetheless, other abbreviations 
have been used including BoNT/A1-Lc (Scheps et al., 2017), LCA (Fernánedez-Salas et al., 
2004b; Vagin et al., 2014), LcA (Toth et al., 2012; Mizanur et al., 2013), A-LC (Zhang et al., 
2017), ALC (Roxas-Duncan et al., 2009), or L (Azarnia Tehran et al., 2017). 
Heavy chain 
In this thesis, the abbreviations HC/A or HC/E correspond to the 100 kDa polypeptide located 
at the C-terminus of BoNT/A or BoNT/E, respectively. HC/T refers to the heavy chain of 
TeNT. These forms have been used before (Jacky et al., 2013). HCA or simply H have been 
used to designate HC/A too (Azarnia Tehran et al., 2017). 
As a matter of consistency with the abbreviation for the whole heavy chain (HC), I will use 
HCC/A for the C-terminal domain of the HC (i.e. the receptor-binding domain). HCN/A will 
designate the N-terminal domain of the HC (i.e. the channel-forming domain). These 
expressions have been used before (Przedpelski et al., 2018). Other serotypes will follow the 
same rule. 
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Again, a source of confusion could arise from the fact that HCC/A has been abbreviated as 
HCA, HCE or HCT (Harper et al., 2011, Restani et al., 2012a; Wang et al., 2015; Kroken et al., 
2016), HCR/A (Blum et al. 2012), Receptor Binding Domain (RBD) (Fischer et al., 2008; 
Fischer et al., 2013), H(C) (Fischer., 2013) and BoNT/Hc (Webb et al., 2017). HCN/A has been 
named HCT (Chen and Barbieri, 2011), TD (Fischer et al., 2008; Fischer et al., 2013a) and T 
(Galloux et al., 2008), highlighting the translocating activity, or H(N) (Fischer, 2013). 
Catalytically inactive toxins 
Because of their remarkable toxicity, for safety concerns CNTs are usually genetically 
modified to produce catalytically inactive enzymes for research. The abbreviation for the 
‘catalytically dead’, non-toxic derivative (BoNT ad) has been used for it (Pellett et al., 2011; 
Vazquez-Cintron et al., 2014). The expressions Botulinum Toxin Inactive Mutant A (BoTIMA) 
(Wang et al., 2011), Mutant-BoNT/A (M-BoNT/A), catalytically inactive BoNT (ciBoNT) 
(Webb et al., 2017) or Deactivated recombinant BoNT/A (DrBoNT/A) also exist (Baskaran et 
al., 2013; Ravichandran et al., 2016). To avoid confusion with the Latin preposition ad used in 
locutions such as ad hoc (for this [purpose]) and simplify the nomenclature of genetically 
modified proteins (e.g. fused to GFP), I use BoNT/A(0) (used by Fonfria et al., 2015) to refer 
to a full-length BoNT from the serotype A not being able of SNAP-25 cleaving. Similarly, 
LC/A(0) will refer to a catalytically inactive LC/A.
Botulism and uses of BoNTs 
BoNT/A was the most toxic substance known to humankind until 2014 when the recently 
discovered BoNT/H serotype got the first position with a lethal dose lower than 1 ng/kg (Barash 
and Arnon, 2014). 
Paraphrasing Paracelsus (1493 - 1541) in a work on BoNT/A is a cliché, since he founded the 
idea of all substances being poisonous solely depending on their dose (for an English 
translation of the 1564 German edition of the text known as Third Defence, see Deichmann et 
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al., 1986). However, Paracelsus was not the only person unconsciously connecting with BoNT. 
Hugo Simberg (1873 - 1917) painted an allegory of BoNT in Kuoleman Puutarha (Finnish for 
‘The Garden of Death’, Figure 1-10). In it, three figures of Death personified as a human 
skeleton with a black coat take care of a garden. The first of them is watering pots, the second 
one holds a flower in its hands and the third one is facing backwards.  
This painting symbolically explains our current view of BoNTs: the most lethal substances can 
have a beneficial use. We also know some of their applications, but others are yet to explore. 
Botulism 
Botulism occurs after BoNT silencing of peripheral neurons innervating muscles. This leads to 
muscle flaccid paralysis, which, in the most severe cases, affects the diaphragm and blocks 
respiration (Sobel, 2005). 
Figure 1-10. Kuoleman puutarha, by Hugo Simberg.  
A painting by Hugo Simberg depicting Death personified taking care of a garden can be 
interpreted as BoNTs used therapeutically. 
29 
Foodborne botulism 
Paracelsus unconscious connections with BoNT went beyond the dose concept. First, he used 
a neurotoxic compound (mercury) to treat diseases (Deichmann et al., 1986) and, second, he 
claimed that all human poisons were contained in food in a rather esoteric text (for a Spanish 
translation of the complete Latin Opera Omnia, see the reedition Paracelsus, 2015; for an 
English translation of the excerpt referred, see the Appendices).  
Foodborne botulism occurs after the consumption of contaminated raw or fermented food 
stored in anaerobic conditions, such as honey or canned food (Sobel, 2005). When 
contaminated food is ingested, bacteria reach the gut and intoxication is initiated. Currently, 
there is no vaccination against botulism, despite an extensive research on it (Przedpelski et al., 
2018; for a review, see Sundeen and Barbieri, 2017). Current immunological treatments only 
stop progression (Sobel, 2005; Rosow and Strober, 2015). 
Infant botulism 
Infants of less than one year are particularly susceptible of contracting botulism because of C. 
botulinum colonisation of the gut (Rosow and Strober, 2015). Once infected, intensive 
supportive care in form of food and ventilation is necessary. The situation of a paralysed infant 
whose guts have been colonised by C. botulinum is even more dramatic than it seems, since 
antibiotics induce the release of BoNT (L’Hommedieu et al., 1979). So far, the only existing 
treatment are antibodies that target free BoNT (Rosow and Strober, 2015). Colonisation of the 
gust by C. botulinum in adults can also occur, but it is extremely rare (Sobel, 2005).  
Wound botulism 
A rarer form of botulism is wound botulism, in which the bacteria is enters directly into the 
bloodstream because of contact of blood with a contaminated object (e.g. a needle). In the 
1990s, a botulism outbreak occurred in California as a consequence of heroin injections with 
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nearly one hundred affected people (Werner et al., 2000). Recently, in Norway, there was a 
small outbreak (four confirmed cases) with the same cause (MacDonald et al., 2013). 
Inhalation botulism 
Paralysis can arise after inhalation of contaminated material. For instance, inhalation of 
contaminated cocaine produced botulism in two individuals in France (Roblot et al., 2006). 
Furthermore, causing inhalation botulism is one of the major goals in biological warfare 
development (see section 1.4.2 below). 
Animals 
Apart from humans, other animals also suffer botulism. Indeed, some studies suggest that the 
action of CNTs on humans has caused no adaptation, which is present in murine species 
(Vaidyanathan et al., 1997; Carle et al., 2017). Although BoNT/C and /D are the most common 
serotypes detected, all BoNT/A-/E have been detected in fish, birds or mammals (Anniballi et 
al., 2013; Montecucco et al., 2016). This has an enormous ecological impact, since a single 
outbreak can kill up to one million birds (Friend and Franson, 1999). 
Warfare 
As a consequence of their extreme potency, lack of vaccines, and extreme effects (death or 
muscle paralysis) BoNTs are considered to be biological weapons (Arnon et al., 2001).  
The USA government considers them class A Bioterrorism Agents 
(https://emergency.cdc.gov/agent/agentlist-category.asp, accessed  October 2018) because of 
their ease of dissemination, mortality rate, social disruption and lack of social preparedness. 
Several states and organisations have been accused of, or have admitted to, producing BoNT 
for warfare. Weapons produced included BoNT-coated grenades, bombs, bullets and even 
botulism-spreading mosquitoes and flies (Pita, 2009; Pita, 2014). It is calculated that the 
amount of BoNT that has been loaded into arms is enough to extinguish humanity various times 
(Arnon et al., 2001). Several methods, including genetic and proteomic analysis, have been 
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developed for BoNT detection (reviewed by Thirunavukkarasu et al., 2018; Duracova et al., 
2018). However, the extreme efficiency of the toxins challenges the detection of 
physiologically relevant doses. 
Research and clinical use 
Academic research 
BoNTs and TeNTs research not only focuses on their intrinsic biology and lethality. Because 
of their specific SNARE protein cleavage, these proteins are extremely useful tools for the 
study of the different synaptic vesicle pools, which were actually first identified by the use of 
the toxins (Niemann et al., 1994). 
Clinical use  
In 1973 BoNT/A was successfully tested in monkeys to treat strabismus, a disease caused by 
imbalance in muscle tension (Scott et al., 1973). The long persistence of BoNT/A made it an 
optimum candidate due to the low number of injections needed (one every few months) and 
BoNT/A has been indicated for multiple uses. These include cosmetics, hypersialorrhea 
(excessive salivation), hyperhidrosis (excessive sweating), urethral resistance, muscle spasm 
and hypertrophy, dysphagia (swallowing difficulties), puberophonia (high-pitched speech), 
vocal cord paralysis, tics, motor symptoms of cerebral palsy, neuropathic pain, migraine and 
major depression (Pickett and Perrow, 2011; Dutta et al., 2018). BoNT/B is also commercially 
available and BoNT/C and /F have been tested to successfully overcome BoNT/A resistance 
(Eleopra et al., 2006; Dressler and Eleopra, 2006). 
HCC/A induces neurite outgrowth in vitro (Coffield and Yan, 2009) and recently, BoNT/A has 
been reported to promote nerve regeneration in preclinical models (Franz et al., 2018), opening 
a new window for BoNT/A use. This topic is further addressed in Chapter 6. 
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Side effects such as focal weakness and muscle atrophy derived from BoNT application are 
generally considered minor compared with the benefits of the application (Naumann and 
Jankovic, 2004; Salari et al., 2018). However, possible risks of their clinical use include 
botulism, with a case reported after the use of an unlicensed product (Chertow et al., 2006). 
BoNT engineering 
Engineering BoNTs by introducing and removing domains and motifs from other BoNTs or 
other proteins is a field of active research in academia and industry as it generates BoNTs with 
customised characteristics (Fonfria et al., 2018). 
Targeted Secretion Inhibitors (TSIs) are BoNT-derived proteins targeting LC to cells for which 
BoNTs do not have tropism (Stancombe et al., 2012). A particularly fascinating use is HCC
substitution by another protein such as Epithelium Growth Factor (EGF) or Nerve Growth 
Factor (NGF), retargeting LC to a cell which is not primarily targeted by BoNT. This leads to 
an inhibition of secretion by the targeted cell type (Chaddock et al., 2002; Fonfria et al., 2016).  
Another method of retargeting LC action is the method known as protein stapling. This strategy 
removes the receptor binding domain of BoNT (HCC) and substitutes it with a re-targeting 
factor (Arsenault et al., 2013). LC-HCN and the re-targeting molecule are fused to proteins of 
the SNARE complex that zip when the third component is added (see Figure 1-11). Therefore, 
protein linking is achieved in vitro through an artificial SNARE-like complex and no full-
length BoNT-producing bacteria are generated. 
Figure 1-11. Protein stapling strategy.  
Schematic explaining the binding between the re-targeting growth factor fused to syntaxin and 
LC-HCN fused to SNAP-25. In vitro addition of synaptobrevin allows the formation of an 
SNARE complex linking both proteins. 
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These strategies gained particular importance after it was discovered that LC/C and LC/D-
produced SNARE fragments are cytotoxic in neuroblastoma cells (Arsenault et al., 2014a; Rust 
et al., 2016).  
In addition, hybrids of the different BoNTs can be generated to combine properties. For 
instance, substitution of HCC/A in BoNT/A by HCC/B results in a BoNT more potent than 
BoNT/A (Rummel et al., 2011). The actions of a LC/E-BoNT/A(0) chimera (see section 
1.7.3.1) are more persistent than those of BoNT/E (Wang et al., 2011).
Actions of Neurotoxin Accessory Proteins 
Initial steps of primary intoxication 
BoNTs are produced as part of a larger complex called Progenitor Toxin Complex (PTC) 
(Pirazzini et al., 2017). This is a 900 kDa complex formed by BoNT and Neurotoxin Accessory 
Proteins (NAPs), comprising a nontoxic-nonhemagglutinin (NTNH) protein, and several 
hemagglutinin (HA) proteins. NAPs are encoded by genes located in the same cluster as BoNTs 
and their expression is simultaneous (Pirazzini et al., 2017). 
This complex is able to bind the membrane of intestinal cells through BoNT, be internalised 
and be secreted on the basal side of the intestine (Maksymowych and Simpson, 1998; Couesnon 
et al., 2008). Indeed, purified BoNT/A retains the ability of being absorbed by the digestive 
system and produce botulism (Maksyowych et al., 1999; Couesnon et al., 2008). 
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NAPs have a protective action, as they contribute to the protection of the toxin from the low 
pH of the guts (Chellappan et al., 2014). However, structural analysis of D serotype complex 
revealed that regions of the toxin are exposed (Hasegawa et al., 2007). Later, it was seen that 
physical protection was obtained from NTNH, whose tridimensional structure resembled that 
of BoNT/A and coiled with it to protect the toxin (Gu et al., 2012). Moreover, the regions of 
BoNT/A which are exposed are the regions resistant to proteolytic cleavage by gut enzymes. 
The role of the HA proteins in the complex has been proposed to disrupt the intestinal barrier 
to promote transcytosis of non-absorbed toxin (Matsumura et al., 2008; Jin et al., 2009) 
although the in vivo significance remains controversial (reviewed by Simpson, 2013). 
BoNT release and neuronal targeting 
Once it has crossed the gut epithelium, the PTC reaches the blood stream, where dissociation 
occurs (Eisele et al., 2011). Free BoNT/A released in the blood stream can then finds its target: 
neurons (Black and Dolly, 1986; Montecucco and Schiavo, 1994; Al-Saleem et al., 2008).  
Actions of the Heavy Chain 
Mechanism of entry 
Binding to gangliosides 
CNTs have evolved a dual receptor strategy for internalisation using both gangliosides and 
proteins at the cell surface to target neurons and this is cause of the affinity of these toxins 
(Montecucco and Schiavo, 1994; Simpson, 2000; Stenmark et al., 2008).  
Gangliosides consist of a glycosphingolipid and additions of sialic acid molecules at different 
positions. Because these molecules are especially expressed by neurons, including those at the 
NMJ, they provide targets for selective intoxication of neurons by CNTs (Simpson, 2000). 
Binding of the HCC is a requisite for all CNTs but BoNT/D intoxication (Simpson and Rapport, 
1971; Yowler et al., 2002; Kroken et al., 2011a). BoNT/D is thought to be able of entering 
neurons without the assistance of gangliosides and use phosphatidylethanolamine (PE), at least 
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in vitro (Tsukamoto et al., 2005). A schematic representation of the structure of the 
gangliosides used by CNTs is shown in Figure 1-12. 
Gangliosides GD1a or GD1b, GT1b are suggested as the principal gangliosides used by most 
CNTs (but serotype D), although with differences in affinity and variability within different 
reports (Kitamura et al., 1980; Yavin, 1984; Ochanda et al., 1985; Critchley et al., 1986; 
Tsukamoto et al., 2005; Fu et al., 2009). BoNT/A also binds GQ1b (Takamizaka et al., 1986) 
and BoNT/D binds gangliosides GD1b, GT1b and GD2 through a specific ganglioside-binding 
loop (Kroken et al., 2011a). Interestingly, however, BoNT/D, is thought to be able of entering 
neurons without the assistance of gangliosides and use phosphatidylethanolamine (PE), at least 
in vitro (Tsukamoto et al., 2005). TeNT also binds GD3 and GT1b gangliosides (Stoeckel et 
al., 1977; Yavin, 1984; Chen et al., 2008; Chen et al., 2009).  
Protein receptor binding 
For most CNTs, binding to gangliosides locates them at the neuronal surface and enables the 
interaction of CNTs to their respective protein receptors, which are predominantly functional 
Figure 1-12. Ganglioside receptors of clostridial neurotoxins.  
Diagram showing the different sugar organisations of gangliosides. Brown cylinders represent 
ceramide, dark green circles represent sialic acid and light green circles show other sugar 
molecules. 
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proteins at the presynaptic terminal, where CNTs act. Their role for the formation of dual 
receptors is shown in Figure 1-13, while protein receptors alone are summarised in Table 1-1.  
Several BoNTs use synaptic vesicle 2 (SV2) proteins as their protein receptors (Table 1-1). 
SV2 proteins are a family of three (SV2A-C) homologue transmembrane proteins present in 
synaptic vesicles (Feany et al., 1992) whose function is unclear and their potential involvement 
in disease remains to be determined (reviewed by Bartholome et al., 2017). BoNT/A binds 
glycosylated SV2C but not SV2A and SV2B (Dong et al., 2006; Mahrhold et al., 2006; Yao et 
al., 2016), BoNT/E binds glycosylated SV2A and SV2B but not SV2C (Dong et al., 2008). 
Figure 1-13. Dual receptors of clostridial neurotoxins.  
Schematic of the several proposed receptors for the different CNTs with some support from 
the literature. BoNT/A, /D, /E, /F and TeNT use the ganglioside-SV2 ganglioside dual 
receptor. BoNT/A, in addition, can use Fgfr3, without a reported implication of gangliosides
specifically. TeNT could also use Thy-1 and nidogens with or without gangliosides. BoNT/B, 
/DC and /G use the ganglioside-synaptotagmin dual receptor. BoNT/C enters -and TeNT might 
enter- independently of a protein ganglioside-receptor and use a dual ganglioside receptor. 
BoNT/D can enter independently of gangliosides and can use phosphatidylethanolamine (PE), 
perhaps without the necessity of a protein receptor. Protein receptors are shown in grey, while 
lipids are shown in brown and sugars in green. Controversies or lack of evidence regarding the 
implication of a dual receptor are shown with question marks. 
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BoNT/D and /F bind all of them, also after glycosylation (Fu et al., 2009; Rummel et al., 2009; 
Peng et al., 2011). In addition, it seems that BoNT/D entry can be independent of any SV2 
protein as HCC/D binds proteinase-treated synaptosomes (i.e. an isolated presynaptic terminal) 
(Tsukamoto et al., 2005), reinforcing the theory of a PE-mediated entry. SV2-mediated of 
TeNT was also published (Yeh et al., 2010) although later studies argued that the observed 
result was an artefact due to the lack of normalisation for efficiency in their binding 
experiments (Blum et al., 2012). Moreover, TeNT binds nidogens, proteins involved in cell-
matrix interactions (Bercsenyi et al., 2014), and Thy-1, a protein present at the neuronal 
surface, although the authors clarify that this interaction is unnecessary for TeNT 
internalisation (Herreros et al., 2001).  
Table 1-1: Protein receptors for Clostridial neurotoxins.
Serotype Receptor Reference 
BoNT/A SV2C, Fgfr3 Dong et al., 2006, Jacky et al., 2013 
BoNT/B Synaptotagmin I & II Nishiki et al. 1994 
BoNT/C None Tsukamoto et al., 2005; Strotmeier et al., 2010
BoNT/D SV2A, SV2B, SV2C Peng et al., 2011 
BoNT/DC Synaptotagmin I & II Peng et al., 2012 
BoNT/E SV2A, SV2B Dong et al., 2008 
BoNT/F SV2A, SV2B, SV2C Rummel et al., 2009 
BoNT/G Synaptotagmin I & II Rummel et al., 2004 
TeNT SV2A, SV2B Yeh et al., 2010 
Synaptotagmins I and II are the protein receptors for BoNT/B, /DC and /G (Nishiki et al. 1994; 
Dong et al., 2003; Rummel et al., 2004; Peng et al., 2012). These synaptotagmins are largely 
considered as calcium sensors involved in vesicle docking and recycling by interacting with 
the SNARE complex (Lai et al., 2011; Lai et al., 2014).  
BoNT/C has no known protein receptor. Instead, it has been suggested to enter neurons by 
using two gangliosides (Tsukamoto et al., 2005; Strotmeier et al., 2010; Kroken et al., 2011b; 
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Karalewitz et al., 2012). TeNT could also follow this pathway too (Blum et al., 2012). 
However, while HCC/E and HCC/T compete for internalisation, HCC/A and HCC/T do not 
(Herreros et al., 2000; Blum et al., 2012). Therefore, structural analysis of TeNT binding to 
SV2 is necessary to determine whether this is due to a dual ganglioside receptor or differences 
in SV2 binding. 
In addition to gangliosides and typically synaptic proteins, BoNT/A also has Fgfr3 as a receptor 
(Jacky et al., 2013). This is likely due to structural similarities between HCC/A and FGF-2, a 
native ligand of Fgfr3 (Eriksson et al., 1993; Stenmark et al., 2008), shown in Figure 1-14. 
In vitro, HCC/A has been shown to enter HEK293T cells, which lack SV2C, opening the 
possibility to any cell expressing Fgfr3 to be intoxicated (Jacky et al., 2013).  However, the 
physiological relevance of this receptor as a BoNT/A receptor is unknown, since BoNT/A 
primarily targets neurons (Black and Dolly, 1986; Montecucco and Schiavo, 1994).  
Figure 1-14. 3D structures of HCC/A and FGF-2.  
Comparison between the three-dimensional structures of HCC/A, the Fgfr3-binding domain of 
BoNT/A, and FGF-2, a native ligand for Fgfr3. Note similarities between the C-terminal part 
of HCC/A (right hand side in the left panel) and FGF-2 (right panel). PDB: 2VUA (HCC/A) 
and 4FGF (FGF-2). 
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Binding to microdomains 
BoNT/A, /C, /D and TeNT interact with membrane microdomains enriched in cholesterol, 
phosphatidylinositol and sphingomyelin (Herreros et al 2001; Muraro et al., 2009). These 
molecules interact with each other creating lipid rafts where caveolae start to be formed 
(Simons and Toomre, 2000; Kinoshita and Kato, 2008). For TeNT endocytosis, these 
microdomains constitute a way of entry into neurons (Herreros et al., 2001). However, the 
literature on BoNT/A and lipid rafts and/or caveolae is inconclusive, as cholesterol extraction 
from neuronal membranes prevents or promotes BoNT/A action depending on the model used 
(Petro et al., 2006; Couesnon et al., 2009; Ayyar and Atassi, 2016; Thyagarajan et al., 2017).  
Endocytosis 
CNTs enter into the nervous system through presynaptic terminals innervating the 
neuromuscular junction (Montecucco and Schiavo, 1994; Harper et al., 2011; Colasante et al., 
2013). Currently, there is not a single pathway of entry for any of the BoNTs. Rather, they 
appear to have multiple mechanisms (Harper et al., 2011; Restani et al., 2012a; Jacky et al., 
2013; Wang et al., 2015; Harper et al., 2016). BoNT/A, /B, /C, /D, /E and TeNT uptake is 
enhanced in vitro by depolarisation induced by potassium, which is known to promote synaptic 
vesicle exocytosis and endocytosis (Keller et al., 2004; Baldwin et al., 2007; Kroken et al., 
2011b; Harper et al., 2011; Restani et al., 2012a; Harper et al., 2016). For TeNT, activity-
dependent uptake does not occur at the NMJ and it could be restricted to central neurons 
(Schmitt et al., 1981; Deinhardt et al., 2006).  
BoNT/A and TeNT have been shown to enter into presynaptic terminals through synaptic 
vesicles (Harper et al., 2011; Blum et al., 2012; Colasante et al., 2013). However, although 
BoNT/A and TeNT block neurotransmitter release induced by depolarisation (Marsal et al., 
1989; Egea et al., 1990) at least BoNT/A does not block its own endocytosis (Neale et al., 1999; 
Wang et al., 2015). 
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The synaptic vesicle population exploited by BoNT/A is not homogeneous, as HCC/A enters 
both recycling and non-recycling synaptic vesicles (see Figure 1-15) in vitro and in vivo 
(Restani et al., 2012a; Harper et al., 2016). TeNT also enters non-recycling synaptic vesicles 
(Restani et al., 2012a), but, as explained earlier (section 1.6.1.2), HCC/A does not compete with 
HCC/T to enter synaptic vesicles (Blum et al., 2012). 
Since BoNT/B, /DC and /G are internalised by their interaction with synaptotagmins (present 
in recycling vesicles), it is possible that they enter recycling vesicles, either exclusively or not 
(Nishiki et al. 1994; Rummel et al., 2004; Peng et al., 2012).  
In addition, HCC/A enters via CME at the presynaptic terminal and uses dynamin-dependent 
endocytosis, at least under depolarisation induced by potassium (Harper et al., 2011) but also 
uses clathrin-independent and dynamin-independent endocytosis (Montesano et al., 1982; 
Figure 1-15. BoNT/A endocytosis at the presynaptic terminal.  
Schematic explaining findings regarding BoNT/A trafficking unveiled by using HCC/A. 
HCC/A enters through recycling and non-recycling vesicles, whose endocytosis is promoted 
by K+-induced depolarisation. 
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Harper et al., 2011). TeNT entry into neurons can also be by clathrin-mediated endocytosis 
(Deinhardt et al., 2006; Blum et al., 2012) and dynamin-independent mechanisms (Harper et 
al., 2011; Blum et al., 2012). 
Trafficking after endocytosis 
Following internalisation, HCC/A, /E and /T are retrogradely transported through the axon 
towards the soma and this is thought to be the cause of their central effects (Restani et al., 
2012a; Restani et al., 2012b). BoNT/D also has distal actions away from the originally 
intoxicated site (Bomba-Warczak et al., 2016). 
For TeNT, its retrograde action is a requisite for pathology of tetanus, since the toxin needs to 
reach GABAergic neurons upstream in the motor system (Price et al., 1976). Inhibition of this 
inhibitory population of neurons produces an over-activation of muscle contraction, causing 
rigid paralysis, in contrast with flaccid paralysis caused by BoNTs (Hassel et al., 2013; Surana 
et al., 2018).  
However, BoNT internalisation in peripheral neurons is sufficient to cause botulism and 
BoNTs do not require to intoxicate the CNS (Sobel, 2006). Therefore, its biological 
significance is not determined. Some individuals present central effects after contracting 
botulism or after intramuscular injection, including differences in excitability, in brain waves 
and/or loss of reflexes (reviewed by Caleo and Schiavo, 2009). CNS effects of SNAP-25 
cleavage, antibody targeting of the HC or radioactive signal after radiolabelling of the full-
length toxin in upstream motor and sensory neurons are widely recorded in the literature (Black 
and Dolly, 1986; Antonucci et al., 2008; Restani et al., 2011; Restani et al., 2012b; 
Papagiannopoulou et al., 2016). These effects are indicative of BoNT/A release within the 
CNS, although the precise form of BoNT release has not been clarified.  
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In the recent years, many interesting findings have been made on the molecular basis of 
retrograde trafficking of CNTs (shown in Figure 1-16 as an update of Figure 1-15). HCC/A 
HCC/E and HCC/T retrogradely traffic in autophagosomes together with neurotrophin receptors 
(Deinhardt et al., 2006; Restani et al., 2012a; Wang et al., 2015). HCC/A has been shown to 
enter early endosomes and lysosomes under potassium-induced depolarisation and this is 
thought to occur after retrograde trafficking, since neither HCC/A nor HCC/A colocalise with 
lysosomal markers under resting conditions or while travelling through the axon (Couesnon et 
al., 2009; Harper et al., 2011; Restani et al., 2012a; Wang et al., 2015). Interestingly, this 
lysosomal targeting of HCC/A distribution is promoted by depolarisation (Wang et al., 2015). 
The authors suggest that this toxin is degraded in this organelle, although there is no data 
regarding degradation of the toxin other than LC/A degradation (see 1.7.3.2).  
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These data appear to explain how CNTs reach the CNS. However, an alternative explanation 
comes from an observation on GFP-LC/A transfection into Neuro2A cells, where an 
incomplete transfection leads to a complete SNAP-25 cleavage (Arsenault et al., 2014b). This 
could suggest that LC/A is able to translocate to different cells or be an artefact derived from 
permeability changes induced by the transfection itself.  
Figure 1-16. BoNT/A retrograde trafficking after endocytosis.  
Graphic description of HCC/A trafficking. Non-recycling vesicles progress into early 
endosomes and autophagosomes positive for retrograde trafficking markers such as 
neurotrophin receptors. Potassium promotes HCC/A internalisation, retrograde trafficking and 
lysosomal targeting. 
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Channel formation and LC release 
Channel formation 
While the HCC are responsible for toxin internalisation, the HCN are responsible for the 
formation of the LC-releasing channel (Blaustein et al., 1987; Montecucco and Schiavo, 1994; 
Koriazova and Montal, 2003). A schematic on the overall process shared by all CNTs is 
provided in Figure 1-17, while this section will address specific differences among toxins. 
Channel formation by BoNT/A occurs at any value below pH = 7.5. However, maximum 
efficiency os obsverved at pH = 6.1 (Donovan and Middlebrook, 1986). These channels were 
first suggested to be formed by HCN/A alone (Blaustein et al., 1987). Indeed, HCN/A becomes 
insoluble at low pH and this constitutes the driving force for membrane insertion without major 
structural rearrangements (Galloux et al., 2008). HCN molecules can oligomerise and be 
inserted into the membrane, perforating it (Schmid et al., 1993). HCN/A-formed channels can 
exist as dimer, trimer and tetramers, while BoNT/B forms dimers and BoNT/E formed 
monomers and dimers. Tetanus formed dimers and trimers (Ledoux et al., 1993; Schmid et al., 
Figure 1-17. Channel formation and release of the light chain.  
Channel formation starts when an internalised vesicle acidifies. This triggers conformational 
changes on CNT domains and the HCN gets inserted into the membrane and the LC losses its 
native structure (LC*) to translocate through the HCN. When it reaches the cytosol, the 
chaperone Hsp90 mediates the refolding of the LC. The disulfide bond connecting the LC and 
the HC get reduced by the Thioredoxin reductase-Thiorredoxin, liberating the LC. 
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1993). Ganglioside binding appears to have a role in oligomerisation by sensing pH (Sun et al., 
2011).  
For HCN/A alone, the maximum channel activity was detected in acid conditions (pH values 
ranging from 4.5 to 5.5) in the cis side (corresponding to lumen of the vesicle) and neutral pH 
on the trans side and had a diameter of approximately 14 Å (Blaustein et al., 1987; Hoch et al., 
1985). The HCN/E-formed channel has similar characteristics (Parikh and Singh, 2007). These 
pH values correspond to those in an endosome (Overly et al., 1995), and are consistent with 
previous findings that BoNT/A and TeNT do not form channels on the cell membrane of motor 
nerve endings (Dreyer et al., 1983).  
Contribution of LC/A and HCC/A 
In addition to HCN/A, LC/A and HCC/A have been suggested to be play a role in LC delivery. 
First, LC/A was proposed to form a channel, since BoNT/A, HC/A and LC/A applied alone 
induce the release of calcein (a fluorescent reporter) from liposomes in vitro (Kamata and 
Kozaki, 1994). Those authors suggested that this was due to a channel formed by the LC alone.  
However, while both BoNT/A and HC/A appeared to cause liposome aggregation induced by 
protein binding before calcein release, LC/A did not. In addition, previous reports showed no 
conductance when LC/A or LC/T were applied alone (Blaustein et al., 1987; Boquet and 
Duflot, 1982).  
Second, HCC/A and /B, whose main function was attributed to be receptor binding 
(Montecucco and Schiavo, 1994), were proposed to act as chaperones and pH sensors for their 
respective toxins (Fischer and Montal, 2007; Fischer et al., 2008; Sun et al., 2011). 
LC translocation 
After the channel has been formed, the next step is the delivery of the LC into the cytosol 
(Figure 1-17 in section 1.6.2.1). 
46 
The diameter of BoNT/A channel is smaller than the size of native LC (Hoch et al., 1985; Lacy 
et al., 1998). Therefore, to transit through the HCN-formed channel, the LC must undergo 
conformational changes. Indeed, it has been shown that LC/A losses its native confirmation 
and refolds at the trans side (Koriazova and Montal, 2003), a process that occurred optimally 
at pH = 5.0, coincident with the value at which HCN/A elicits maximum channel activity 
(Blaustein et al., 1987; Cai et al., 2006). Conformational changes happened at similar values 
for BoNT/A /B, /C, /E and /F (Puhar et al., 2004). This process is facilitated by chaperones at 
both the cis and trans side. At the trans side, HCC/A acts as a chaperone (Fischer and Montal, 
2007) whereas at the cis side, the chaperone Heat-shock protein 90 (Hsp90) refolds LC/A 
(Azarnia Tehran et al., 2017).  
The specific case of TeNT 
Interestingly, optimum values for HCN/T channel formation are at pH = 3.6 and K
+
permeability only was present in pH < 5.0, lower than those for BoNTs (Boquet and Duflot, 
1982; Puhar et al., 2004). This is parallel to TeNT action, as it is thought to be first endocytosed 
to be exocytosed and then re-endocytosed to deliver LC/T. Therefore, lower pH values for 
channel formation ensure that LC/T is released at the final destination (GABAergic neurons at 
the spinal cord) and not at lightly acidic vesicles of the originally intoxicated neuron 
innervating muscles (Hassel et al., 2013).  
Once it has entered inhibitory neurons within the spinal cord, LC/T blocks the inhibitory input 
of motor units, resulting in a spasmodic paralysis instead of the flaccid paralysis caused by 
BoNTs (Hassel et al., 2013). 
Disulfide bridge reduction 
Once the LC has reached the cytosol, it must be liberated from the HC (Figure 1-17 in section 
1.6.2.1). As explained, LC and HC are connected by a disulfide bridge (see section 1.3.2) and 
LC release requires the reduction of this bond to cleave its SNARE target (Schiavo et al., 1990; 
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Dolly et al., 1990; Montecucco and Schiavo, 1994). The position of the disulfide bridge-
forming cysteines is shown on toxins sequences in the Appendices. 
After LC translocation, the disulfide bridge is on the trans side of the vesicle (i.e. in the 
cytoplasm) and it must be reduced on that side. If the reduction happens on the vesicle lumen, 
translocation does not occur for BoNT/A or /E (Fischer and Montal, 2007). Similarly, abolition 
of the disulfide bridges connecting LC and HC of BoNT/A and TeNT inactivates the toxins 
(Schiavo et al., 1990; Fischer and Montal, 2007).  
The disulfide bridge for most of the CNTs (BoNT/A, /B, C, /D, /E and TeNT) is reduced by 
the thioredoxin reductase-thioredoxin system (Pirazzini et al., 2013; Pirazzini et al., 2014). 
Although it seems likely that other CNTs use the same system, no data is currently available.  
The thioredoxin reductase-thioredoxin system is a complex able to to reduce disulfide bridges 
in proteins coming from oxidising environments such as the endoplasmic reticulum lumen (for 
a review, see Berndt et al., 2008). CNTs exploit this machinery on the trans side synaptic 
vesicles (Pirazzini et al., 2014) and a fraction of BoNT/A is translocated from these (Colasante 
et al., 2013; Pirazzini et al., 2014). Inhibition of the thioreductase system prevents botulism 
(Zanetti et al., 2015). 
Interestingly, TeNT was discovered to have an extra disulfide bridge within the HC as part of 
its tertiary structure which is insensitive to thioredoxin system (Kistner and Habermann, 1992). 
The function of this bond is unknown. 
The HC beyond the LC 
Trafficking after LC release 
Since LCs are the catalytic component of BoNTs, what happens to HCs after LC is released 
has been largely overlooked. Moreover, many studies have assumed that BoNT or TeNT 
trafficking is fully represented by HCC trafficking (Harper et al., 2011; Restani et al., 2012a; 
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Wang et al., 2015; Pellett et al., 2016). TeNT trafficking is different than HCC/T trafficking 
(Blum et al., 2014a; Blum et al., 2014b) and LC and HCN also contribute to membrane binding 
(Montecucco et al., 1988; Ayyar et al., 2015).  
However, away from the neurotoxin field, comparison with Botulinum C2 toxin is possible. 
Unlike BoNTs or TeNT, C2 toxin is not a protease, but an ADP-rybosylase and its components 
are synthesised separately (see 1.3.1.2). Nonetheless, it has a catalytic component (C2I) and a 
delivery mechanism (C2IIa) (Aktories, 1994; Sakaguchi et al., 2015). After internalization of 
C2, C2I release into the cytoplasm is thought to happen when C2 toxin is still in an early 
endosome. C2IIa then traffics independently to the plasma membrane or progressed towards 
late endosomes and lysosomes (Nagahama et al., 2014). 
BoNT could follow a similar pathway. I outlined in section 1.6.1.5 how HCC/A is trafficked to 
lysosomes (Harper et al., 2011; Wang et al., 2015). However, it is possible that full-length 
BoNT/A does not traffic to that compartment, rather, given LC/A release that starts as early as 
in synaptic vesicles, it may be that HCC/A does after LC/A has been releases (Colasante et al., 
2013; Pirazzini et al., 2014). If this is the case, LC/A would be released before any lysosomal 
degradation happened, ensuring maximal efficiency. 
Effects beyond SNAP-25 
BoNT/A presents many effects that cannot be explained solely by SNAP-25 cleavage 
(reviewed by Matak and Lacković, 2015). These effects may be due to action free HC and are 
reviewed separately in section 6.2.1. 
Differences in disease onset 
While the molecular causes of persistence of the LC action has been extensively studied, 
different C. botulinum strains have different tropisms and the onset is a less investigated (see 
1.4.1). Human botulism caused by BoNT/E has the shortest incubation period, followed by A 
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and by B (Woodruff et al., 1992). BoNT/D has a slower onset than BoNT/A (Pellett et al., 
2015b). BoNT/A-induced paralysis has a slower onset than TeNT-induced paralysis (Restani 
et al., 2012a). Table 1-2 summarises data from this section. 
Table 1-2: Comparative timescale of parameters determining CNT onset.
Action Order Reference 
Retrograde transport speed HCC/T = /A = /E  Restani et al., 2012 
Retrograde trafficked vesicles  (%) HCC/T > /A = /E  Restani et al., 2012 
Translocation rate BoNT/E > /A  Wang et al., 2008 
Translocation rate BoNT/E  > /B   Sun et al., 2012 
SNARE cleavage in vitro BoNT/E > /EA > /A ≫ /AE Wang et al., 2008 
Onset of paralysis BoNT/E >  /A > /B Woodruff et al., 1992 
Onset of paralysis BoNT/D > /A Pellett et al., 2015b 
Onset of paralysis TeNT > BoNT/A Restani et al., 2012 
Cleavage at the CNS BoNT/A ≈ TeNT  Restani et al., 2012 
HCC/A, HCC/E and HCC/T share retrograde trafficking routes and speed of retrogradely 
transported vesicles is similar for the three binding domains (Restani et al., 2012a). However, 
HCC/T has a larger proportion of vesicles directed to retrograde traffic (Restani et al., 2012a). 
BoNT/E has a higher translocation rate than BoNT/A and BoNT/B (Wang et al., 2008; Sun et 
al., 2012). SNAP-25 cleavage occurs quicker after treatment with a LC/E-HCN/E-HCC/A (i.e. 
BoNT/E with the binding domain of BoNT/A, BoNT/EA) chimera than for LC/A-HCN/A-
HCC/E (i.e. BoNT/A with the binding domain of BoNT/E, BoNT/AE). Furthermore, BoNT/EA 
chimera cleaves SNAP-25 at the same rates as BoNT/E (Wang et al., 2008). Cleavage of the 
SNARE targets in central neurons after retrograde trafficking of BoNT/A and TeNT occurs in 
the same time scale (Restani et al., 2012a). Combined, these studies suggest that BoNT/E onset 
is influenced by the translocation efficiency mediated by HCN/E and that HCC/T is efficiently 
retrogradely trafficked to undergo transcytosis and release LC/T into a secondarily intoxicated 
neuron (see section 1.6.2.4). 
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However, the contribution of each domain appears to be different within the same serotype (see 
Table 1-3). Botulism onset first appears for BoNT/A2 intoxications, followed by BoNT/A1, 
/A3, /A4 and /A5 (Pellett et al., 2015c). In cultured neurons, BoNT/A2 has quicker and greater 
effect than BoNT/A1 and these differences are thought to be due to the higher affinity of SV2C 
to HCC/A2 than HCC/A1 (Pier et al., 2011). In addition, HCC/A1 and HCC/A2 share endocytic 
routes and traffic within neurons at the same rate. Therefore, a more efficient binding leads to 
a faster and more pronounced effect (Kroken et al., 2017).  
Table 1-3: Comparative timescale of parameters determining BoNT/A onset.
Action Order Reference 
Time of onset BoNT/A2 > /A1 > /A3 > /A4 > /A5 Pellett et al., 2015c 
Affinity for SV2C BoNT/A2 > /A1 Pier et al., 2011 
Traffic rate BoNT/A = /A2 Kroken et al., 2017 
Actions of the Light Chain 
All LCs are characterised by having a signature motif at the catalytic site (HExxH) responsible 
for zinc coordination (Schiavo et al., 1992a; Schiavo et al., 1992c), which is shown on toxins 
sequences in the Appendices. Other than that, LCs share no sequence major similarities with 
other zinc proteases (Lacy and Stevens., 1999).  
Autolysis 
Recent studies indicate that HCs are not the only responsible for the duration of effect of CNTs, 
as mutations on the C-terminus of LC/A lead to differences in onset (Scheps et al., 2017). 
Although SNARE proteins are the main target of all the LCs, LC/A, B and E can act as a 
protease on their own chains at several positions (Ahmed et al., 2001; Ahmed et al., 2003; 
DasGupta et al., 2005). The products of the reaction derived from auto-proteolysis appear to 
be functional. However, the optimum pH for this auto-proteolysis is close to pH = 4.5, whereas 
SNARE cleavage occurs at pH = 7.3 (Ahmed et al., 2003). Autoproteolysis at sites upstream 
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of Cys430 (the cysteine residue at the LC forming the disulfide bridge) of LC/A can dissociate 
LC/A and HC/A and are able to translocate without the need disulfide bridge reduction.  Thus, 
autolysis has been proposed to be a second mechanism for LC release, occurring when BoNT/A 
is within an acidic organelle (DasGupta et al., 2005; Ahmed et al., 2013; Mizanur et al., 2013). 
Indeed, mutations at sites upstream Cys430 lead to a quicker onset and shorter duration of 
action (Scheps et al., 2017). 
SNARE cleavage 
SNARE targets 
All LCs cleave peptide bonds in SNARE proteins (see Figure 1-18) at the presynaptic terminal 
leading to an inhibition of synaptic transmission (Monteccucco and Schiavo, 1994).  
Figure 1-18. Targets of Clostridial Neurotoxins.  
Diagram showing a vesicle with the SNARE proteins cleaved by the different clostridial 
neurotoxins. SNAP-25 is cleaved by BoNT/A, /C and /E. Syntaxin is cleaved by BoNT/C. 
Synaptobrevin is cleaved by the rest of CNTs (BoNT/B, /D, /DC, /G, /FA, /X and TeNT). 
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Both LC/A and LC/E cleave SNAP-25 (Schiavo et al., 1993a, Blasi et al., 1993a; Binz et al., 
1994; Schiavo et al., 2014). BoNT/B, /D, /F, /G, /FA (or BoNT/H), /X and TeNT cleave 
synaptobrevin (Schiavo et al., 1992b; Schiavo et al., 1992c; Schiavo et al., 1993a; Schiavo et 
al., 1993b; Binz et al., 1993; Yamasaki et al., 1994; Hacket et al., 2018; Masuyer et al., 2018). 
BoNT/C cleaves syntaxin (Blasi et al., 1993b) and SNAP-25 (Schiavo et al., 1995; Foran et al., 
1996). However, the concentration of LC/C necessary to cleave SNAP-25 is 1000 times higher 
than for LC/A or /E (Vaidyanathan et al., 1999). 
Consequences of SNARE cleavage on presynaptic function 
The three SNAP-25-cleaving LCs (LC/A, /C and /E) have been suggested to preferably affect 
a recycling pool of synaptic vesicles (Stigliani et al., 2003; Kitamura et al., 2009). BoNT/A 
only affects the exocytosis of primed vesicles in chromaffin cells (Yang et al., 2002; Sørensen 
et al, 2003). However, BoNT/A cleaves SNAP-25 before the formation of the SNARE complex 
(Hayashi et al., 1994) and this cleavage also affects replenishment of the RRP and affects slow 
endocytosis (Xu et al., 2013). On the other hand, although BoNT/A does not completely block 
synaptic release after total SNAP-25 cleavage, BoNT/E and /C do (Xu et al., 1998). BoNT/E 
also targets the RP (Xu et al., 1999). However, defining the specific effects of toxin serotypes 
awaits more complete understanding of the contributions of the different SNAREs in vesicle 
docking, priming and release (Zimmermann et al., 2014, Schupp et al., 2016).  
Mechanisms underlying differences in persistence 
In comparative studies, BoNT/A shows similar recovery times as BoNT/C after injection and 
this occurs in the scale of months (without recovery after 90 days) (Eleopra et al., 1997; 
Washbourne et al., 1998; Eleopra et al., 1998). The paralysis caused by BoNT/E is significantly 
shorter at 30 days and injected individuals show full recovery after 90 days (Washbourne et 
al., 1998; Eleopra et al., 1998). In vitro, the persistence of BoNT/D and BoNT/E effects is 
similar, measured as persistence of cleaved SNARE proteins (Pellett et al., 2015b). 
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Furthermore, within the serotype A, differences in recovery of muscle function were observed. 
The fastest rate of recovery corresponded to BoNT/A3, followed by the rest of the subtypes 
without major differences (Pellett et al., 2015c). Duration of action was attributed to persistence 
of LC/A activity (Pellett et al., 2018a). Another study showed that point mutations on the C-
terminal end of LC/A1 also lead to differences in the duration of action, as they could be related 
to its autocatalytic activity (Scheps et al., 2017).  
The differences between BoNT/A and BoNT/E, which share protein receptor and SNARE 
target, have been extensively studied. This research has generated four non-mutually exclusive 
explanations for these differences: location, degradation, phosphorylation and SNARE 
complex disturbance.  
Location 
Different LCs have different location. LC/A localises at the plasma membrane, LC/E localises 
in the cytosol and LC/B is distributed throughout the cell (including the nucleus) (Ferández-
Salas et al., 2004a). This location is the same in neuron-like and other cell lines (Fernández-
Salas et al., 2004a; Chen and Barbieri, 2011). These differences in location have suggested to 
be responsible for the differences in persistence between BoNT/A and BoNT/E, particularly 
after the discovery of sequences targeting LC/A to the membrane (Fernández-Salas et al., 
2004b). These sequences were located at the N and C-termini of LC/A (MPFVNKQF and 
FEFYKLL respectively, see the Appendices), and their deletion abolished LC/A distribution 
at the membrane and retargeted it to the cytosol. While the mechanism of the signal at the N-
terminus was not identified, the C-terminal signal was identified to contain an active dileucine 
motif (Fernández-Salas et al., 2004b). These motifs are present mostly in transmembrane 
proteins and they regulate their trafficking by linking them to the cytoskeleton (Johnson et al., 
1998; Boehm and Bonifacino, 2002).  
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The LC/A dileucine motif was directly linked to its long persistence, as genetic inactivation of 
the motif lead to an increase in LC/A degradation (Wang et al., 2008; Vagin et al., 2014). This 
study also revealed that several septins (in order of protein score, Septin-2, Septin-7, Septin-9, 
Septin-6, Septin-11, Septin-3 and Septin-5), a group of proteins linking cytoskeleton to other 
components (Mostowy and Cossart, 2012), bound the active dileucine motif of LC/A (Vagin 
et al., 2014). Moreover, LC/A colocalised with Septin-2 and genetic downregulation or 
pharmacological inhibition of this protein caused a disruption in LC/A location and an increase 
in its degradation. These data gave rise to the hypothesis that the dileucine motif locates LC/A 
at the plasma membrane and to creates a protective environment.  
However, it has been reported that when co-expressed LC/A and LC/E present the same 
distribution, either the corresponding to LC/A (at the membrane) or to LC/E (cytosolic) without 
intermediate phenotypes (Tsai et al., 2010). This observation was not explored or discussed 
further. Other studies show that LC/A is coexpressed with LC/T, this pairing effect is not 
observed and that colocalisation of LC/A and /E only occurs at the cytosol (Chen and Barbieri, 
2011). In addition, expression of a mutant of SNAP-25 with cytosolic location retargets LC/A 
to this space in Neuro2A cells (Chen and Barbieri, 2011). Therefore, LC/A location can be 
altered by manipulating its relation with SNAP-25. In PC-12 or Neuro2A cells, SNAP-25 is 
confined to the membrane (Bajohrs et al., 2004; Fernández-Salas et al., 2004; Chen and 
Barbieri, 2011) but not in primary neuronal cultures (Tafoya et al., 2008, Lau et al., 2010).  
Interestingly, a LC/E-BoNT/A(0) (i.e. an active LC/E followed by the inactive LC/A(0)) 
chimera has longer duration of action than BoNT/E without affecting the SNAP-25 cleaving 
site (Wang et al., 2011).  The duration of SNAP-25 cleavage by LC/E-HCN/E-HCC/A chimera 
is also longer than for LC/E (Wang et al., 2008). LC/C (SNAP-25 cleaving) effects also have 
a remarkable long persistence (Eleopra et al., 1997), while it lacks an active dileucine motif 
(Fernández-Salas et al., 2004b).  
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Thus, taken together, these data indicate that LC location is not the sole mechanism responsible 
for LC/A action duration. 
Degradation 
In SiMa cells, non-ubiquitinated LC/A and LC/E are proposed to be degraded in the lysosome 
through the autophagosome, whereas ubiquitinated forms of LC/A and LC/E would be 
degraded by the proteasome (Vagin et al., 2014). In PC-12 cells, LC/E is more ubiquitinated 
than LC/A (Tsai et al., 2010). This was due to an interaction with the Tumour Necrosis Factor 
Receptor (TNFR)-associated factor 2 (TRAF), a protein that forms ubiquitin-ligating 
complexes (Yang and Sun, 2015). Similarly, conjugation of a cleavage-resistant mutant of 
SNAP-25 to an ubiquitin ligase reduced LC/A lifetime (Tsai et al., 2010). In HEK293T cells, 
genetic knock-down of two deubiquitinating enzymes, Ubiquitin Specific Peptidase 9 X-
Linked (USP9X) and Valosin-containing protein p97/p47 Complex-Interacting Protein p135 
(VCIP135) destabilised LC/A (Tsai et al., 2017). VCIP135 immunoprecipitated with LC/A but 
not with LC/E, while USP9X did not immunoprecipitate with either of the LCs and USP9X-
mediated effects were attributed to increased autophagy. The ubiquitinating enzyme 
Homologous to the E6-AP Carboxyl Terminus Domain E3 ubiquitin protein ligase 2 
(HECTD2) was identified as the ubiquitin ligase for LC/A ubiquitination. Taken with previous 
results from the same group (Tsai et al., 2010), it was suggested that VCIP135 deubiquitinated 
LC/A but not LC/E.  
Phosphorylation 
LC/A to /E and /G are tyrosine-phosphorylated by Src (abbreviation for Sarcoma), a 
cytoplasmic kinase and phosphorylation of LC/A and /E increases their stability (Ferrer-
Montiel et al., 2016). LC/A phosphorylation prevents its autocatalytic activity and this could 
be related to longer persistence (Toth et al., 2012).  
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SNARE complex disturbance 
The fourth explanation is not based on the LCs, but on their cleaved SNAP-25 fragments. 
BoNT/A and /E cleave SNAP-25 at different positions (Binz et al., 1994). The long LC/A-
cleaved SNAP-25 fragment (SNAP-25197) resists degradation when in complex with syntaxin 
(i.e. in the SNARE complex) but not the 9 aminoacid C-terminal fragment (Raciborska and 
Charlton, 1999). SNAP-25197 retains the ability of forming a non-functional SNARE complex 
(Bajohrs et al., 2004) whereas SNAP-25180 is not able to form a SNARE complex and is cleared 
from the synapse (Rickman et al., 2004), leading to a quicker recovery of synaptic function 
than for SNAP-25197 (Meunier et al., 2003).
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Project aims 
As outlined, BoNTs are capable of hijacking intrinsic neuronal machinery to deliver a long-
lasting protease which potently blocks neurotransmitter release. In addition, and seemingly 
paradoxically, it has emerged that they can also have neurotrophic effects. However, 
notwithstanding the extensive literature on individual BoNT domains, the trafficking of full-
length toxins within the cell, the reasons for the persistence of LC/A and the non-toxic effects 
of BoNTs on neuronal outgrowth remain poorly understood. Investigating how BoNTs achieve 
these actions is an interesting and challenging goal in itself. As importantly, greater 
understanding of the mechanisms holds immense potential for the re-engineering of BoNTs 
and/or the biodesign of new proteins with particular BoNT-like properties for many known and 
as yet unexplored therapeutic and synthetic biology applications.  
Therefore, the aims of the work in this PhD thesis were to: 
 Produce tools to study the differences in persistence of action between BoNT/A and 
BoNT/E. 
 Study the endocytic route of BoNT/A and its fate after endocytosis. 
 Identify the molecular basis of BoNT/A-induce neurite outgrowth.   
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Chapter 2 Materials and Methods 
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Materials 
Pipettes and tips 
Pipettes 
P2, P20, P200 and P1000 pipettes were from Gilson. 
Serological pipette controller  
Serological pipette controller was from Integra. 
Tips  
Non-sterile tips for general laboratory use were non-filtered tips from Starlab. Tips were 
sterilised before use. Sterile, filtered tips for cell culture were from Cellstar.  
Serological pipettes 
Serological pipettes were bought to Sterilin.  
Chemicals and reagents 
Chemicals 
General laboratory reagents (e.g. ammonium persulfate (APS) or glycerol) or materials (e.g. 
Parafilm M) were purchased from Sigma unless indicated otherwise. 
Botulinum Neurotoxin 
Both BoNT/A(0) and HCC/A were provided by Ipsen. Aliquots were kept at -70 ºC at a 
concentration of 1 mg/mL. Once an aliquot was thawed, it was kept at 4 ºC for a maximum of 
7 days. Sequences are available at the Appendices. 
Endocytosis blockers 
Both Pitstop 2 (Cat. No. ab120687) and Dynasore (Cat. No. ab120192) were from Abcam. 
Methyl--Cyclodextrin (MCD) was purchased from Sigma (Cat. No. M7439-1G) and 
myristyl-trimethyl ammonium bromide (MiTMAB) from VWR (324411-500MG). Working 
concentrations were 30 M for Pitstop 2, 80 M for Dynasore, 1 mM for MCD and 25 M 
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for MitMAB, all being diluted 1:1000 in dimethyl sulfoxide (DMSO). Stocks were kept at -70 
ºC. 
Signalling blockers 
SU5402 was obtained from VWR (Cat. No. 572630-500) and NSC23766 from Sigma (Cat. 
No. SML0952-5MG). SU5402 stock was 20 mM in DMSO and NSC23766 stock was 50 mM 
in 50% (v/v in water) DMSO and these were kept at -70 ºC. Working concentrations were 20 
M for SU5402 and 100 M for NSC23766. 
Degradation blockers 
Leupeptin was purchased from Generon (Cat. No. 51867.02) and stock was prepared diluting 
the compound in DMSO to a concentration of 30 mM. MG132 was from Thermo Fisher 
Scientific (Cat. No. 15465519) and the stock prepared in DMSO to a concentration of 10 mM. 
Stocks were kept at -70 ºC. 
Synapse activity modulators 
Tetrodotoxin (TTX) (Cat. No. T8024) and bicuculline (Bic) (Cat. No. 14340) were purchased 
to Sigma. Stocks were kept at a concentration of 1 mM and TTX was kept at a locked 
compartment at 4 ºC.  
Buffers and Solutions 
10X phosphate-buffered saline (PBS) consisted of 1.37 M NaCl, 27 mM KCl, 100 mM 
Na2HPO4 and 18 mM K2HPO4 and it was diluted ten times with distilled water before use. 
10X tris(hydroxymethyl)aminomethane (Tris)-buffered saline-Tween (TBS-T) consisted of 1 
M NaCl, 500 mM Tris and 1% (v/v) Tween 20 and pH = 7.6 and it was diluted ten times with 
distilled water before use. 
10X running buffer consisted of 1.92 M glycine, 250 mM Tris and 1% (v/v) sodium dodecyl-
sulfate (SDS) and it was diluted ten times with distilled water before use. 
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10X transfer buffer consisted of 1.92 M glycine and 250 mM Tris. To make 1X transfer buffer, 
one volume of 10X transfer buffer were mixed with two volumes of methanol and seven 
volumes of distilled water. 
0.5X Tris-acetate-ethylenediaminetetraacetic acid (EDTA) (TAE) buffer consisted of 40 mM 
Tris acetate, 1 mM EDTA. 
Buffers for cell culture are detailed in section 2.1.6.5. 
Disposable plastic equipment 
Plates 
Plates and dishes for cell culture were purchased from Sigma (Cat. No. M8812 for 24-well 
plates, Cat. No. M8562 for 6-well plates). 
Tubes 
Centrifuge tubes were from Sigma (Cat. No. 3810X) and tubes for polymerase chain reaction 
(PCR) protocols were from Starlabs (Cat. No. I1405-8100). Conical centrifuge tubes were 
Falcon 15 and 50 mL conical centrifuge tubes by Fisher Scientific (Cat. No. 10788561 and Cat. 
No. 14-959-53A). Tubes were sterilised before use by using an autoclave. 
Cell scraper 
Cell scrapers were from Sigma (Cat. No. C5981). 
Cell strainer  
A Greiner Bio-One CELLSTAR EASY Cell Strainer (Fisher Scientific, Cat. No. 542070) was 
used to filter cortical cells during primary neuronal culture preparation.  
Molecular biology 
Competent cells 
DH-5 Escherichia colI was used for general cloning purposes and were stocked at -70 ºC. 
MAX Efficiency DH-5 Competent Cells (Invitrogen, Cat. No. 18258-012) or XL-1 Blue cells 
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(Agilent, Cat. No. 200236) were used to produce competent cells. BL-21(DE3) E. coli strain 
(Sigma, Cat. No. CMC0015) was used for protein production. Genotypes of these strains are 
as follow: 
E. coli DH5a supE44 Δlac u169 (φ80 lacZΔ M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 
E. coli XL-1Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIq 
Z∆M15 Tn10 (Tetr )] 
E. coli BL21(DE3) F- ompT hsdSB(rB
-mB
-) gal dcm (DE3) 
Inoue’s transformation buffer consisted of a solution with 55 mM MnCl2, 15 mM CaCl2, 250 
mM KCl, 10 mM PIPES and pH = 6.7. 
Media 
Lysogeny broth (LB) medium was from Fisher Scientific (Cat. No. BP1427), 2xYT broth was 
from Fisher Scientific (Cat. No. 50-489-141). 
LB Agar 
LB agar powder to prepare plates for bacterial growth was purchased from Fisher Scientific 
(Cat. No. BP1425). 
Antibiotics 
Ampicillin (Amp) was diluted to a concentration of 100 µg/mL with 50% (v/v) ethanol. 
kanamycin (Kan) was diluted to a concentration of 25 µg/mL with distilled water. Both were 
purchased to Sigma (Cat. No. 10835242001 and Cat. No. 60615-5G). 
Plasmids 
Plasmids for expression in mammalian cells were pXLG3 (modified in the laboratory), pEGFP-
C1 (Clontech) and pCDH-CMV (Systen Biosciences). The plasmid used for bacterial 
expression was pJ401 (Ipsen). 
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Oligonucleotides 
Oligonucleotides were purchased from Sigma. Sequences and purpose are summarised in 
Table 2-1. 
Table 2-1: List of oligonucleotides used.
















































KOD Hot Start Polymerase was from Millipore (Cat. No. 71086). Restriction enzymes, 
CutSmart buffer (Cat. No. B7204S) and calf intestinal phosphatase (CIP) (Cat. No. M0290S) 
were purchased from New England Biolabs. Deoxyribonucleic Acid (DNA) ligase was from 
Takara (Cat. No. 6023). 
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DNA size ladder 
Gene Ruler 1kb DNA ladder was obtained from Thermo Fisher Scientific (Cat. No. SM0311).  
DNA loading buffer 
DNA loading buffer was composed of 50% glycerol and 0.002% (w/v) bromophenol blue 
(Sigma, Cat. No. B0126). 
DNA purification  
GeneJET Plasmid Miniprep Kit (Cat. No. K0502), GeneJET Plasmid MidiDprep Kit (Cat. No. 




Wistar rats used for primary neuronal culture or neural stem cell culture were provided by the 
University animal facilities. SH-SY5Y cells were obtained from the European Collection of 
Cell Cultures (ECACC).  
Primary neuron culture media 
Plating medium consisted of Neurobasal medium (Thermo Fisher Scientific, Cat. No 
21103049) with 5% horse serum (Thermo Fisher Scientific Cat. No 26050088), 1% (v/v) 
GlutaMAX (Thermo Fisher Scientific, Cat. No. 35050061) and B27 complement (Thermo 
Fisher Scientific, Cat. No. 17504044), 100 U/mL penicillin and 100 g/mL streptomycin 
(Sigma Cat. No. P4333). 
For feeding medium, no horse serum was added and the concentration of GlutaMAX was 0.6% 
(v/v). The rest of components were the same. 
To wash cells during dissociation in dissections, Hank’s balanced salted solution (HBSS) from 
Thermo Fisher Scientific (Cat. No. 14170112) was used. 
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Cell counting 
0.4% Trypan blue solution (Thermo Fisher Scientific, Cat. No. 15250061) was used to stain 
cell suspension for counting. Bright-line haemocytometer was from Sigma (Cat. No. Z359629). 
Dissociation reagents 
Both trypsine-EDTA (Cat. No. 25300054) and StemPro Accutase cell dissociation reagents 
(Cat. No. A11105-01) were from Thermo Fisher Scientific. 
Water and buffers 
Endotoxin-free cell culture grade HyClone water was acquired from Fisher Scientific (Cat. No. 
10001342) and 10X DPBS was from Thermo Fisher Scientific (Cat. No 14200075). 
Poly-L-Lysine 
Poly-L-lysine (PLL) was obtained from Sigma (Cat. No. P2636). 
Transfection reagents 
Lipofectaimne 2000 was purchased from Thermo Fisher Scientific (Cat. No. 11668019). 
SDS-PAGE 
Acrylamide  
National Diagnostics ProtoGel 30 Percent Solution acrylamide was purchased to Fisher 
Scientific (Cat. No. 12381469) to prepare SDS-PAGE gels.  
Plastics 
Glass plates, holders, lids and tanks for gel preparation were those by Bio-Rad included in Cat. 
No. 1658033FC (also present in other references in the Bio-Rad catalogue). 
Sample buffer 
4X sample buffer consisted of 40% (v/v) glycerol, 250 mM Tris-HCl pH = 6.8, 0.8% (w/v) 
SDS and 0.009% (w/v) bromophenol blue was used as lysis buffer and sample loading buffer. 
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Molecular weight marker 
PageRuler prestained protein ladder (Thermo Fisher Scientific, Cat. No.  26616) was used as a 
molecular weight marker when running SDS-PAGE. 
Western blot 
Protein transfer 
A polyvinylidene fluoride (PVDF) Immobilon-P membrane (Sigma, Cat. No. IPVH00010) was 
used to transfer SDS-PAGE gels prior to blocking and probing.  
Plastics were those by Bio-Rad included in Cat. No. 1658033FC (also present in other 
references in the Bio-Rad catalogue). 
Blocking reagents 
Dried non-fat milk was from Co-operative food. Bovine serum albumin (BSA) was acquired 
from Thermo Fisher Scientific (Cat. No. BP9703-100). 
Stripping buffer 
RestorePLUS Western blot stripping buffer purchased from Thermo Fisher Scientific (Cat. No. 
46430). 
Electrochemiluminescence substrates 
Electrochemiluminescence (ECL) substrates used were SuperSignal West Pico PLUS 
Chemiluminescent Substrate from Thermo Fisher Scientific (Cat. No. 34580), Immobilon 
Forte Western HRP substrate from Merk (Cat. No. WBLUF0100), and SuperSignal West 
Femto Maximum Sensitivity Substrate from Thermo Fisher Scientific (Cat. No. 34095). 
X-ray films 




16% paraformaldehyde (PFA) stock was obtained from Thermo Fisher Scientific (Cat. No. 
28908). This was diluted using PBS to 4% and stored at -20 ºC for use. 
PFA blocking 
Glycine powder was bought to Severn Biotech (Cat. No. 30-21-60). 
Cell membrane permeabilising reagents 
Triton X-100 was obtained from Sigma (Cat. No. X100).
Microscope slides 
Microscope slides were from VWR (Cat. No. 631-1551). 
Coverslips 
Glass coverslips slides were from VWR (Cat. No. 631-0148). 
Mounting medium 
Mounting medium used for immunofluorescence protocols was Fluoromount G with 4′,6-
diamidino-2-phenylindole (DAPI) from Thermo Fisher Scientific (Cat. No 00-4959-52). 
Immersion oil 
Type N immersion oil by Nikon was used for wide field imaging. Type A immersion oil by 
Leica was used for confocal imaging. 
Antibodies 
Primary antibodies 
For western blotting, the following antibodies were used (Table 2-2). 
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Table 2-2: List of antibodies used for western blot.
Antibody Species Provider Cat. No. Concentration 
BoNT/A Rabbit Ipsen ­ 1:600 
ERK1/2 Mouse Sigma M3807 1:300 
GAPDH Mouse Abcam ab8245 1:10000 
GFP Mouse Abcam ab1218 1:10000 
LC/A Mouse Listlabs 731L 1:1000 
pERK1/2 Mouse Sigma M7802 1:1000 
Rac1 Mouse CST 8815 1:1000 
SNAP­25 
(cleaved) 
Mouse Ipsen ­ 1:1000 
SV2A Mouse Calbiochem 573801 1:1000 
Primary antibodies used for immunofluorescence are listed below: 
Table 2-3: List of antibodies used for immunofluorescence.
Antibody Species Provider Cat. No. Concentration 
AnkG Mouse Neuromab N106136 1:500 
BoNT/A Rabbit Ipsen ­ 1:200 
EEA1 Mouse BD Biosciences 610457 1:200 
LC/A Mouse Listlabs 731L 1:500 
Tuj1 Rabbit Sigma T2200 1:200 
Secondary antibodies 
HRP-coupled secondary antibodies for western blotting and fluorescently labelled secondary 
antibodies for immunofluorescence protocols were from Jackson ImmunoResearch. Western 
blot secondary antibodies were diluted 1:10000 in 5% milk (w/v) TBS-T and 
immunofluorescence antibodies were diluted 1:500 in 3% BSA (w/v) in PBS. 
Electronic devices 
Centrifugues 
Benchtop centrifuges were from Eppendorf.  
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Bacterial incubator 
Temperature-controlled shaking bacterial incubator was from RS Biotech. Static incubator was 
from LTE Scientific. 
PCR machine 
MJ Research PTC-2000 thermal cycler was used to control temperature while cloning. 
Heat block 
For sample boiling, a heat block with shaking mechanism by Eppendorf was used. 
Microscopes 
For wide field microscopy, a Nikon Ti microscope with a Plan Apo VC 60x oil DIC lens and 
Andor DU-885 camera.  
A Leica SP5-AOBS confocal laser scanning microscope with a Leica DM I16000 inverted 
epifluorescence microscope was used for confocal imaging. 
SDS-PAGE power supply 
PowerPac Basic packs were from Bio-Rad (Cat. No. 1645050).  
SDS-PAGE imaging system 
Gel Doc XR+ Gel Documentation System (Bio-Rad Cat. No. 1708195) was used to image 
results of stained SDS-PAGE gels. 
Spectrophotometers 
A NanoDrop machine from Thermo Fisher Scientific was used for measuring DNA 
concentration. A Plate reader from BioRad was used for measuring absorbance in culture 
plates. 
Software 
Office 365 software (Word, Excel, PowerPoint) by Microsoft were used for the writing of this 
thesis, calculations and the design of tables and figures. 
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In silico DNA worked used A plasmid Editor (ApE) software by M. Wayne Davis (earliest 
version used was v2.0.49) as a basis. Translation of DNA sequences was done using ExPASy 
by the Swiss Institute of Bioinformatics. DNA sequences were aligned using Clustal Omega 
service by the European Molecular Biology Laboratory-European Bioinformatics Institute 
(EMBL-EBI). Modification of the display of protein 3D structures was done using the Protein 
Data Bank (PDB) on-line tool. 
NIS-Elements AR software was used to acquire images with wide field microscopes unless 
indicated otherwise. Leica Application Suite was used to acquire images with confocal 
microscopes. Fiji is Just ImageJ (FIJI) was used for processing and analysing images.
Methods 
Molecular Biology 
Polymerase chain reaction  
Fragment amplification 
Amplification of sequences for cloning or bacteria colony screening was done by PCR. PCR 
cycles consisted of 98° C for 2 min, followed by three steps consisting of temperatures at 98° 
C for 10 seconds (s), 55° C for 15 s and 70° C for 30 s, repeated 25 (40 for colony screening) 
times and a last step at 70° C for 5 min. Primers were designed with a variable sequence 
matching the template plus a restriction site plus six extra random nucleotides at the 5’ end. 
Theoretical melting temperatures were adjusted to 60 ± 1° C to standardise protocols. Primer 
concentration was 0.3 M. 
Site directed mutagenesis 
Site-directed mutagenesis (SDM) reactions were set as follows. Two independent tubes were 
prepared with the concentrations for each individual primer being 0.3 M as for general PCR 
purposes. Then, two individual PCR reactions were set under the following protocol: 5 min at 
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98° C and a loop repeated 3 times of steps being 30 s at 98° C, 30 s min at 55° C and 4 min at 
70° C. After this, contents from both tubes were mixed and another PCR was run with the same 
time and temperature conditions as the previous reaction, and the same cycle structure but 
repeated 18 times. Reaction was finished with an extra elongation step at 70° C for 5 min. 
Oligonucleotides annealing 
Annealing of complementary oligonucleotides was achieved by mixing both oligonucleotides 
at a 20 M concentration in CutSmart buffer and running a program in a thermal cycler 
consisting of 98° C for 2 min, and steps at 70° C, 65° C, 60° C and 55° C for 4 min each, and 
a finishing step at 37° C for 20 min.  
Endonuclease digestion 
DNA digestion using bacterial endonucleases was done using appropriate restriction enzymes 
in CutSmart buffer and incubated for 2 hours (h) at 37° C. DNA was not diluted to perform 
this step. Reaction was finished by heat inactivation at 95 ºC for 10 min and the reaction was 
left to cool down at room temperature for 15 min before starting following steps. 
DNA dephosphorylation 
Removal of phosphate groups of digested DNA was done by addition of 1 L of Calf Intestinal 
Phosphatase (CIP) 1 h after starting the digestion of the DNA fragment and left for 1 h at 37° 
C. Then, CIP (and endonuclease present in the tube) was heat-inactivated by at 95° C for 5 min 
and the reaction was left to cool down at room temperature for 15 min before starting following 
steps. 
Ligation of DNA fragments 
Ligation of DNA fragments was done by incubation with T4 ligase for 2 h at room temperature 
or 16° C overnight.  
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Agarose gel electrophoresis 
For DNA visualisation, samples were loaded onto agarose gels and run for 30 min at 135 V. 
Agarose content was adjusted depending on the size of the DNA to be visualised, typically 
using 0.8% (for > 1000 base pairs (bp)) or 1.5% agarose gels (for < 1000 bp) in 0.5 X TAE 
buffer. 
Competent cell production 
The protocol to prepare competent cells was adapted from Inoue et al (1990). Cells were plated 
on a LB-Agar plate and grown overnight at 37° C. Single colonies were picked and inoculated 
in a flask containing 2xYT medium at 37° C and constant shacking for 8 h. After this time, 
samples of the culture were inoculated into different flasks and grown at 18° C with constant 
shacking until the culture reached a OD600 = 0.55. When this occurred, the flask was cooled 
down on ice for 10 min and cells were harvested by centrifugation at 2500 g for 10 min at 4° 
C. Pelleted cells were washed by resuspension in cold Inoue’s transformation buffer and 
centrifugation under the same conditions. Cells were again resuspended in cold Inoue’s 
transformation buffer and added DMSO to a final concentration of 7.5% (v/v) and aliquoted. 
XL-1 blue E. coli strain was used for cloning into the pXLG3 vector. 
Bacterial transformation 
Competent cells were transformed by mixing 50-500 ng of DNA to 50 mL of bacteria 
suspension and incubated on ice for 10 min. DNA uptake was forced by heat shock (42° C for 
90 s for DH-5a cells, 60 s for XL-1 blue cells). After it, bacteria were placed back on ice for 2 
min, added 1 mL of LB medium and recovered for 1 h at 37° C. Cells were harvested by 
centrifugation at 8000 g for 1 min, then resuspended in 200 L of medium and plated in 
antibiotic-containing agar plates. 
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Bacterial culture 
Single colonies were picked with sterilised pipette tips and inoculated into LB medium for 
DNA purification (3 mL for miniprep, 100 mL for midiprep). Kanamycin or ampicillin were 
added to the cultures to a final concentration of 30 g/mL and 100 g/mL, respectively. DH-
5a cells were grown over a period of 16-18 h, while XL-1 blue cells were grown for 24-26 h 
before starting the purification protocol. 
DNA purification 
Minipreps were performed using described kits following instructions by the manufacturer. 
Midipreps were performed following the instructions by the manufacturer until column 
binding. 1 mL aliquot of the cell lysate was incorporated into miniprep columns and eluted 
following miniprep protocol. The remaining lysate was stored at -20 ºC. 
DNA quantification 
DNA concentration was measured using NanoDrop technology with the solution in which 
DNA was eluted as blank reference. 
Sequencing 
DNA sequencing reactions were externalised using Eurofins Genomics services. 
In silico DNA work 
DNA sequences were aligned using Clustal Omega service by the EMBL-EBI. 
Translation of DNA sequences was done using ExPASy by the Swiss Institute of 
Bioinformatics. 
Plasmids were designed and annotated using ApE software by M. Wayne Davis (earliest 
version used was v2.0.49). 
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Cell culture 
Primary neuronal culture 
Hippocampal and cortical neurons were extracted from Wistar rat embryos at embryonic day 
18 (E18). Pregnant rats were anesthetised with isoflurane prior to sacrifice by cervical 
dislocation by a trained member of the laboratory following Schedule 1 technique according to 
the regulation at the time. Embryos were taken with a ventral incision on the pregnant rat and 
killed by decapitation. Brains were extracted and midbrain and meninges were removed. Then, 
hippocampus was extracted and saved for dissociation. The rest of the brain was considered as 
cortex and saved for dissociation.  
Hippocampi and cortices were washed three times in HBSS (10 mL for hippocampi, 30 mL for 
cortices) and then dissociated by adding 10% trypsin-EDTA in HBSS (to a total of 10 mL for 
hippocampi, 30 mL for cortices) and left for 10 or 15 min for hippocampi and cortices 
respectively in a water bath at 37 ºC. Then, these were washed with HBSS as described before 
and washed once with plating medium with 1 mL or 5 mL for the respective parts. 1 mL or 5 
mL of plating medium were added to them and dissociated by mechanical disruption. Then, 
cortical cell suspension was transferred to a fresh tube through a cell strainer. Volumes were 
raised to 5 mL and 25 mL with plating medium and cells counted.  
Unless indicated otherwise, cortical neurons were used for biochemical procedures and 
hippocampal neurons were used for imaging. This decision was taken because of the smaller 
amount of hippocampal cells available after dissection and the larger size of these when 
compared to cortical cells, making them more reliable for imaging studies Cells were plated at 
a density of 500,000 cells/well (of a 6-well plate) for biochemistry and 200,000 cells/well for 
imaging to facilitate single-cell imaging. 
On Day In Vitro (DIV) 1, plating medium was substituted with feeding medium. 
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PLL coating 
Plate wells or coverslips were coated with PLL at a final concentration of 0.1 mg/mL at 37° C 
for at least 2 h. PLL was washed three times with water. For SH-SY5Y, Dulbecco's modified 
Eagle medium (DMEM) with 10% FBS and antibiotics was added after coating. For NSCs this 
was growth medium and for neurons, plating medium. 
Coverslips were stored in 70% ethanol and washed three times before coating.  
Cell counting and plating 
Cells were counted by mixing cells with Trypan blue solution in a 1:10 ratio, placing the 
content into a haemocytometer and counted manually using a microscope. Cells were plated 
into coated dishes containing pre-warmed medium. Cells subject to immunofluorescence 
protocols were plated on coverslips. 
Lipid-based transfection 
Transfection procedures were done using Lipofectamine 2000. Variable amounts of DNA (1-
4 g DNA) and the corresponding amount of Lipofectamine 2000 (1-4 L) were incubated 
with 250 L of plain Neurobasal medium, vortexed briefly and incubated at room temperature 
for 5 min. Then, DNA and Lipofectamine 2000 solutions were mixed drop by drop, vortexed 
for 10 s and incubated for 45 min at room temperature. Then, 0.5 mL of pre-warmed plain 
Neurobasal medium were mixed with the DNA-Lipofectamine mix and applied to the cells. 
For transfections of cells cultivated on coverslips, coverslips were taken from their original 
culture wells, washed by immersion in an independent well containing pre-warmed plain 
Neurobasal medium and placed into wells containing DNA-Lipofectamine mixes diluted 1:1 
with plain Neurobasal medium, being incubated for 2 h at 37° C. After this time, coverslips 




Cultures were exposed to 25 nM BoNT/A(0) or HCC/A for 10 min for endocytosis studies 
unless indicated otherwise. These exceptions are experiments where treatment length is a 
compared variable between conditions and experiments studying long-term effects of the toxin. 
Other time durations are specified for specific experiments.  
Toxin treatments were prepared in a single tubes and applied simultaneously for all the 
conditions within an experiment unless stated otherwise.  
Endocytosis blockers  
Pitstop 2 (30 M) or Dynasore (80 M) were prepared by diluting the drug in plain Neurobasal 
medium. MiTMAB or MCD were diluted in feeding medium to working concentrations of 25 
M and 1 M, respectively. Treatments were applied 30 min before BoNT/A(0) was applied 
to the culture and left in presence of the toxin. 
Potassium depolarisation 
A membrane depolarising stimulus was achieved by setting KCl concentration to 50 mM.  
Synaptic modulators 
TTX was used at a concentration of 1 M and applied 16 h before BoNT/A(0) was incorporated 
to the culture. Bic was used at a concentration of 1 M and applied 1 h before BoNT/A(0) was 
applied to the culture. 
Signalling inhibitors 
SU5402 was used at 20 M, and NSC23766 at 100 M. Treatments were applied in 
combination with BoNT/A(0) unless studying endocytosis, when SU5402 was added 30 min 
prior to toxin treatment.  
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Degradation inhibitors 
Leupeptin was diluted to a working concentration of 30 M, and MG132 to 10 M in 
conditioned medium and feeding medium separately. Treatments prepared in conditioned 
medium were applied 30 min before applying BoNT/A(0). After this time, these treatments 
were removed, and pre-warmed feeding media containing both the toxin and the degradation 
inhibitor at the concentration specified was applied to the corresponding cultures and kept 
during treatment (10 min). After that time, BoNT/A(0)-containing feeding medium was 
removed, cells washed and conditioned media with the respective treatments was reapplied and 
left for 18 h in the incubator. 
SDS-PAGE 
Gel preparation 
Acrylamide resolving gels consisted of 375 mM Tris-HCl, 8% (w/v) acrylamide, 0.1% (w/v) 
SDS, 0.1% (w/v) APS, 0.01% (v/v) tetramethylethylenediamine (TEMED) and pH = 8.8. These 
components were gently mixed and the solution was poured between two glass plates sealed at 
the bottom before polymerisation occurred. Then, a small volume of propan-2-ol was used to 
equilibrate the top of the gel. This was washed after polymerisation. Then, a second gel was 
made. This stacking gel consisted of 125 mM Tris-HCl, 5% (w/v) acrylamide, 0.1% (w/v) SDS, 
0.1% (w/v) APS, 0.01 (v/v) TEMED, pH = 6.8. This gel was poured between the glass plates 
before polymerisation. A comb was also introduced before this occurred. 
Sample preparation 
To prepare samples to be run by SDS-PAGE, 4X sample buffer was diluted four times. Unless 
specified otherwise, cells were washed with PBS twice and 1X sample buffer was directly 
applied onto them. Then, cells were scraped from the plate and the suspension was transferred 
to a centrifuge tube to be boiled for 10 at 95 ºC. 
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Electophoresis 
Samples were loaded into 8% acrylamide gels and run in running buffer for 30 min at 80 V and 
60 min at 200 V, unless specified otherwise. 
Western blot 
PVDF membrane activation 
PVDF membranes were cut to the appropriate size for the gel and were activated by immersion 
in pure methanol for 1 min under constant shaking. 
Transfer of proteins 
Proteins in acrylamide gels were transferred by placing the gel on a PVDF membrane 
submerged in transfer buffer and applying a current of 0.4 A for 90 min with an ice pack within 
the tank and constant stirring. 
Blocking 
After protein transfer, membranes by immersion in TBS-T with 5% (w/v) dry milk for 1 h at 
room temperature and constant mixing. 
Antibody probing 
Antibodies were diluted to the specified concentration in TBS-T with 2% (w/v) milk and 
incubated with the membranes overnight at 4 ºC under constant shaking or rotation. Then, they 
were rinsed in TBS-T and washed three times in TBS-T for 10 min. Secondary antibodies were 
diluted in TBS-T milk and incubated with the membranes for 1 h at room temperature under 
constant shaking and then washed as done for the primary antibody.  
Membrane stripping 
Membranes to be re-probed were washed and dried by contact with a piece of absorbent paper. 
Then, they were immersed in stripping buffer for 10 min under constant mixing. 
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Membrane developing 
Membranes were washed with PBS and the excess was eliminated by contact with absorbent 
paper. ECL was applied and evenly distributed on the membranes, which were then sealed with 
plastic film. In a darkroom, an X-ray film was placed onto the membrane for a variable amount 
of time and placed into the developer. Molecular weight was inferred by annealing a 
luminescent mark in the cassette with its print in the developed X-ray film.  
Densitometry analysis 
X-ray films were scanned and, using FIJI software, images were cropped and intensity of bands 
and background measured. Intensity of the bands was subtracted from the value of the 
background and normalised to the corresponding control. 
Immunofluorescence 
Fixation 
Coverslips were washed two times with PBS and then fixed with pre-warmed 4% PFA in PBS 
for 10 min at room temperature on a nutator.  
Membrane permeabilisation 
Fixed coverslips were washed two times with PBS and two times with 100 mM glycine. In 
order to block non-specific interactions and permeabilised cell membranes, coverslips were 
incubated with PBS with 3% (w/v) BSA and 0.1% Triton X-100 for 20 min at room temperature 
on a nutator. Coverslips were then washed once with PBS with 3% BSA to remove residual 
Triton X-100. 
Antibody probing 
Antibodies were diluted with PBS with 3% (w/v) BSA to their appropriate working 
concentrations. Antibodies mix (25 L for 13 mm coverslips, 75 L for 25 mm coverslips) was 
placed onto a clean Parafilm surface. Coverslips were picked with forceps, dried by contact 
80 
with a piece of absorbent paper and placed facing down onto the drop of antibody mix for 45 
min at room temperature, except for -BoNT/A antibody, which was incubated at 4 ºC 
overnight, as well as antibodies incubated together with -BoNT/A. Then, coverslips were 
washed three times with PBS. Secondary antibodies were diluted with PBS with 3% (w/v) BSA 
and coverslips were incubated as described above for 1 h at room temperature. Coverslips were 
then washed twice with PBS and twice with distilled water to eliminate any salt.  
Mounting 
Coverslips were picked with forceps, dried with a piece of absorbent paper and mounted onto 
microscope slides. To do this, 13 mm and 25 mm coverslips used 13 L and 40 L of mounting 
medium with DAPI, respectively. Preparations were left at least 24 h before any imaging was 
done to ensure drying of mounting solution. 
Microscopy 
Fixed cell microscopy 
Imaging of fixed cells on coverslips was performed using the mentioned microscopes. For 
confocal microscopy, channels were sequentially acquired after the previous one. For wide 
field microscopy, this was done manually without altering the focus of the image. 
Image processing 
Unless specified otherwise, scale bar sizes used within a figure are applicable to all images. In 
addition, images within a figure have the same dimensions unless specified otherwise. These 
were calculated using FIJI freeware. 
Channel images were merged using FIJI, as well as stack production.  
Dendritic/axon zoom panels were generated using FIJI by rotating neurons so the neurite was 




Colocalisation analysis were done using Coloc 2 tool. Values represented in this thesis 
correspond to Manders’ coefficient of colocalisation (Manders et al., 1993), representing the 
fraction of a channel’s signal overlapping with pixels with a positive signal in the second 
channel. 
Axon length 
Axons were identified as AnkyrinG-positive neurites and their length measured with the 
freehand line selection tool of FIJI. 
Filopodia counting 
Filopodia were counted as neurite protrusions with three requisites: 1) without an end wider 
than the body of the protrusion, 2) with a length at least twice than the width, 3) with a length 
shorter than 10 m. 
NSC differentiation quantification 
Differentiated NSC cells were those positive for III-tubulin (TuJ1) staining. 
Statistical analysis 
Statistical analysis was done using MatLab and plots and graphs created using Microsoft Office 
Excel, as well as data handling and calculations. The following tests were carried out: Student’s 
t-test (ttest), one-way analysis of variance (ANOVA) (anova1) followed by multiple 
comparison tests (multcompare) with Tukey’s correction (tukey-krame). 
Data are presented as mean ± standard error of the mean (SEM) unless indicated otherwise. 
Safety 
All procedures were approved by the corresponding officers from the University of Bristol and 
Ipsen.  
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In the course of this project, no protease active full-length botulinum neurotoxin was produced. 
It is important to note that in the context of BoNT production, protein activation specifically 
refers to hydrolysis of the peptide bond connecting LC and the HC and not to reconstitution of 
peptidase activity. Toxins labelled as (0) denote toxins in which protease activity has been 
removed by site-directed mutagenesis on their respective genes (see section 1.3.3.4 and 4.2.2). 
This is only applicable to LC and BoNT, as HC does not present any protease activity. 
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Chapter 3 Production and Expression of eGFP-LC Constructs 
84 
Aims 
The aim of this chapter was to develop and validate tools to study the mechanisms underlying 
LC/A effects persistence. To do this, I cloned fluorescently tagged constructs with focus on 
LC/A and its N- and C-terminal sequences (NA and CA), involved in location and persistence. 
I overcame difficulties regarding protein expression and later determined the potential of these 
sequences to target proteins to particular cellular comparments, as well as assessing the role of 




Due to the structure of BoNTs, independent labelling of the two chains to perform live imaging 
studies of each chain independently is an intricate task. 
GFP-tagged molecules are one of the simplest ways to monitor the localisation and fate of the 
protein. However, expression of BoNT with a GFP-tagged LC could alter toxin function, since 
the size and tight structure of Green Fluorescent Protein (GFP) (Ormö et al., 1996) could 
interfere with the LC translocation process to cross the membrane through the channel formed 
by the HC (Koriazova and Montal, 2003).  
Instead, heterologous expression of GFP-LC constructs is possible for studies other than 
endocytosis and trafficking of the toxin. This has to been done by other groups (Fernández-
Salas et al., 2004a; Fernández-Salas et al 2004b; Tsai et al., 2010; Chen and Barbieri, 2011; 
Wang et al., 2015). However, location of the GFP tag has been shown to alter the expression 
of LCs as well as its location (Fernández-Salas et al., 2004b). 
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Differences in persistence between LC/A and LC/E effects 
As explained in the introduction (section 1.7.3), four current models aim to explain persistence 
of effects caused by LC/A and these will be the focus of this chapter. 
Materials and Methods 
Materials 
LDH release assay 
Lactate Dehydrogenase (LDH) Activity Assay Kit (Sigma-Aldrich, Cat. No MAK066) was 
used to measure LDH release. 
SH-SY5Y medium 
For SH-SY5Y culture, DMEM medium from Sigma (Cat. No. D5030), and it was 
supplemented with 10% Foetal Bovine Serum (FBS) (Cat. No. 10082147) and 100 U/mL 
penicillin and 100 g/Ml (Sigma Cat. No. P4333) was used. 
Methods 
LDH release assay 
LDH release assay was done following the recommendations by the provider. 
SHSY5Y cell culture 
SH-SY5Y cells were grown in DMEM with 10% FBS, and 100 U/mL penicillin and 100 g/mL 
streptomycin. They were split when confluence reached 80% approximately and only cells with 




I amplified the LC/A-encoding gene by PCR from the non-tagged protein sequence in a pK8 
plasmid and cloned it into pEGFP-C1 vector, creating a eGFP-LC/A construct. Cells were 
transfected with this vector and the pEGFP-C1 vector control. eGFP-LC/A expression was 
undetectable while control cells expressed eGFP to a normal level. Since this LC construct did 
not express (Figure 3-1B), another vector was created to study the roles of certain sequences 
within LC/A that could affect its location. 
Figure 3-1. Expression of LC/A-derived constructs in neurons. 
A) Summary of the constructs used. eGFP is shown in green, LC/A in blue and NA and 
CA in purple. 
B) Representative images of DIV14 hippocampal neurons transfected with eGFP-based 
constructs. Scale bars are 10 m. 
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As explained in the introduction (section 1.7.3.1), NA and CA have been shown to be necessary 
for LC/A location but not to be sufficient for it (Fernández-Salas et al., 2004a). To test whether 
these are sufficient, without the possibility of expressing eGFP-LC constructs at the moment, 
I cloned NA and CA into the N- and C-termini of eGFP by restriction at both sides and ligation 
of annealed oligonucleotides encoding for these sequences. A diagram of the three constructs 
is provided (Figure 3-1A). GFP, eGFP-LC/A and NA-eGFP-CA were transfected into neurons 
(Figure 3-1B, third panel). Expression of NA-eGFP-CA was successful with the fluorescent 
signal distributed homogeneously throughout the cell body and processes. This indicates that 
NA and CA are not sufficient to target a protein to the compartment that LC/A uses in cells to 
protect itself.  
eGFP-4G-LC expression 
Expression of LC constructs in neurons 
NA-eGFP-CA was expressed in neurons but the main tools needed, i.e. vectors expressing 
eGFP-tagged LCs were not. To solve the problem of expression, I redesigned the protein to 
contain a glycine bridge (Gly-Gly-Gly-Gly-Ser), hereafter abbreviated as 4G, between eGFP 
and the LC. This bridge has been shown to improve flexibility of tagged proteins and improve 
protein expression (van Rosmalen et al., 2017).  
In addition to LC/A two more constructs containing LC/E were created. Unlike LC/A, LC/E is 
not targeted to the membrane but shares many characteristics with LC/A, most notably cleaving 
the same SNARE protein (Fernández-Salas et al., 2004a; Fernández-Salas et al., 2004b). 
Therefore, since NA and CA were not sufficient to target a protein (enhanced GFP, eGFP) to 
the membrane, I created a LC/A-LC/E hybrid consisting in eGFP-4G-NA-LC/E-CA with the 
sequence of LC/E flanked with LC/A-targeting sequences. 
Furthermore, I explored the possibility of whether cleaving SNAP-25 influenced LC/A 
location, as LC/A colocalises with cleaved SNAP-25 but not with total SNAP-25 (Fernández-
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Salas et al., 2004a). I created an endo-negative version of LC/A, LC/A(0), with two mutations 
targeting the zinc-binding pocket: E224Q and H227Y. 
For eGFP-4G-LC/A, the glycine bridge was incorporated by site-directed mutagenesis using 
the eGFP-LC/A vector shown in Figure 3-1 and introducing the coding sequence (for 
protocols, see 2.2.1.1).  eGFP-4G-LC/E was generated from a pEGFP plasmid by the same 
means. LC/A(0) sequence to clone eGPF-4G-LC/A(0) was generated by PCR from a vector 
coding BoNT/A(0). eGFP-4G-NA-LC/E-CA was generated from eGFP-LC/E by restriction and 
ligation of the NA and CA-coding annealed oligonucleotides and site-directed mutagenesis to 
introduce the glycine bridge.  
These results were verified by sequencing. The structure of these constructs is summarised in 
Figure 3-2. 
I first tested SNAP-25 cleavage by LC/A. Cell lysates of cell cultures transfected with these 
constructs were run in a western blot and probed with an antibody specifically targeting LC/A-
cleaved SNAP-25 (Figure 3-3A). A band at the height of LC/A-cleaved SNAP-25 appeared at 
Figure 3-2. Summary of eGFP-4G-LC constructs.
Scheme of the proteins encoded by the cloned vectors. eGFP is shown in green, the glycine 
bridge in red, LC/A in blue, NA and CA in purple, and LC/E in peach colour. An X denotes an 
inactivated catalytic site. 
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the lane corresponding to LC/A-transfected cells, but not for eGFP, eGFP-4G-LC/A(0) or  
eGFP-4G-NA-LC/E-CA. This confirmed that eGFP-4G-LC/A was an active molecule capable 
of SNAP-25 cleaving producing SNAP-25197, whereas LC/A(0) as inactive. eGFP-4G-NA-
LC/E-CA did not cleave SNAP-25 at the BoNT/A site suggesting that NA and CA do not provide 
substrate specificity. Furthermore, bands at 75 kDa were observed for LC-transfected lane 
samples, confirming expression of the LCs.  
To further explore the factors causing LC/A specific location, hippocampal cultures were 
transfected with constructs encoding for eGFP, eGFP-4G-LC/A, eGFP-4G-LC/A(0) and 
eGFP-4G-NA-LC/E-CA, and imaged. A construct expressing eGFP-4G-LC/E was included as 
a control for cytosolic expression of a LC (Figure 3-3B). 
Differences in location between these constructs were observed. The control eGFP-4G-LC/E 
was expressed in the cytoplasm and not solely in the cell membrane. eGFP-4G-LC/A(0) was 
expressed throughout the cell body, suggesting SNAP-25 cleavage plays a role in LC location. 
eGFP-4G-NA-LC/E-CA presented the same distribution as eGFP-4G-LC/E, suggesting that 
these sequences have a limited importance in LC location. Interestingly, LC/A displayed 
variable distribution patterns ranging from diffuse in the cytosol to being clustered at the 
membrane.  
Unfortunately, however, the efficiency of the transfection with LCs, but not with eGFP alone, 
was low and health of all of the LC-transfected neurons transfected was compromised, as it can 
be interpreted by the low number of nuclei present in the images (Figure 3-3B). 
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Figure 3-3. Expression of eGFP-4G-LC constructs in neurons.
A) Western blot results of total lysate samples from DIV14 cortical neuron transfected 
with eGFP or eGFP-4G-LCs containing LC/A sequences probed for eGFP, and SNAP-
25197. 
B) Representative images of DIV14-17 hippocampal neurons transfected with eGFP or 
eGFP-4G-LC constructs. Triangle represent gradient of distribution. Scale bars are 10 
m. 
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Toxicity of LC constructs 
I specifically tested toxicity of my constructs. This was measured using LDH release, an 
indicator of membrane integrity and cell health (Grundmann and Pichmaier, 1973; Kaja et al., 
2017). Cortical cultures were transfected with LC constructs and released LDH measured after 
1 day. Quantification of this assay corresponds to Figure 3-4. 
For eGFP-4G-LC/A, LDH release was 1.17 ± 0.07 times higher than control values. eGFP-4G-
LC/A(0) presented values 1.16 ± 0.08 times higher than the control and eGFP-4G-NA-LC/E-
CA had values 1.22 ± 0.14 times higher than those for the control. None of these results were 
significantly higher than the control. However, the similar trend was observed within the LC 
groups. In addition, because only a small fraction of neurons was transfected and putatively a 
higher amount of LDH, I thought that LC constructs were toxic in this model regardless of 
Figure 3-4. Toxicity of eGFP-4G-LC constructs in neurons.
LDH assay quantification for DIV14 cortical cells transfected with eGFP or eGFP-4G-LC 
constructs. Data is represented as mean values ± SEM. ANOVA followed by Tukey post hoc 
test. N = 4. 
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SNAP-25 cleavage. This, together with the low efficiency of transfections, lead me to explore 
alternative assay systems. 
Expression of LC constructs in SH-SY5Y 
I then tested a different model, SH-SY5Y cells, to determine if this cell line improved the 
transfection efficiency and reduced toxicity. These are a human neuroblastoma cell line that 
can be differentiated to form dopaminergic-like cells (Oyarce and Fleming, 1991) and have 
been used to study BoNTs previously (Purkiss et al., 2001). Transfection with eGFP or the LC 
constructs yielded similar results to those observed in neurons (Figure 3-5). After 3 days, a 
noticeably lower transfection yield for the different eGFP-LC constructs than for the eGFP 
control was observed, with transfected cells forming clusters after proliferation of the originally 
transfected cells.  
To overcome the issue of transfection efficiency I considered the use of lentiviral vectors to 
deliver the different LCs. However, after initial consultation, due to potential safety concerns 
this approach was denied by University of Bristol biological safety committee.  
Therefore, with the low efficiency of transfection and the difficulties regarding toxicity, this 
aspect of the project was ended at this point. 
Figure 3-5. Expression of eGFP-4G-LC constructs in SH-SY5Y cells.
Representative images of DIV3 SH-SY5Y cells transfected with eGFP or eGFP-4G-LC 
constructs. Scale bar is 10 m. 
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Discussion 
First, the successful expression of LCs by introducing a glycine bridge between this peptide 
and the eGFP tag has highlighted the importance of protein flexibility in protein synthesis (van 
Rosmalen et al., 2017). In addition to this confirmation, I made a series of interesting findings. 
Involvement of NA and CA in LC/A location 
Published results affirm that the existence of a membrane targeting peptide (NA) and a dileucine 
motif (CA) in LC/A are responsible for LC/A location and persistence (Fernández-Salas et al., 
2004a; Wang et al., 2008; Vagin et al., 2014). The mechanism relies on the interaction of LC/A 
with septins, as explained earlier (section 1.7.3.1). Deletion or functionally mutation of the NA
and CA interaction sequences in LC/A resulted in cytosolic localisation rather a membrane 
distribution (Fernández-Salas et al., 2004a). These data indicate that NA and CA are necessary 
but do not prove that they are sufficient. I have shown that a fusion construct using NA and CA
(NA-eGFP-CA) is not able to be targeted to the membrane but is present throughout the cell 
(Figure 3-1). Furthermore, like eGFP-LC/E, an eGFP-NA-LC/E-CA construct located at the 
cytoplasm (Figure 3-3; Fernández-Salas et al., 2004a; Fernández-Salas et al., 2004b) 
suggesting that NA and CA domains are not sufficient for membrane localisation. Therefore, 
my data suggest the presence of other factors in LC/A that contribute to its specific location.  
In addition, I consider that addition of these sequences to LC/E did not alter its substrate 
recognition, since SNAP-25 recognition by LC/A or LC/E occurs in the catalytic pocket (Chen 
and Barbieri, 2006) and other regions of SNAP-25 only collaborate to this recognition when 
the cleavage site is absent (Washbourne et al., 1998). These results were in consonance with 
these studies, as eGFP-4G-LC/A but not eGFP-4G-NA-LC/E-CA generated SNAP-25197. 
LC/A location 
As shown in Figure 3-3B (bottom row, right panel), LC/A appeared to be expressed at the 
membrane in clusters in some cells. This distribution has been observed before, and it has been 
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suggested that it is due to the interaction between LC/A and the cytoskeleton components 
septins (Fernández-Salas et al., 2004b; Vagin et al., 2014). However, in addition to the 
membrane clusters, I observed a diffuse distribution and also intermediate phenotypes (Figure 
3-3). Diffuse and membrane location for LC/A has been reported in HeLa cells (Fernández-
Salas et al., 2004a), suggesting that LC/A location at the membrane is not exclusively caused 
by a mechanism present solely in neurons and that this mechanism is variable from cell to cell.  
In primary neuronal cultures, SNAP-25 is present at the presynaptic terminal, but also spreads 
through the cell body (Tafoya et al., 2008; Lau et al., 2010). My results also show that LC/A(0), 
a LC/A mutant unable to cleave SNAP-25, is distributed throughout the cell body (Figure 
3-3B), consistent with SNAP-25 cleavage playing an important role for LC/A location in 
neuron-like cells (Chen and Barbieri, 2011). In PC-12, LC/A and LC/E colocalise with their 
respective cleaved SNAP-25 products (Fernández-Salas et al., 2004b). Therefore, it is possible 
that LCs mainly localise where cleaved SNAP-25 is present.  
However, LC/A can also present a diffuse distribution when this molecule is expressed together 
with LC/E in N18 neuroblastoma cells. Even more interestingly, LC/E can also localise 
exclusively at the membrane when expressed with LC/A under the same conditions (Tsai et al., 
2010). This could indicate that LC/A and LC/E can target each other to the compartment 
thought to be exclusive to one of them, but no mechanism has been suggested for this action.  
Nonetheless, LC/E has been shown to clear LC/A-produced fragments (Eleopra et al., 1998). 
Therefore, in a LC/A-transfected cell, LC/E-cleaved products would be present while LC/A-
cleaved would not. Then, no LC would localise at the membrane, since LC/E-cleaved products 
localise throughout the cell body (Fernández-Salas et al., 2004b), ruling out this possibility.  
In summary, I observed different distribution for eGFP-LC/A within the same model and other 
studies have indicated that LC/A and LC/E colocalise at either location when co-expressed. 
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Abundant research is needed to clarify this question, and I am unable to offer a successful 
model for this behaviour. 
Toxicity of the constructs 
I also observed toxicity caused by LC expression (Figure 3-4). In addition, a low percentage 
of SH-SY5Y cells expressed eGFP-4G-LC constructs compared to eGFP (Figure 3-5). 
Treatment with different SNARE fragments produced by some BoNTs (but not BoNT/A) 
induce apoptosis in neuroblastoma cells (Arsenault et al., 2014a) and similar treatments in 
neurons have been shown to cause degeneration (Peng et al., 2013). However, the SNARE 
fragment hypothesis does not explain my data for LC/A and specially for LC/A(0).  
It has been suggested that tagging of LCs results in differences of expression and location 
(Fernández-Salas et al., 2004b). However, heterologous expression of pathogenic bacterial 
proteins in a mammalian system is an unexplored field and, therefore, problems derived from 
it are hard to approach.
Conclusion 
In this chapter, several constructs for the comparative study of LC/A persistence were created. 
First, I have confirmed the importance of production SNAP-25197 in determining LC/A 
location, as well as shown that NA and CA are not sufficient to target a protein to the cell 
membrane, further enforcing the importance of SNAP-25 cleavage for LC/A location. These 
sequences did not confer substrate specificity, as eGFP-4G-NA-LC/E-CA could not produce 
SNAP-25197. However, due to the low efficiency of transfection and toxicity of my constructs, 
experiments to further characterise these finding were not feasible.  
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Chapter 4 Purification of GFP-tagged BoNT/A(0) and BoNT/E(0) 
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Aims 
The aim of this chapter was to produce and validate tools to study the possible differential 
trafficking between BoNT/A and BoNT/E. I first studied the purification protocol necessary to 
obtain a working yield and then applied it to produce BoNT/A(0)-GFP fused to a histidine tail 
(10HT) and BoNT/E(0)-GFP-10HT until pure proteins were obtained. Finally, I tested the 
usability of these molecules.
Introduction 
Toxicity 
BoNTs are among the deadliest substances known, with a delivery mechanism (HC) and a 
catalytic effector (LC) connected by a disulfide bridge (Montecucco and Schiavo, 1994). 
Although BoNT is synthesised in a larger complex that facilitates its survival and uptake by 
the living organism (Pirazzini et al., 2017), BoNT itself is able to enter neurons from the blood 
stream as an aerosol (Arnon et al., 2001). In this case, the inferred lethal dose for humans is 
10-13 ng/kg for BoNT/A (Arnon et al., 2001). As a consequence, working with the full-length 
toxin in a standard laboratory is heavily restricted.  
Non-toxic derivatives 
There are two main approaches to eliminate toxicity from BoNTs while keeping the value as a 
tool to study its internalisation and trafficking. 
The first option is studying HC trafficking. Since the HC is the mechanism responsible for 
binding and creating the channel that releases the LC to the cytosol (Koriazova and Montal, 
2003), the LC can be removed, rendering a non-toxic molecule. Indeed, many studies have 
used only the C-terminal domain of the HC, HCC, as it is the domain responsible for binding 
and internalisation (Monteccuco and Schiavo, 1994). HCC/A, HCC/E or HCC/T molecules 
labelled with reporters such as fluorescent chemicals are commonly used (Harper et al., 2011; 
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Restani et al., 2012a; Wang et al., 2015). However, although HCC remains widely used, LC and 
HCN has been also been shown to contribute to this process (Montecucco et al., 1988; Ayyar 
et al., 2015). In addition, trafficking of HCC/T differs from that of full-length TeNT, as HCC/T 
colocalises with synaptophysin (Syp1), a protein present in certain synaptic vesicles, while 
TeNT does not (Blum et al., 2014a; Blum et al., 2014b). Moreover, retrograde trafficking of 
TeNT(0) is more efficient that that of HCC/T (Ovsepian et al., 2015). 
The second option is modifying the LCs to make them catalytically inactive and unable to 
cleave SNAP-25. A non-toxic derivative has been shown to target the neuromuscular junction 
(NMJ) in vivo and binds BoNT/A SV2 receptors as well as SNAP-25 (Pellett et al., 2011). 
Clostridial neurotoxins are zinc-dependent proteases (Schiavo et al., 1992a; Schiavo et al., 
1992c). For BoNT/A, this atom is sits in a tri-dimensional pocket (Lacy et al., 1998; 
Breidenbach and Brunger, 2004) formed by residues His223, Glu224, His227 and Glu262, with 
Glu224 being the only residue indirectly binding zinc through a water molecule. Several 
mutations in this pocket result in loss of action (Zhou et al., 1995; Kukreja et al., 2007), but 
this loss is dependent on the nature of the mutation. When Glu224 was substituted by a 
similarly charged amino acid (i.e. Asp), LC activity was reduced but detectable. However, 
when a structurally similar, non-negative aminoacid was introduced (E224Q), no activity was 
detected. Similarly, disrupting the zinc-binding pocket with the H227Y mutation yielded an 
inactive LC. BoNT/E presents a similar pocket and the E212Q mutation abolishes its activity 
(Agarwal et al., 2004). 
Importantly, catalytically inactive mutants enter neurons similar to catalytically active toxins 
as shown by the use of BoNT/A(0) (Baskaran et al., 2013). 
Full-length toxin labelling 
On the other hand, it is also possible to tag BoNTs at their C-terminus, close to the binding 
sites and away from more mobile domains (LC, the catalytic domain, and HCN, the pore-
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forming domain). By doing so, LCs would theoretically be able to translocate from to the 
cytosol. 
For HC, GFP-HC constructs have been produced and successfully tested to enter cells but not 
to translocate (Ho et al., 2011). With all these data, I decided to use full-length toxins to study 
the mechanisms underlying BoNT/A and /E entry.
Materials and Methods 
Materials 
Acrylamide gels 
NuPage Novex pre-casted gels (Thermo Fisher Scientific, Cat. No. NP0323BOX) were used 
to run acrylamide gels. 
Total protein gel staining 
After SDS-PAGE, total protein was stained using SimplyBlue Safestain by Thermo Fisher 
Scientific (Cat. No. LC6065). 
Sample buffer 
NuPAGE LDS Sample Buffer (4X) from Thermo Fisher Scientific (Cat. No. NP0008). 
Protein ladder 
BenchMark Protein Ladder (Thermo Fisher Scientific, Cat. No. 10747012) was used. 
Protein purification 
Columns 
A 5 mL HisTrap HP histidine-tagged column (GE Healthcare, Cat. No. 17524701) was used 
for affinity chromatography.  
A 5 mL HiTrap Q HP column (GE Healthcare, Cat. No. 17115401) was used for anion 
exchange chromatography.  
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A 1 mL HiTrap Phenyl HP column (GE Healthcare, Cat. No. 17135101) was used for 
hydrophobic interaction chromatography. 
Superdex 200 10/300 GL column (GE Healthcare Cat. No. 17517501) was used for size-
exclusion chromatography. 
Proteases 
Lys-C endoprotease used during protein purification was from Sigma (Cat. No. ENDOLYSS-
Ro). TrypZean was also from Sigma (Cat. No. T3568)  
Protein concentrators 
Pierce Protein Concentrator PES, 30K MWCO (Thermo Fisher Scientific, Cat. No. 88529) was 
used for protein concentration. 
Buffers 




Samples were loaded into pre-casted gels with a 4-12% gradient of acrylamide and run in 50 
mM 3-(N-morpholino)propanesulfonic acid (MOPS), 50 mM Tris Base 0.1% SDS, 1 mM 
EDTA and pH = 7.7 for 50 min at 200 V. 
Sample preparation 
NuPAGE LDS Sample Buffer (4X) was diluted twice and mixed with an equal volume of a 
sample from a fraction eluted from the protein purification protocol. This was boiled at 95° for 
10 min. For Dithiothreitol (DTT)-containing samples, this was added before samples were 
boiled.  
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Total protein gel staining 
Gels were rinsed in distilled water and covered with water in a plastic box. This was placed 
into a microwave at 1000 W and heated for a min. Water was discarded and the stain was 
incorporated and the gel placed into the microwave under the same settings. Then, it was left 
for incubation with constant shaking for 10 min. If necessary, gels were distained by placing 
the gel in distilled water for 30 min and then overnight.  
Protein expression and extraction 
Single colonies of transformed BL-21(DE3) bacteria were grown in 100 mL TB medium for 
16 h at 37° C. 10 mL of bacterial culture were inoculated into 1 L of TB medium with ampicillin 
and grown at 37 ºC. Expression of BoNT/A1(0)-GFP-10HT was induced by addition of 100 
M Isopropyl--D-1-Thiogalactopyranoside (IPTG) and left overnight at 21 ºC. 
Cells were lysed by liquid homogenisation and bacterial lysates were collected by 
centrifugation at for 16000 g for 1 h. 
Chromatography 
Affinity chromatography 
A protein capture was done using a 5 mL HisTrap HP, which was equilibrated with 2 column 
volumes (CV). Lysis buffer was composed of 50 mM HEPES and 150 NaCl with pH = 7.2. 
Elution buffer was composed of buffer A with 0.5 M imidazole and pH = 7.2. Flow rate was 
set at 5 mL/min and column pressure limit at 0.6 MPa. Column was first equilibrated with 2 
CV of lysis buffer. The total lysate was injected into the system at a flow rate of 5 mL/min and 
column was washed with 6 CV of lysis buffer. Volume of the fractions was set at 1 CV unless 
indicated otherwise. Elution of proteins bound to the column was achieved by linearly 
increasing imidazole concentration from 0 to 250 mM for 20 fractions and from 250 mM to 
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500 mM for 5 fractions, after which 500 mM imidazole concentration was maintained for four 
fractions of 2 CV.  
Anion exchange chromatography 
A 5 mL Q column was used after equilibration with 2 CV. Buffer A consisted of 50 mM Tris 
and Buffer B consisted of 50 mM Tris 1 M NaCl. Flow rate and column pressure limit were set 
at 5 mL/min and 0.6 MPa, respectively. Column was equilibrated with 1 CV and the input was 
injected at a rate of 4 mL/min. Column was washed with 5 CV and elution started by linearly 
increasing NaCl concentration from 0 mM to 500 mM over 20 fractions with 5 mL of volume. 
Another segment was set from 500 mM to 1 M NaCl for 5 fractions and was maintained at 1 
M for five fractions of 10 mL. 
Hydrophobic interaction chromatography 
A 1 mL HiTrap Phenyl HP column was used. Buffers were composed by 50 mM Tris pH = 8.0 
with (loading) or without (elution) 1 M (NH₄)₂SO₄. Flow rate was set at 1 mL/min and column 
pressure limit at 0.5 MPa. Equilibration was done with 2 CV. Injection was done at 1 mL/min 
rate and column was washed with 3 CV. Elution occurred under a linear gradient from 1 M to 
0 M (NH₄)₂SO₄ for 25 CV. Calibration to of samples to 1 M (NH₄)₂SO₄ was done by adding 
an equal volume of 2 M (NH₄)₂SO₄. 
Size-exclusion chromatography 
Column was equilibrated with 50 mM Tris pH = 8.0 for 2 CV. Samples were run with a flow 
of 0.4 mL/min using Superdex 200 size exclusion chromatography and 1 mL fractions were 
collected. 
BoNT Activation 
Lys-C protease was used to activate BoNT/A(0)-GFP-10HT and TrypZean for BoNT/E(0)-
GFP-10HT at a concentration 15 g/mL for 16 h at 4° C for Lys-C or 20° C for TrypZean 
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unless indicated otherwise. Note that activation refers to reduction of the disulfide bond linking 
LC and HC and not restoration of catalytic activity. 
Protein dialysis and concentration 
Protein dialysis was achieved by placing protein solution into a semipermeable membrane 
which was submerged into the desired final buffer overnight at 4 ºC. 
Samples were concentrated using Pierce Protein Concentrator PES with a molecular weight 
cut-off of 30 kDa.
Results 
GFP-tagged BoNT/A and BoNT/E protein design  
Full-length BoNT is self-sufficient for its own internalisation and LC delivery. Direct 
expression in neurons would result in an abnormal processing, as CNTs need to be proteolysed 
to form two chains connected by a disulfide bond (Schiavo et al., 1990; Montecucco and 
Schiavo, 1994; Fischer and Montal, 2007). In addition, as it was explained in the introductions 
for Chapter 3 (section 3.2.1) and this Chapter 4 there are inherent difficulties to detect the LC 
and the HC simultaneously.  
Therefore, I cloned C-terminally GFP tagged BoNT/A(0) and BoNT/E(0), resulting in 
BoNT/A(0)-GFP-10HT and BoNT/E(0)-GFP-10HT molecules, where a glycine bridge was 
introduced between BoNTs and GFP. Serotypes used were 1 and 3 respectively. A histidine 
tail was introduced at the end of the GFP tag to facilitate purification after bacterial expression. 
Once purified, these proteins should enter neurons as the native toxins do. 
I designed a purification protocol with three chromatography steps and accessory steps (Figure 
4-1) which consisted of: 
1. Bacterial expression of the toxin followed and capture by affinity chromatography. 
2. Desalination and anion exchange chromatography. 
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3. Activation, hydrophobic interaction chromatography and sample concentration.  
Figure 4-1. Strategy for BoNT purification.
BoNT/A(0)-GFP-10HT or BoNT/E(0)-GFP-10HT-expressing bacteria were lysed and the 
soluble component separated by centrifugation. This was run through an affinity 
chromatography. After this, salt was removed from BoNT-enriched fractions and the product 
run through an anion exchange chromatography column. The toxin in BoNT-enriched 
fractions was activated with Lys-C protease and this was run through a hydrophobic interaction 
chromatography column. The resulting BoNT-enriched fractions were pooled and 
concentrated. 
105 
Three-step BoNT/A(0)-GFP-10HT  
Affinity chromatography 
BoNT/A(0)-GFP-10HT expressed in BL-21/DE3 bacteria and expressed protein was recovered 
as described in section 4.3.2.4. Cells were lysed using liquid homogenization and passed 
through a histidine tail-capturing column (HisTrap) and eluted in increasing concentrations of 
imidazole. Samples of these were run in a gel as described in section 2.2.3. 
Figure 4-2 shows the process of protein recovery as the first step of BoNT/A(0)-GFP-10HT 
purification. The total lysate (L) lane presents a high amount of protein at a wide range of 
molecular weights, corresponding to all the proteins present within the bacteria. A soluble 
fraction was separated from the cell debris by centrifugation, which yielded a resuspended 
pellet (RP) and a soluble fraction (S) corresponding to the second and third lanes on Figure 
4-2. For the RP fraction, a much smaller concentration of protein was observed compared to 
the total lysate, confirming an effective lysis and protein segregation. However, this lysis is not 
complete and some proteins precipitated together with the debris, without necessarily meaning 
an incomplete extraction of BoNT. The third lane corresponds to the soluble protein present in 
the supernatant (S) of the RP fraction after these were separated. The high amount of protein 
confirmed a successful cell lysis as contrasted to the L and the RP fractions. Fraction S was 
loaded into the column and the flow through (FT) was run in the fourth lane. This fraction also 
contained a high amount of protein and a decrease in concentration of a band corresponding to 
the molecular weight of BoNT/A(0)-GFP-10HT (175 kDa) was observed, indicating specific 
BoNT/A(0)-GFP-10HT capture. As most of the proteins did not bind the column, HisTrap can 
be used to separate an important proportion of protein for my expression system.  
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Lanes following the ladder (|=|) correspond to eluted fractions (1-35) in a linearly increasing 
concentration of imidazole from 0 M to 0.5 M. Fractions 1 and 2, corresponding to the lower 
range of concentration of imidazole in the gradient, show minimal protein elution. From 
fraction 3 onwards, clear bands at several positions appear in the gels, with distinct patterns 
among them. A band corresponding to a protein with a mass close to 175 kDa is present in all 
lanes from lane 3. From Lane 11 onwards there are decreased levels of protein in general but 
specific bands were enriched. 
The 175 kDa-sized protein band clearly increased its presence from fraction 20 to fraction 26 
and was putatively assigned as BoNT/A(0)-GFP-10HT. However, as well as minor bands 
Figure 4-2. Small scale purification of BoNT/A(0)-GFP-10HT: HisTrap. 
SDS-PAGE gel showing cell lysis and BoNT/A(0)-GFP-10HT capture with a HisTrap column. 
Total lysates (L) were centrifuged and produced a pellet loaded after resuspension (RP) and a 
soluble fraction (S). The S fraction was loaded onto the column, whose flow through eluate 
(FT) is also shown. Elution was achieved with increasing concentrations of imidazole and 
collected fractions are shown after the molecular weight marker (|=|) and labelled with 
numbers 1-35. Total lysate (L). Resuspended pellet. Soluble and column flow-through after 
column loading.  Putative BoNT/A(0)-GFP-10HT bands and main contaminants are 
highlighted in green and red squares, respectively.  
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present in these fractions, a major band with 50 kDa of molecular mass appeared in the same 
fractions. This protein (or proteins) mainly eluted in fractions 24 to 26, indicating a possible 
tighter binding to the column than the putative BoNT/A(0)-GFP-10HT protein.  
Fractions 20 to 25 were enriched in the protein with 175 kDa and presented a lower 
concentration of the 50 kDa contaminant. Thus, these were pooled together. Fraction 26 was 
not pooled because of its high content of the 50 kDa contaminant (or contaminants). 
Anion exchange chromatography 
The pooled enriched fractions were used as an input for the next chromatography step. NaCl 
and imidazole present in the sample were eliminated by dialysis and elution buffer for the 
affinity chromatography was exchanged with loading buffer for the anion exchange 
chromatography (see section 4.3.2.7). 
I noted, however, salt elimination turned the solution cloudy, indicative of protein precipitation. 
Nevertheless, I continued the protocol as showed in Figure 4-1. The input (In) corresponds to 
the first lane after the ladder in the first gel. Samples were eluted using increasing 
concentrations of NaCl. In lanes 1 to 12, presence of the putative BoNT/A(0)-GFP-10HT band 
was minimal, as well as the 50 kDa contaminant band. From band 13, this band increased but 
its intensity also correlated with the intensity of the 50 kDa contaminant band. In lane 19, a 
sudden decrease in concentration occurred probably caused by the sampling system 
erroneously skipping a tube, as from lane 20 onwards the concentration of the bands continued 
normally.  
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Unlike affinity chromatography, anion exchange chromatography did not resolve any 
contaminant from the sample and, as a consequence of salt elimination, protein precipitated 
compromising capture by the column. Therefore, an extra purification step was required to 
remove the 50 kDa contaminant. 
Protein activation 
Before proceeding to the next purification attempt it was necessary to activate the botulinum 
neurotoxin. Activation, in this context, means production of a structurally functional BoNT and 
not rescuing its proteolytic activity. As described above, my BoNT is produced in a bacterial 
E. coli system similar to the naturally producing BoNT C. botulinum. However, E. coli lacks 
the ability to cleave BoNT to produce LC and HC as individual peptides and this has to be done 
exogenously with a protease.  
I treated my samples (pool of fraction 13-18) with Lys-C protease and DTT as described in 
section 4.3.2.6 to check for presence of a disulfide bridge connecting LC/A(0) and HC/A-GFP-
10HT. DTT is a chemical reducing agent that can cause the hydrolysis of the bond resulting in 
Figure 4-3. Small scale purification of BoNT/A(0)-GFP-10HT: Q Column. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT capture and purification using a Q column. 
Input (In) was loaded to the column and its components eluted using increasing concentrations 
of NaCl. Collected fractions are labelled with numbers from 1 to 35. Putative BoNT/A(0)-
GFP-10HT bands and main contaminants are highlighted in green and red squares, 
respectively.  
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two separate chains with different molecular sizes, 50 kDa for LC/A(0) and 125 for HC/A-
GFP-10HT (Figure 4-4). 
For non-cleaved samples, BoNT/A(0)-GFP-10HT presented bands at 175 kDa and 50 kDa, 
corresponding to the toxin and the contaminant observed in the chromatography. In samples 
cleaved without DTT the same band pattern was observed, although a second band at ~50 kDa 
appeared. This was likely not to be LC/A(0) but a contaminant, since no band at 125 kDa, 
corresponding to HC/A-GFP-10HT, was observed. When samples were treated with DTT 
however, most of the 175 kDa band shifted to a position at 125 kDa and the band at 50 kDa 
appeared stronger, indicating correct activation. 
Figure 4-4. Small scale purification of BoNT/A(0)-GFP-10HT: Activation.
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT before (Non-Act) and after (Act) treatment 
with Lys-C in absence (-) or presence (+) of DTT. Putative BoNT/A(0)-GFP-10HT bands and 
main contaminants are highlighted in green and red squares, respectively. 
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Hydrophobic interaction chromatography 
After activation, a hydrophobic interaction step of purification was introduced to remove the 
main contaminant present in my sample. The salt concentration in sample was corrected to 1 
M (NH₄)₂SO4 before performing the chromatography, which was done as described in section 
4.3.2.5, and the results are shown by Figure 4-5. Input (In) corresponds to the fraction showed 
in the third lane of the gel in Figure 4-4. 
From fractions 1 to 25, no major bands were observed. In fraction 26, a minor band at 175 kDa 
appeared, with an increased intensity from fraction 26. Fractions 31-33 contained a 50 kDa 
protein with a low intensity. These results are consistent with the successful purification of 
BoNT with the contaminant largely remaining bound to the column. 
Thus, this protocol including hydrophobic interaction chromatography successfully resolved 
BoNT/A(0)-GFP-10HT from the 50 kDa present from the first column. Fractions 27-30 were 
Figure 4-5. Small scale purification of BoNT/A(0)-GFP-10HT: HiTrap. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT capture and purification using a HiTrap 
Phenyl column. Input (In) was loaded to the column and its components eluted using 
decreasing concentrations of NH4SO4. Collected fractions are labelled with numbers from 1 
to 35. Putative BoNT/A(0)-GFP-10HT bands and main contaminants are highlighted in green 
and red squares, respectively.  
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pooled and the sample concentrated. The final sample is shown in Figure 4-6 in absence and 
presence of DTT. Although highly purified, the protein yield was only 0.10 mg in a total 
volume of 0.5 mL. This amount is minimal for this protocol to be considered useful to produce 
a tool for this project. Therefore, another protein purification procedure was designed, 
eliminating the anion exchange chromatography, as it did not resolve BoNT/A(0)-GFP-10HT 
and the contaminant band and it caused precipitation of our protein. 
Two-step BoNT/A(0)-GFP-10HT  
Test activation in presence of imidazole 
In order to eliminate the anion exchange chromatography step, BoNT/A(0)-GFP-10HT had to 
be activated after the affinity chromatography, as the toxin needs to be activated before the last  
Figure 4-6. Small scale purification of BoNT/A(0)-GFP-10HT: Final sample.
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT final sample in absence (-) or presence (+) 
of DTT. Putative BoNT/A(0)-GFP-10HT bands are highlighted in green squares. 
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purification step, as the protease responsible for the activation needs to be removed. Therefore, 
I first tested if the protease activation occurred in the presence of imidazole.  
As mentioned, Fraction 26 eluted from the HisTrap column (Figure 4-2) was not used in the 
initial purification protocol due to the high proportion of contaminants. However, the 
BoNT/A(0)-GFP-10HT concentration was sufficient to test for activation in presence of 
imidazole (Figure 4-7). As discussed for Figure 4-4, the band corresponding to full length 
BoNT/A1(0)-GFP-10HT had a diminished intensity when compared to the activated sample 
not containing DTT, while a 175 kDa band was still present. This was likely due to the presence 
of other proteins with similar molecular weight. The recurrent 50 kDa band was also present. 
Most importantly, a band corresponding to a protein with a mass of 125 kDa which was not 
present in the first three lanes of the gel appeared in the activated reduced sample with DTT, 
suggesting HC/A-GFP-10HT dissociation from the LC/A(0) and that activation can occur in 
the presence of imidazole.  
Figure 4-7. Purification of BoNT/A(0)-GFP-10HT: activation in imidazole. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT before (Non-Act) and after (Act) treatment 
with Lys-C in absence (-) or presence (+) of DTT. Putative BoNT/A(0)-GFP-10HT bands and 
main contaminants are highlighted in green and red squares, respectively.  
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Thus the protocol consisting of an affinity chromatography followed by activation and 
hydrophobic interaction chromatography was adopted to purify BoNT/A(0)-GFP-10HT. This 
is depicted in Figure 4-8.
Figure 4-8. Two-step strategy for BoNT purification.
BoNT/A(0)-GFP-10HT-expressing bacteria were lysed and the soluble component separated 
by centrifugation. This was run through an affinity chromatography. The toxin in BoNT/A(0)-
GFP-10HT-enriched fractions was activated with a protease and this was run through a 
hydrophobic interaction chromatography column. The resulting BoNT/A(0)-GFP-10HT-
enriched fractions were pooled and concentrated. 
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Larger scale affinity chromatography 
Samples were treated the same way as for the previous batch of purification. To maximise the 
outcome, the volume of culture processed was three times higher the one used for the 
purification explained in the previous section. 
From the first purification step shown in Figure 4-2, it was established that BoNT/A(0)-GFP-
10HT eluted at high concentrations of imidazole. Therefore, the protocol was adapted to start 
at a higher concentration of imidazole. Figure 4-9 shows the outcome of this purification step.  
Figure 4-9. Purification of BoNT/A(0)-GFP-10HT: HisTrap. 
SDS-PAGE gel showing cell lysis and BoNT/A(0)-GFP-10HT capture with a HisTrap column. 
Total lysates (L) were centrifuged and produced a pellet loaded after resuspension (RP) and a 
soluble fraction (S). The S fraction was loaded onto the column, whose flow through eluate 
(FT) is also shown. Elution was achieved with increasing concentrations of imidazole and 
collected fractions are shown after the molecular weight marker (|=|) and labelled with 
numbers 1-35. Putative BoNT/A(0)-GFP-10HT bands and main contaminants are highlighted 
in green and red squares, respectively.  
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The first lanes correspond to the total lysate (L), the resuspended pellet (RP), the soluble 
protein-containing supernatant (S) and the column flow-through (FT). Fractions 1-7 
correspond to the eluted fractions. Fraction 1 contains a low amount of protein, while fraction 
2 specially and fraction 3 contain the majority of protein. A 175 kDa band was present in 
fractions 3 and 4 and less intensely in fraction 5, which was thought to be BoNT/A(0)-GFP-
10HT. In fractions 6 and 7 this tendency continued as it did for the first purification, in Figure 
4-2.  
Despite the apparent high content of BoNT/A(0)-GFP-10HT, Fraction 3 was discarded due to 
its high content in other proteins which could compromise the quality of the final sample. 
Fraction 5 was discarded because of the relatively low concentration of presumptive 
BoNT/A(0)-GFP-10HT. Fraction 4 had intermediate characteristics between Fraction 3 and 
Fraction 5, and it was selected to be further processed. 
Activation  
The selected fraction from the previous fraction was treated with a protease to separate LC/A(0) 
and HC/A-GFP-10HT. This was done as described (section 4.3.2.6) in and its result is shown 
in Figure 4-10. The result did not differ from the result described in section 4.4.3.1. For the 
non-treated samples, there were intense bands at 175 kDa and 50 kDa. For the protease-treated 
samples, these bands were present at the same positions. When the protease-treated sample was 
exposed to DTT, an intense band at 125 kDa appeared, corresponding to HC/A-GFP-10HT. 
Notably, the band at 175 kDa reduced its intensity not only in this sample, but also for the 
sample not treated with protease but with DTT present (second lane), suggesting that the band 
at 175 kDa is composed not only of BoNT/A(0)-GFP-10HT but also of multiple proteins.  
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The protease-treated fraction was loaded into a column to separate the discussed 175 kDa and 
the 50 kDa proteins by anion exchange chromatography, as shown in section 4.4.2.4. The 
results are summarised in Figure 4-11. The lanes labelled as In and FT represent the column 
input (i.e. third lane from Figure 4-10) and the flow-through from the purification system. In 
this second lane the presence of protein is null except for the presence of a light band above 
the 175 kDa height. This indicates very efficient protein capture by the column and minimal 
protein loss. 
Hydrophobic interaction chromatography 
The activated sample was then run in a hydrophobic interaction chromatography Figure 4-11.  
Figure 4-10. Purification of BoNT/A(0)-GFP-10HT: Activation. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT before (Non-Act) and after (Act) treatment 
with Lys-C in absence (-) or presence (+) of DTT. Putative BoNT/A(0)-GFP-10HT bands and 
main contaminants are highlighted in green and red squares, respectively.  
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Fraction 1 and 2 did not have any detectable protein presence. Fraction 3 and 4, however, 
presented a sole band above the 25 kDa mark which was also present in Fraction 5 with lower 
intensity. In this fraction, other proteins with several molecular weights started eluting, as well 
as in the following fractions. In fractions 8 to 10 a band under 160 kDa appeared with relatively 
high intensity but stopped being eluted in Fraction 11. In this fraction, the only band present is 
a band a the 200 kDa position aproximately. A strong band of 175 kDa appeared in Fraction 
12 and was thought to be BoNT/A(0)-GFP-10HT. Other proteins with minor presence also 
were present in this fraction. From fraction 12 until the end of the purification, a recurrent band 
at this position was also present, together with other bands. The 50 kDa band mainly eluted 
from fraction 17 and after the majority of BoNT/A(0)-GFP-10HT eluted, as it did in the 
previous purification (section 4.4.3.4). It is notable that both the 175 kDa and the 50 kDa 
proteins were separated.  
Figure 4-11. Purification of BoNT/A(0)-GFP-10HT: HiTrap. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT capture and purification using a HiTrap 
Phenyl column. Input (In) was loaded to the column and its components eluted using 
increasing concentrations of NaCl. Collected fractions are labelled with numbers from 1 to 27. 
Putative BoNT/A(0)-GFP-10HT bands and main contaminants are highlighted in green and 
red squares, respectively. 
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As discussed for Figure 4-5, the band at 175 kDa was thought to be BoNT/A1(0)-GFP-10HT 
and fractions 12-16 were kept. Its content was concentrated as described previously (section 
4.3.2.7).  
Summary 
A gel summarising the complete process was run (Figure 4-12).  
The first two lanes represent the input (HT-In) and the output (HT-Out) of the HisTrap affinity 
column. After this column, samples were activated and are labelled to indicate this (Act). Lanes 
labelled as Ph correspond to the input fraction into the HiTrap Phenyl column for hydrophobic 
interaction in absence (-) and presence (+) of DTT. The output corresponds to the non-
Figure 4-12. Purification of BoNT/A(0)-GFP-10HT: Summary.
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT purification summary. Samples before 
treatment with Lys-C (Non-Act). HT stands for HisTrap, Ph is the input for the HiTrap Phenyl 
column. NC and C the non-concentrated and concentrated final samples. Putative BoNT/A(0)-
GFP-10HT and main contaminants are highlighted in green and red squares, respectively. 
Arrows point at 175 kDa, 125 kDa and 50 kDa next to the molecular weight marker.  
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concentrated sample (NC) in absence and presence of DTT. After the concentration process, 
samples in absence and presence of DTT (labelled as C), the purity of the sample can be 
observed. Loaded volumes were adjusted to produce an interpretable figure. 
BoNT/E0)-GFP-10HT production 
Affinity chromatography 
Expression and protein extraction were done as described for the optimised BoNT/A(0)-GFP-
10HT purification. Similarly, this protein extract was incorporated to a HisTrap column and 
eluted under the same conditions. Figure 4-13 summarises this process. From fraction 1 to 8, 
protein presence was minimal. From 9 to 22, individual bands could be appreciated at different 
molecular sizes but without corresponding with the size of BoNT/E(0)-GFP-10HT. From 
fraction 23, at high concentrations of imidazole, a band which putatively corresponded to 
BoNT/E(0)-GFP-10HT eluted. This is analogous to the behaviour of BoNT/A(0)-GFP-10HT. 
However, in this case, main contaminants were two bands at the 25-30 kDa position with 
similar binding properties as BoNT/E(0)-GFP-10HT.  
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Activation  
Fractions 23 to 29 were combined and treated with a protease to separate LC/E(0) and HC/E-
GFP-10HT.  
A gel showing correct activation is represented in Figure 4-14. The non-activated samples 
show an intact BoNT/E(0)-GFP-10HT, as well as other contaminants. In the activated sample 
without DTT, this band was also present, while in the lane for the activated sample with DTT, 
bands corresponding to HC/E-GFP-10HT and LC/E(0) were present.  
Figure 4-13. Purification of BoNT/E(0)-GFP-10HT: HisTrap. 
SDS-PAGE gel showing cell lysis and BoNT/A(0)-GFP-10HT capture with a HisTrap column. 
Total lysates (L) were centrifuged and produced a pellet loaded after resuspension (RP) and a 
soluble fraction (S). The S fraction was loaded onto the column, whose flow through eluate 
(FT) is also shown. Elution was achieved with increasing concentrations of imidazole and 
collected fractions are shown after the molecular weight marker (|=|) and labelled with 
numbers 1-35. Putative BoNT/A(0)-GFP-10HT bands and main contaminants are highlighted 
in green and red squares, respectively.  
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A band corresponding to a protein with a size of 150 kDa appeared in the activated sample in 
absence of DTT, whereas it disappeared in its presence. Bands observed at 25-30 kDa shifted 
to positions with lower molecular weight, or the upper band of the contaminants at 30 kDa 
disappeared in the activated samples, while another band at the 25 kDa position appeared. 
Nevertheless, the 175 kDa band present in the first three lanes mostly disappeared in the DTT-
treated activated samples, resulting in 50 kDa and 125 kDa bands, confirming successful 
activation. 
Hydrophobic interaction chromatography 
After activation, as done for BoNT/A(0)-GFP-10HT (section 4.4.3.4), a hydrophobic 
interaction  purification step using was done. Figure 4-15 shows the result of this 
chromatography. Although this process effectively removed some minor contaminants, it did 
Figure 4-14. Purification of BoNT/E(0)-GFP-10HT: Activation. 
SDS-PAGE gel showing BoNT/A(0)-GFP-10HT before (Non-Act) and after (Act) treatment 
with TrypZean in absence (-) or presence (+) of DTT. Putative BoNT/A(0)-GFP-10HT bands 
and main contaminants are highlighted in green and red squares, respectively.  
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not separate the major contaminant at 25 kDa but did remove the 30 kDa protein, which 
appeared to stay bound from the column as it was not observed in the eluted fractions. 
An almost synchronous co-elution of the 25 kDa contaminant (or contaminants) together with 
a protein of 150 kDa (green squares) and BoNT/E(0)-GFP-10HT suggests that these proteins 
have very similar properties.  
Size exclusion chromatography 
The nature of the 25 kDa and 150 kDa proteins could be inferred from several observations. 
First, contaminants appeared only after protease action. Second, elution of these contaminants 
was very similar to that of BoNT/E(0)-GFP-10HT, indicating close nature. Third, combined 
molecular weight of these is 175 kDa, corresponding to the molecular weight of BoNT/E(0)-
GFP-10HT. Fourth, the GFP fluorescence of fractions such as Fraction 30 from Figure 4-15
was abnormally high and cannot be attributed to the limited presence of BoNT/E(0)-GFP-
Figure 4-15. Purification of BoNT/E(0)-GFP-10HT: HiTrap. 
SDS-PAGE gel showing BoNT/E(0)-GFP-10HT capture and purification using a HiTrap 
Phenyl column. Input (In) was loaded to the column and its components eluted using 
decreasing concentrations of NH4SO4. Collected fractions are labelled with numbers from 1 
to 35. Putative BoNT/A(0)-GFP-10HT bands and main contaminants are highlighted in green 
and red squares, respectively.  
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10HT. Thus, in combination I hypothesised that these bands correspond to GFP-10HT (25 kDa) 
and BoNT/E(0) (150 kDa). 
Due to the size difference, a size exclusion chromatography was performed as a test to resolve 
putative BoNT/E(0)-GFP-10HT and putative GFP-10HT. A small fraction of the sample was 
loaded into the column and run, retrieving the fractions shown in Figure 4-16.  
The column successfully separated these two bands. Then, I collected aliquots from each of the 
eluted fractions and exposed them to UV light using a transilluminator (Figure 4-16). Bands 
at 25 kDa in fractions 4, 5 and 6 emitted light as a reaction to UV light exposure but lack 
BoNT/E(0)-GFP-10HT suggesting the fluorescent 25 kDa protein is likely to be GFP-10HT. 
This confirmed that size exclusion chromatography was appropriate for my purification aims 
samples were concentrated and run two independent columns (due to the large volume of 
sample for a single purification), to resolve GFP-10HT and BoNT/E(0)-GFP-10HT. 
Figure 4-16. Purification of BoNT/E(0)-GFP-10HT: Size exclusion test.
A) SDS-PAGE gel showing a test BoNT/E(0)-GFP-10HT purification using a size 
exclusion chromatography column. Putative BoNT/E(0)-GFP-10HT bands and main 
contaminants are highlighted in green and red squares, respectively.  
B) Captured light emitted from samples as shown in A) when exposed to UV light.  
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Figure 4-17 shows the correct separation of GFP-10HT and lower molecular mass proteins 
from BoNT/E(0)-GFP-10HT in both gels. Fractions 5 to 17 contained bands at 175 kDa and 
fractions 9 to 12 contained bands at 25 kDa. Other contaminants were present at lower levels.  
Figure 4-17. Purification of BoNT/E(0)-GFP-10HT: Size exclusion. 
SDS-PAGE gel showing BoNT/E(0)-GFP-10HT purification using a size exclusion column. 
Putative BoNT/E(0)-GFP-10HT bands and main contaminants are highlighted in green and 
red squares, respectively. Top and bottom set of gels correspond to two independent 
purifications due to the large volume of the sample. 
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Summary 
As for the previous protocols, a schematic with the overview of the purification is provided 
(Figure 4-18).  
Figure 4-18. Three-step strategy for BoNT/E(0)-GFP-10HT purification.
BoNT/E(0)-GFP-10HT-expressing bacteria were lysed and the soluble component separated 
by centrifugation. This was run through an affinity chromatography. BoNT-enriched fractions 
were activated with TrypZean protease and the resulting sample was run through a 
hydrophobic interaction chromatography column. Toxin-enriched fractions were pooled, 
concentrated and run through a size exclusion chromatography. The resulting BoNT-enriched 
fractions were pooled and concentrated. 
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Fractions 5 to 8 from the size exclusion chromatography columns were combined together with 
fraction 4 from the test run (Figure 4-16) and concentrated to produce the final sample.  
Figure 4-19 shows this fraction together as a summary of the purification.  
Lysate and input for HisTrap affinity chromatography column (His-In) are at the start of the 
gel. Then, the output of the affinity chromatography purification, with non-activated and 
activated samples in absence and presence of DTT shows correct activation and generation of 
the GFP-10HT band. Then, the sample used as input for the HiTrap Phenyl column, 
corresponding to the activated output of HisTrap corrected to 1 M (NH₄)₂SO₄. On the second 
Figure 4-19. Purification of BoNT/E(0)-GFP-10HT: Summary. 
SDS-PAGE gel showing BoNT/E(0)-GFP-10HT-expressing bacteria lysate (Lys), plus His-
Trap input and, in absence (-) and presence (+) of DTT, its output before and after treatment 
with TrypZean, followed by HiTrap Phenyl column input and output (Ph-In, Ph-Out) and size 
exclusion column input and output (SE-In, SE-Out), as well as the final sample. Putative 
BoNT/E(0)-GFP-10HT bands and main contaminants are highlighted in green and red squares, 
respectively.  
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gel, the output is present, with minimal elimination of some contaminants. SE-In represents the 
concentrated HiTrap Phenyl column output, which was used as input for the size exclusion 
chromatography. This is followed by the output (SE-Out), with successful removal of 
contaminants with lower molecular mass.  
Lastly, the final sample after its concentration is shown (loaded volume was corrected to 
produce an interpretable image), with a high degree of purity. Must be noticed that, unlike 
BoNT/A(0)-GFP-10HT, BoNT/E(0)-GFP-10HT activation is not total.  
BoNT/A(0)-GFP-10HT test 
Once the tools were produced, I tested BoNT/A(0)-GFP-10HT by treating hippocampal 
neurons with BoNT/A(0)-GFP-10HT for 10 min, followed by fixing and visualisation (Figure 
4-20). There was no signal increase in treated cells compared to the control. As BoNT/A 
endocytosis is thought to be enhanced by membrane depolarisation, the same experiment was 
performed introducing a high potassium (50 mM) condition to ensure detection. However, this 
treatment was insufficient for us to visualise binding or internalisation and no clear entry was 
detected. I therefore concluded that BoNT/A(0)-GFP-10HT was unsuitable for my purposes 
and discontinued this avenue of investigation. 
Figure 4-20. BoNT/A(0)-GFP-10HT test
Representative images of DIV14-17 hippocampal neurons treated for 10 min with 25 nM toxin 
in normal conditions or 50 mM KCl. Scale bars are 10 m. 
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Discussion 
Purification of BoNT/A(0)-GFP-10HT was optimised to provide a good yield and a high degree 
of purity (Figure 4-1 to Figure 4-6 and Figure 4-7 to Figure 4-12). Purification of BoNT/E(0)-
GFP-10HT was also achieved, with minor contaminants primarily due to non-perfect protease 
action particularly for BoNT/E(0)-GFP-10HT (Figure 4-13 to Figure 4-19).  
Therefore, these fragments could correspond to toxin fragments that co-eluted with the full-
length toxin because of their similar properties. I added the toxin directly onto neuronal culture, 
as CNTs alone are able to enter cells without any other vehicle (Montecucco and Schiavo, 
1994). However, little or no GFP signal was detected (Figure 4-20). It has been reported that 
HCC/A internalisation is promoted by membrane depolarisation induced by high K
+
concentrations (Harper et al., 2011; Restani et al., 2012a; Wang et al., 2015) but, in my hands, 
no increase in signal was observed for BoNT/A(0)-GFP-10HT (Figure 4-20). I argue that this 
could be an effect of GFP blocking HCC/A binding sites.
Conclusion 
In this chapter, it is shown how I expressed and purified BoNT/A(0)-GFP-10HT and 
BoNT/E(0)-GFP-10HT in bacteria. I performed a test purification for BoNT/A(0)-GFP-10HT 
consisting of affinity, anion exchange and hydrophobic interaction chromatographies. Salt 
removal necessary for anion exchange chromatography resulted in protein precipitation and 
was discarded. BoNT/A(0)-GFP-10HT final purification yielded a highly pure sample. 
BoNT/E(0)-GFP-10HT followed the same protocol. However, activation resulted in a 
fragmentation of the protein and the resulting BoNT/E(0) and GFP-10HT proteins were 
separated by size-exclusion chromatography. Finally, I tested BoNT/A(0)-GFP-10HT 
function. Unfortunately, I was not able to detect internalisation and these molecules were o 
longer used in this project.
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Building on the results described in the previous chapter the aims of the work in this chapter 
were to: 
1. Validate the usability of BoNT/A(0) and an anti-BoNT/A antibody.  
2. Investigate the dynamics of BoNT/A(0) entry into neurons. This includes exploring 
known endocytic mechanisms such as the synaptic vesicular uptake, Fgf3-mediated 
endocytosis or dynamin-dependent endocytosis.  
3. Define the intracellular localisation of BoNT/A(0) after endocytosis. 
4. Determine the stability and fate of BoNT/A(0)  by examining degradation pathways.  
5. Explore the possibility of full-length toxin escaping degradation and re-intoxicating 
surrounding cells.
Introduction 
BoNT detection difficulties 
LC constructs 
In the previous chapter, I produced several LC constructs to examine the mechanisms 
underlying the location of LC/A. Expression of these constructs gave some insight into the 
details of LC/A location. However, difficulties regarding toxicity and transfection efficiency 
of these constructs made me finally abandon it.  
BoNT(0)-GFP-10HT 
GFP-tagged BoNT/A(0) and BoNT/E(0) molecules were designed to be used in trafficking 
studies, including live imaging experiments. Despite the production of pure samples, test 
experiments with BoNT/A(0)-GFP-10HT suggested that this molecule was not suitable for the 
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purposes of this study and they were discarded as reliable tool. Therefore, an alternative 
approach was taken to study BoNT trafficking.  
Research with non-tagged full-length BoNT 
Although BoNTs are classified in serotypes according to their immunoreactivity, antibodies 
for research are limited and removal of tags from the expressed protein complicates BoNT 
detection. However, due the toxicity of catalytically active BoNTs they can be easily detected 
by the cleavage SNARE proteins. This has generated various protocols for BoNT detection 
(Lévêque et al., 2013; Bak et al., 2017; Yadirgi et al., 2017), although these must be viewed 
with some caution, as BoNT/A levels do not fully correlate with those of cleaved SNAP-25 
(Kalandakanond and Coffield, 2001). However, as explained in the introduction of the previous 
chapter (section 4.2.1), due to safety concerns I was unable to work with a full-length 
catalytically active BoNT/A.  
Nonetheless, I was keen to investigate the properties of full-length toxin because LC/A and 
HCC/A could play a role in BoNT/A trafficking (Montecucco et al., 1988; Blum et al., 2014a; 
Blum et al., 2014b; Ayyar et al., 2015). This could include site occlusion or interaction between 
LC/A(0) or HCN/A and other molecules at the membrane or the vesicle, or others. In addition, 
how LC/A traffics before dissociation from HC/A is an unexplored field. This is important 
because this project aims to determine the causes underlying LC/A stability and little 
information is available on the persistence using full-length toxin in cultured neurons.  
Materials and Methods 
As Materials and Methods for this chapter are shared with other chapters, these are contained 
within Chapter 2. 
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Results 
BoNT/A(0) is a suitable tool for research 
Detection of BoNT/A(0) and its components 
As outlined in the introduction, many planned experiments relied on an antibody capable of 
specifically detecting BoNT/A(0). Ipsen raised an ‘in-house’ antibody. The serotype and 
subtype of the protein was BoNT/A1(0), but hereafter will be simplified as BoNT/A(0). 
To confirm the specificity of this antibody, neurons were treated with 25 nM BoNT/A(0) for 
different times (10 min, 30 min, 1 h and 18 h) and then washed and lysed. As explained in the 
introduction (1.3.2) and confirmed experimentally in the previous chapter (Figure 4-10, 
Figure 4-14), a disulfide bridge is the only covalent bond linking LC and HC resulting the 150 
kDa BoNT (Schiavo et al., 1990; Montecucco and Schiavo, 1994). The reducing agent -
mercaptoethanol (Me) can separate LC/A(0) (50 kDa) and HC/A (100 kDa) and half of each 
of 10 min, 30 min, 60 min and 18 h samples were therefore treated with Me and probed by 
western blotting. 
Non-reduced samples 
As expected, for samples run in absence of Me, bands at 150 kDa were observed in the lanes 
corresponding to the BoNT/A(0)-treated samples, while no band at 150 kDa was detected in 
the lane corresponding to the non-treated sample (Figure 5-1A, left panels). These data 
confirmed antibody specificity and BoNT/A(0) binding or endocytosis. No bands at 100 kDa 
were present under these conditions. This result can be interpreted in several ways. It is possible 
that this antibody could not detect HC/A. Also, it could mean that BoNT/A(0) did not dissociate 
into LC/A(0) and HC/A in a detectable proportion. Finally, it could also suggest dissociation 
and immediate HC/A degradation. At the 50 kDa position, saturated bands appeared for all the 
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conditions, indicating non-specific binding of the antibody and impossibility of LC/A(0) 
detection. 
Me-treated samples  
In the lanes corresponding to Me-treated samples, no bands with a size of 150 kDa were 
detected, indicating full dissociation of LC/(A0) and HC/A caused by the reducing agent. 
Furthermore, bands at 100 kDa were present in lanes corresponding to BoNT/A(0)-treated 
samples, but not in the non-treated one (Figure 5-1, right panels). These confirmed that bands 
at 150 kDa and 100 kDa corresponded to full-length BoNT/A(0) and HC/A, respectively. 
Unfortunately, I was unable to detect LC/A(0) because of non-specific bands, as seen in the 
samples without Me. As it can be seen, intensity increased with treatment time length. 
I also tested this antibody for imaging studies. Hippocampal neurons were treated for 10 min 
with 25 nM BoNT/A(0), and cells on coverslips were then fixed and stained according to the 
protocol described previously (section 2.2.5). When examined under the microscope, staining 
was present in treated cells and was absent in non-treated cells (Figure 5-2A). Therefore, this 
Figure 5-1. BoNT/A(0) is internalised by neurons. 
Representative western blot results of samples from DIV14-17 cortical neurons treated for 18 
h, 1 h, 30 min or 10 min, with 25 nM BoNT/A(0) and run in absence or presence of Me.  
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antibody recognised BoNT/A(0) specifically. Figure 5-2B shows a magnified field, where a 
clear punctate distribution can be observed. 
As this antibody recognised full-length BoNT/A, I also tested an anti-LC/A monoclonal 
antibody from Listlabs (see section 2.1.10.1). First, samples containing Me from Figure 5-1
were run in a western blot. Despite the exposure time being much longer than the exposure 
times to retrieve results from Figure 5-1, no bands were detected at the molecular weight 
position for LC/A(0) (Figure 5-3A). Non-specific bands were present in all the samples, 
Figure 5-2. Antibodies targeting BoNT/A are suitable for immunostaining.
A) Representative fluorescence images of DIV14-17 hippocampal neurons treated with 
25 nM BoNT/A(0) for 10 min and a non-treated control. Cells were fixed and stained 
with an anti-BoNT/A antibody. White squares are magnified in B. Scale bars represent 
10 mm. 
B) Magnifications of white squares from A. 
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including the non-treated one, at the 90 kDa and 170 kDa positions. This antibody, therefore, 
was not suitable for detection of LC/A(0) by western blot. The antibody was also tested by 
microscopy as done for the anti-BoNT/A antibody. The antibody specifically recognised LC/A 
but its staining appeared to be more diffuse at the concentrations tested (Figure 5-3B). This 
suggests that the antibody recognises LC/A(0) in its native state but not when the protein is 
when denatured. 
Figure 5-3. Anti-LC/A antibody recognises its epitope in native state but not when 
denatured.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
for 10 min with 25 nM BoNT/A(0) and run in presence of Me. Membranes were 
probed with an anti-LC/A antibody. 
B) Representative images of DIV14-17 hippocampal neurons treated for 10 min with 25 
nM BoNT/A(0) and stained with the same antibody. Scale bars are 10 m. 
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Based on these results I concluded that anti-BoNT/A antibody and non-tagged BoNT/A(0) 
could be used together as tools to study BoNT/A(0) endocytosis, but the study of LC/A(0) after 
release would be limited. In addition, since BoNT/A(0) could be detected after only 10 min of 
treatment, this time point was chosen as a basic protocol. 
BoNT/A(0) endocytosis is enhanced by potassium-induced depolarisation 
As explained in the introduction (section 1.6.1.4), HCC/A internalisation is enhanced by cell 
depolarisation induced by high extracellular K+ concentration, which depolarises cells and 
promotes synaptic vesicle exocytosis and endocytosis (Harper et al., 2011, Restani et al., 
2012a; Wang et al., 2015).  
I therefore tested if this is also the case for BoNT/A(0). Neurons were treated for 10 min or 30 
min in either feeding medium, with a K+ concentration of [K+] = 5.3 mM or feeding medium 
with added KCl to a concentration of [K+] = 50 mM. As part of the validation, samples were 
run in presence of Me. Results are shown in Figure 5-4. Cells treated for 30 min showed 2.46 
± 0.25 more internalised toxin than those which have been treated for 10 min (p** < 0.01) 
when compared to the control). Potassium treatment for 10 min increased intake by 1.93 ± 0.14 
(p* < 0.05) and potassium treatment for 30 min did it by 2.31 ± 0.11 (p* < 0.05).  
This result indicates that BoNT/A(0) entry into neurons can occur through a activity-dependent 
mechanism like BoNT/A or HCC/A (Harper et al., 2011; Restani et al., 2012a; Wang et al., 
2015) and validates it as a tool for my study.  
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Figure 5-4. K+-induced cell depolarisation increases BoNT/A(0) uptake.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
for 10 min or 30 min with 25 nM in absence or presence of 50 mM KCl, plus a non-
treated control. Membranes were probed with anti-BoNT/A and anti-GAPDH 
antibodies. 
B) Quantification of the results, represented as mean values ± SEM. ANOVA followed 
by Tukey post hoc test, *p < 0.05, **p < 0.01. N = 3 
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BoNT/A(0) enters neurons through different pathways 
BoNT/A(0) enters neurons through the synapse 
BoNT/A has been shown to gain entry into neurons via the synapse (Kristenssonn et al., 1998; 
Colasante et al., 2013) and HCC/A incorporates into several pools of synaptic vesicles (Pellett 
et al., 2015; Harper et al., 2016). I tested whether full-length BoNT/A(0) was internalised in 
the synapse in my cultures. To do this, I treated neuronal cultures with the Na+-channel blocker 
tetrodotoxin (TTX) that prevents action potentials and suppresses synaptic activity (Bane et al., 
2014) or with the GABA A receptor (GABAA) antagonist bicuculline (Bic) which, by inhibiting 
inhibitory synapses, increases the overall activity of the network (Olsen et al., 2018). 
Neurons were pre-treated with either vehicle (DMSO), TTX or Bic (see section 2.2.2.5) and 
then treated with 25 nM BoNT/A(0) for 10 min prior to lysis. Toxin uptake was assessed by 
western blot with samples run in absence of Me. No bands were present in non-treated 
samples. In toxin-treated samples, the main band in the lane had a molecular weight of 150 
kDa and corresponded probably to the intact toxin (Figure 5-5). In addition, other bands with 
molecular wright over 150 kDa were observed in toxin-treated samples but not in non-treated 
ones were detected. 
BoNT/A(0) uptake was significantly higher in Bic-treated neurons when compared to the 
DMSO control, being this difference statistically different (1.81 ± 0.14; p* < 0.05). BoNT/A(0) 
uptake in TTX-treated neurons was significantly lower than the control (0.475 ± 0.162; p* < 
0.05) and the Bic-treated group (p** < 0.01). While these data confirm that BoNT is 
internalised via the synapse it is interesting to note that TTX treatment did not completely block 
toxin uptake. 
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Figure 5-5. Synaptic activity regulates BoNT/A(0) uptake.
A) Representative western blot results of samples from DIV14-17 cortical neurons pre-
treated for 1 h with 0.1% vehicle DMSO, 1 h with 1 M Bic or 18 h with 2 M TTX 
min and treated for 10 min with 25 nM BoNT/A(0) in presence of these compounds. 
Membranes were probed with anti-BoNT/A and anti-GAPDH antibodies. 
B) Quantification of the results, represented as mean values ± SEM. ANOVA followed 
by Tukey post hoc test, *p < 0.05, **p < 0.01. N = 3. 
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BoNT/A(0) enters neurons through Fgfr3 
Since BoNT/A(0) uptake was not fully abolished by TTX I next inhibited the activity of Fgfr3, 
which has been reported to be a BoNT/A-specific receptor in neuron-like cells (Jacky et al., 
2013), to quantify its contribution to BoNT/A(0) uptake in neurons. I used SU5402, which 
blocks ATP binding to the receptor impeding cross-phosphorylation of the dimer and 
consequent internalisation (Toledo et al., 1999). 
Cultures were pre-treated with SU5402 before treatment with 25 nM BoNT/A(0) lysed and 
samples run in a western blot (Figure 5-6). 
Figure 5-6. Fgfr3 activation inhibition by SU5402 reduces BoNT/A(0) uptake
A) Representative western blot results of samples from DIV14-17 cortical neurons pre-
treated for 1 h with 0.1% vehicle DMSO or 20 M SU5402 and treated for 10 min with 
25 nM BoNT/A(0) in presence of this compounds, plus non-treated controls. 
Membranes were probed with anti-BoNT/A and anti-GAPDH antibodies. 
B) Quantification of the results, represented as mean values ± SEM. Student’s t test, *p < 
0.05. N = 3.
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After 10 min of exposure, BoNT/A(0) uptake was significantly reduced compared to control 
(0.588 ± 0.119; p* < 0.05). These results indicate that Fgfr3 activation and cross-
phosphorylation also contribute to BoNT/A internalisation.  
As shown previously (Figure 5-5), bands with a higher molecular weight than BoNT/A(0) 
were present for BoNT/A(0)-treated samples but not in non-treated ones. These bands will be 
discussed later. 
BoNT/A(0) uses dynamin-dependent endocytosis and cholesterol to enter neurons 
To further explore the mechanism by which BoNT/A(0) is endocytosed, cells were treated with 
two different inhibitors of endocytosis. Dynamin-dependent endocytosis has been proposed as 
one of the endocytic routes for BoNT/A, but these experiments were done under depolarising 
conditions (Harper et al., 2011), and HCC/A trafficking is altered under these conditions (Wang 
et al., 2015). I used Pitstop 2, an endocytosis blocker which blocks clathrin-dependent 
endocytosis and some types of clathrin independent endocytosis (Dutta et al., 2012) and 
Dynasore, a dynamin inhibitor (Macia et al., 2006).  
Cells were treated for 30 min with the endocytosis blockers and then exposed for 10 min to 25 
nM BoNT/A(0). These treatments were done in Neurobasal medium and not in feeding 
medium. Cells were lysed and run in a western blot. 
I did not observe any decrease in BoNT/A(0) uptake (Figure 5-7). Numerical values were 1.33 
± 0.57 for Pitstop 2 and 0.99 ± 0.32 for Dynasore. Considering the high variability between the 
performed experiments (N = 4), and the lack of a positive control, these results were regarded 
as uninformative.  
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Figure 5-7. Pitstop 2 and Dynasore do not inhibit BoNT/A(0) uptake.
A) Representative western blot results of samples from DIV14-17 cortical neurons pre-
treated for 30 min with vehicle 0.1% DMSO, 30 M Pitstop 2 or 80 M Dynasore and 
treated for 10 min with 25 nM BoNT/A(0) in presence of these compounds, plus non-
treated controls. Membranes were probed with anti-BoNT/A and anti-GAPDH 
antibodies. 
B) Quantification of the results, represented as mean values ± SEM. N = 4. 
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I also looked at the distribution of BoNT/A(0) in the presence and absence of endocytosis 
inhibitors. The same experiment was conducted but instead of lysing cells and analysing 
samples via western blot, cells were fixed and an immunofluorescence assay was performed 
(Figure 5-8). In cells not exposed to endocytosis inhibitors, signal was present in BoNT/A(0)-
treated cells which was absent in non-treated cells. This confirmed antibody specificity for 
immunostaining protocols. It is notable that only less than 50% of the cells presented positive 
signal for BoNT/A(0), suggesting BoNT/A(0) tropism for a particular cell type. Moreover, the 
BoNT/A(0) immunoreactivity was mostly punctate and present in most processes in the cells 
treated with BoNT/A(0), as observed in Figure 5-2.  
Figure 5-8. Pitstop 2 and Dynasore do not alter BoNT/A(0) staining profile.
Representative images of DIV14-17 hippocampal neurons pre-treated for 30 min with vehicle 
0.1% DMSO, 30 M Pitstop 2 or 80 M Dynasore and treated for 10 min with 25 nM 
BoNT/A(0) in presence of these compounds, plus non-treated controls. Staining was done with 
Anti-BoNT/A antibody. Scale bars are 10 m. 
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The same profile was observed in BoNT/A(0)-treated cells treated with endocytosis blockers, 
with no differences in levels or distribution of endocytosed BoNT/A(0). I concluded that 
BoNT/A(0) endocytosis was not affected by Pitstop 2 or Dynasore in my experimental 
conditions, either by their mechanism of action not being relevant or by inactivity of the 
compounds. 
I went on to test other endocytosis inhibitors, namely MiTMAB and Methyl--Cyclodextrin 
(MCD). MiTMAB constitutes a dynamin I and dynamin II inhibitor which binds to their lipid-
binding domain (Quan et al., 2007). MCD is a complexing agent, shown to extract cholesterol 
from membranes, therefore affecting processes which highly depend on this molecule such as 
lipid rafts and endocytosis in caveolae (Mahammad and Parmryd, 2015). The dependence of 
BoNT/A on lipid domains to be internalised is controversial (Couesnon et al., 2009; Ayyar and 
Atassi, 2016; Thyagarajan et al., 2017). 
Cells were pre-treated with these inhibitors as done for Pitstop 2 and Dynasore and exposed to 
25 nM BoNT/A(0) for 10 min. In this case, both inhibitors caused a significant decrease in 
BoNT/A(0) endocytosis (Figure 5-9). In MiTMAB-treated neurons, internalised BoNT/A(0) 
was 0.572 ± 0.122  times (p* < 0.05)  the amount internalised in the control, whereas it was 
0.136 ± 0.109 in MCD-treated neurons. This result was significantly lower than the control 
(p** < 0.01) but also lower than MiTMAB group (p* < 0.05).  
The reduction of internalised BoNT/A(0) suggests that the toxin uses dynamin-independent 
endocytosis to enter cells. In addition, these data indicates that BoNT/A(0) uses endocytic 
mechanisms particularly sensitive to MCD treatment. Furthermore, as observed before 
(Figure 5-5, Figure 5-6), bands above the main BoNT/A(0) band were observed. 
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Figure 5-9. Methyl--cyclodextrin and MiTMAB inhibit BoNT/A(0) uptake.
A) Representative western blot results of samples from DIV14-17 cortical neurons pre-
treated for 30 min with vehicle 0.1% DMSO, 25 M MiTMAB or 1 mM Methyl--
Cyclodextrin and treated for 10 min with 25 nM BoNT/A(0) in presence of these 
compounds, plus non-treated controls. Membranes were probed with anti-BoNT/A and 
anti-GAPDH antibodies. 
B) Quantification of the results, represented as mean values ± SEM. ANOVA followed 
by Tukey post hoc test, *p < 0.05, **p < 0.01. N = 3. 
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BoNT/A(0) traffics to early endosomes 
The punctate distribution of internalised BoNT/A(0) suggested that the toxin entered into 
neurons through endocytosis in a vesicle-like structure. I then investigated the nature of those 
vesicles. A pulse chase was performed to examine whether BoNT/A(0) trafficked through the 
endosomal pathway. Early endosomes were labelled by immunofluorescence using a primary 
antibody targeting Early Endosome Antigen 1 (EEA1), an early endosome marker (Wilson et 
al., 2000; Barysch et al., 2009). 
Cells were treated for 10 min with 25 nM BoNT/A(0) in feeding medium, and then washed and 
their conditioned medium replaced for different amounts of time (0 min, 10 min, 30 min or 60 
min) leaving the toxin to traffic, and the cells were then fixed. A non-treated control was also 
included.  
In non-treated samples, no signal was detected (Figure 5-10). At the elapsed time t = 0, the 
fraction of BoNT/A(0) colocalising with EEA1 using Manders’ coefficient (see section 2.2.6.3) 
was M = 0.591 ± 0.112, indicating positive but incomplete trafficking through early 
endosomes. Values were normalised to this time point and after 10 min, only 42.6 ± 6.8 % of 
the original BoNT/A(0) signal colocalised with EEA1, and remained constant with values of 
55.6 ± 3.3 % after 30 min and  57.8 ± 3.8 % after 60 min, being this decrease significantly 
different from the control (p** < 0.01 when comparing the control to any time point). This 
suggests that BoNT/A(0) traffics into early endosomes and about 50% exits them after a short 
period of time. However, a fraction of BoNT/A(0) colocalised with early endosomes after 1 h. 
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Figure 5-10. BoNT/A(0) traffics through early endosomes.
A) Representative images of DIV14-17 hippocampal neurons treated with 25 nM 
BoNT/A(0) for 10 min. After toxin exposure, cells were washed allowing toxin to 
traffic for 0 mins, 10 mins, 30 mins or 1 h. Cells were treated at different time points 
and fixed at the same time. Staining corresponds to EEA1 and BoNT/A(0). Scale bars 
are 1 m. 
B) Quantification of the results, represented as mean values ± SEM. Quantification of the 
colocalisation, measured using Mander’s coefficient. Colocalisation data was 
normalised to the value at time 0. ANOVA followed by Tukey post hoc test. **p < 
0.01. N = 3. 
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A fraction of BoNT/A(0) is degraded by the proteasome 
A fraction of BoNT/A(0) is resistant to degradation 
HCC/A enters through the endocytic pathway (Couesnon et al., 2009; Harper et al., 2011; Wang 
et al., 2015) and exits it in a short period of time (Figure 5-10), while staying clustered 
suggesting that BoNT/A(0) or its components traffic to another vesicular body in the cell 
including the autophagosome (Wang et al., 2015). This could be the degradation for 
BoNT/A(0) pathway so I first performed a time course experiment to determine the time scale 
of BoNT/A(0) degradation. 
Cells were treated for 10 min with 25 nM BoNT/A(0) in feeding medium. After this time, cells 
were washed and their conditioned media replaced for incubation for 1 day, 2 days and 3 days. 
In addition, a set of neurons was exposed to the toxin for the same amount of time and then 
lysed immediately. This was considered as the internalised amount of BoNT/A(0) prior to 
degradation and results were normalised to it. Cells were lysed on the same day while 
BoNT/A(0) treatment was applied on different days. 
Western blot results indicated that after 1 day, 28.0 ± 13.3 % of the originally internalised 
BoNT/A(0) remained in the interior of the cells (Figure 5-11). Surprisingly, 28.3 ± 10.8 % 
(p** < 0.01) of the toxin remained intact after 2 days (p** < 0.01 to the control, with no 
statistical difference with the previous value), and 20.1 ± 8.3 % after 3 days (p** < 0.01 to the 
control, no difference with the previous time points), indicating a quick degradation of 
BoNT/A(0) but a stabilisation of its levels over time.  
This could be indicative of BoNT/A(0) persistence. However, although the toxic effects of 
BoNT/A are very persistent, this is thought to be caused by LC/A (see section 1.7.3). My results 
suggest that full-length BoNT/A(0) is also protected from degradation by unknown 
mechanisms. 
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Figure 5-11. BoNT/A(0) is degraded to a level stable in time.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
with 25 nM BoNT/A(0) for 10 min, then washed and incubated with their 
corresponding conditioned medium for different amounts of time. Cells were treated 
on different days and lysed at the same time. Membranes were probed with anti-
BoNT/A and anti-GAPDH antibodies. 
B) Quantification of the results, represented by mean values ± SEM. ANOVA followed 
by Tukey post hoc test. ** = p < 0.01. N = 4. 
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BoNT/A(0) is degraded by the proteasome and not the lysosome 
To examine the pathway degrading BoNT/A(0) I chose the 24 h time point, as it was the time 
during which most of full-length BoNT/A(0) degradation occurred. As outlined in the 
introduction (sections 1.6.1.5 and 1.7.3.2), the two main mechanisms thought to be involved in 
BoNT/A degradation are the lysosome (HCC/A) and the proteasome (LC/A).  
To study these pathways, I used Leupeptin, an organic compound that blocks lysosomal 
degradation by inhibiting cysteine, serine and threonine proteases, many of them localised at 
the lysosome (Seglen et al., 1979). MG132 blocks proteasome action by blocking the 
degradation of ubiquitinated proteins by this complex (Lee et al., 1998). 
Neurons were pre-treated with either of these inhibitors, both, or a vehicle (DMSO) for 30 min 
before incorporating the toxin. Then, 25 nM BoNT/A(0) was applied for 10 min in presence (if 
applicable) of leupeptin or MG132 and then removed. Neurons were then washed and their 
respective conditioned media containing leupeptin or MG132 (if applicable) reintroduced for 
18 h. A positive control with cells treated for 10 min with 25 nM BoNT/A(0) and DMSO was 
included to assess the levels of protein before degradation.  
18 h after treatment in absence of degradation inhibitors (Figure 5-12), 25.5 ± 3.0% of the 
BoNT/A(0) originally entered remained intact as a 150 kDa protein, as compared to the control 
(10 min treatment) (p** < 0.01). Leupeptin-treated neurons had similar values, with 28.6 ± 
6.3% of the original BoNT/A(0) not having been degraded (p > 0.05 when compared to cells 
treated with plain medium, p** < 0.01 when compared to the control). This suggested that full-
length BoNT/A(0) escapes lysosomal degradation. However, MG132 treatment significantly 
reduced BoNT/A(0)  degradation, with 105 ± 24.4% of the original BoNT/A(0) being present 
after 18 h. This value was significantly higher (p** < 0.01) when compared to the cells without 
Leupeptin or MG132 and did not statistically differ from the cells lysed after the 10 min-long 
initial treatment (p < 0.05).  
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Figure 5-12. BoNT/A(0) degradation is rescued by MG132 but not by Leupeptin
A) Representative western blot results of samples from DIV14-17 cortical neurons pre-
treated for 30 min with 0.1% vehicle DMSO, 30 M Leupeptin, 5 M MG132 or a 
combination of both in conditioned medium before a 10 min-long 25 nM BoNT/A(0) 
treatment was applied for 10 min in presence of these compounds. Cells were then 
washed and added their corresponding conditioned medium with proteolysis inhibitors 
and incubated for 18 h. Control cells were exposed for 10 min to 25 nM BoNT/A(0) 
before lysis. Membranes were probed with anti-BoNT/A and anti-GAPDH antibodies.
B) Quantification of the results, represented by mean values ± SEM. ANOVA followed 
by Tukey post hoc test. * = p < 0.05, ** = p < 0.01. N = 3. 
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Similarly, a combination of both treatments preserved 86.9 ± 9.7% of BoNT/A(0), being this 
difference significantly higher than the group without proteolysis inhibitors (p* < 0.05) and 
similar to the MG132 alone group and the positive control (p < 0.05). In the blots, no bands for 
HC/A (100 kDa) were detected. This result suggests that BoNT/A(0) degradation occurred 
through the proteasome and not the lysosome. 
BoNT/A(0) is able to exit neurons and re-enter them 
It has been published that:  
1. HCC/A undergoes retrograde trafficking in neurons (Restani et al., 2012a, Wang et 
al., 2015). 
2. BoNT/A mediated SNAP-25 cleavage can occur in neurons away from the injection 
site (Antonucci et al., 2008). 
3. LC/A effects can spread from cell to cell after LC/A transfection (Arsenault et al., 
2014b).  
4. Antibodies targeting HC/A block distal effects of BoNT/A (Bomba-Warcza et al., 
2016). 
I examined if my BoNT/A(0) molecule was internalised by neurons, and then secreted and 
internalised into other neurons. To do this I performed the experiment shown in (Figure 
5-13A). 
Neurons were first treated with 25 nM BoNT/A(0) for 18 h (Figure 5-13A, fourth column). 
After that time, medium was replaced with fresh feeding medium. After 24 h, the newly added 
medium was removed, transferred to non-treated cells and incubated for 24 h (Figure 5-13A, 
third column). The originally BoNT/A(0)-treated culture (fourth column) was added new fresh 
medium and incubated in parallel. After incubation, an independent culture was treated for 10 
min as a positive control (second column). Finally, a non-treated culture was included as a 
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negative control (first column). No phenotypical changes were observed at the end of the 
experiment. Samples were lysed at the same time and run in a western blot (Figure 5-13B). 
Figure 5-13. BoNT/A(0) is internalised from medium conditioned by BoNT/A(0)-treated 
cells. 
A) Schematic of the experiment. DIV14-17 cortical neurons were treated with 25 nM 
BoNT/A(0) (represented by green star) for 18 h. After this time, cells were washed and 
medium was replaced with fresh feeding medium and incubated for 24 h. This 
conditioned medium (in dark orange) was removed and applied to non-intoxicated cells 
and incubated for 24 h. A 10 min-long 25 nM BoNT/A(0) treatment was included as a 
positive control, and non-treated cells as a negative control. Cells were lysed on the 
same day. Membranes were probed with anti-BoNT/A and anti-GAPDH antibodies. 
B) Representative western blot result for the experiment described in A. N = 3. 
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As it was expected, in the positive control a band at the 150 kDa position was present, while 
absent in the non-treated negative control. In the conditioned neurons (Figure 5-13A, fourth 
column), a band corresponding to internalised BoNT/A(0) were present. Finally, BoNT/A(0) 
was also present in samples from neurons treated only with the conditioned medium produced 
by BoNT/A(0)-treated neurons, suggesting that BoNT/A(0) is endocytosed by neurons as a 
full-length toxin after it has been exocytosed by the neurons that originally internalised it. 
Discussion 
Validation of BoNT/A(0) as a tool 
In the previous chapter, I explained how I designed and produced tools to study the unique 
behaviour of BoNT/A. Unfortunately, these tools had a limited usability and were discontinued 
(section 4.4.5). To overcome this difficulty, I tested a different tool, BoNT/A(0).  
I initially tested entry of the toxin into my cultures by using a polyclonal antibody targeted to 
the full-length toxin (Figure 5-1, Figure 5-2). This experiment revealed that neurons 
internalised BoNT/A(0) and that my antibody could detect full-length BoNT/A(0) as well as 
HC/A, but not LC/A. The use of a monoclonal antibody to detect the LC was also discarded, 
as it only recognised LC/A in native state and diffuse staining was observed (Figure 5-3). 
Importantly, I was able to detect BoNT/A(0) entry after 10 min by western blot under resting 
conditions, facilitating further trafficking studies.  
BoNT/A(0) entry into neurons was increased by depolarisation consistent with previous 
publications for BoNTs (Harper et al., 2011; Restani et al., 2012a; Wang et al., 2015) (Figure 
5-4). This indicates that this mechanism of entry for BoNT/A(0) does not greatly differ from 
the ones involved in HCC/A endocytosis.  
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BoNT/A(0) endocytosis 
BoNT/A(0) enters through the synapse 
Our results have also shown that BoNT/A(0) enters through the synapse (Figure 5-5). In 
experiments enhancing the net activity of the network with the GABAA antagonist bicuculline 
(Olsen et al., 2018) there was an increase in toxin endocytosis, indicating that BoNT/A(0) 
enters neurons via activity-dependent pathways (Figure 5-5). This is entirely consistent with 
the current model for BoNT/A internalisation (see section 1.6.1). Moreover, treatment with 
TTX, which blocks neuronal activity (Bane et al., 2014), reduced BoNT/A(0) internalisation. 
However, this reduction was not complete and BoNT/A(0) was still internalised by my cells. 
This suggests that BoNT/A(0) can also enter cells independent of the synapse. 
Whether bicuculline promotes or not BoNT/A endocytosis has been studied only in vivo
(Drinovac et al., 2014). This work has been done in the context of chronic pain, which is 
thought to respond to abnormal GABAergic activity (Graeff et al., 1986). Injection of 
bicuculline intraperitoneally or intracisternally reduced the anti-nociceptive action of BoNT/A, 
whereas intrathecal injection did not (Drinovac et al., 2014). This would mean that BoNT/A 
action is reduced by bicuculline in the CNS, which would be contrary to my results. However, 
this discrepancy could be explained by the different models used, as my system does not 
resemble the complex organisation of the CNS. Indeed, the authors of the cited study consider 
that their observed effect is due to an indirect interaction between opioid and GABAergic 
signalling and not to differences in BoNT/A endocytosis (Drinovac et al., 2014). 
Our work showed that, in a neuronal culture, a decrease in network activity by TTX leads to a 
reduction of  BoNT/A(0) uptake, whereas bicuculline increased it (Figure 5-5). This indicates 
that synapses are a mechanism of entry for BoNT/A(0).  
Furthermore, TTX, Bic or K+-induced changes cannot be explained by differences in 
BoNT/A(0) binding to the membrane, as BoNT/A binding to the membrane is independent of 
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neuronal activity (Simpson et al., 1980). Rather, these are indicators of effects on endocytosis 
of BoNT/A(0). 
BoNT/A(0) can also enter neurons by activating Fgfr3 
HCC/A can enter PC-12 cells via the Fgfr3 receptor, which is also expressed at the NMJ (Jacky 
et al., 2013). In my experiments, blocking Fgfr3 cross-phosphorylation reduced BoNT/A(0) 
endocytosis in neurons (Figure 5-6), indicating that Fgfr3 also provides a route of entry for 
BoNT/A in neurons, with quantitatively similar contribution to those published in neuron-like 
cell lines (Jacky et al., 2013). Cross-phosphorylation of the receptor is necessary for Fgfr3 
internalisation and triggers signalling (Li et al., 1997). Because SU5402 acts intracellularly 
(Toledo et al., 1999), it is unlikely that SU5402 interferes with binding of BoNT/A(0) to the 
cell surface. Moreover, it shows that Fgfr3 is an active receptor for BoNT/A. Fgfr3 has a higher 
affinity for BoNT/A than SV2C (Jacky et al., 2013) and my data shows that it also is a route of 
entry for BoNT/A in neurons.  
In conclusion, my results demonstrate that synapse-independent endocytosis can occur in 
neurons, as blocking neuronal activity with TTX did not block BoNT/A(0) entry (Figure 5-5) 
and this could be mediated by Fgfr3 (Figure 5-6). 
BoNT/A(0) enters neurons through dynamin-dependent and dynamin-independent 
mechanisms 
To characterise the mechanisms underlying the endocytic processes described, I used a series 
of endocytosis blockers. I used Dynasore, which acts on dynamin I and II and Dynamin-related 
protein 1 (Drp1) (Preta et al., 2015), and Pitstop 2, which blocks clathrin-dependent and some 
types of clathrin-independent endocytosis (Dutta et al., 2012). In my experimental conditions, 
neither Dynasore or Pitstop 2 were able to inhibit BoNT/A(0) entry, revealed by western blot 
and immunofluorescence assays (Figure 5-7, Figure 5-8).  
157 
To overcome this difficulty, I tested MiTMAB, also a dynamin I and II inhibitor (Quan et al., 
2007), following the same protocol as for Dynasore and Pitstop 2. MiTMAB reduced 
BoNT/A(0) uptake (Figure 5-9). This effect was limited, indicating the existence of dynamin-
independent endocytosis routes for BoNT/A. Likewise, inhibition of this process with Dyngo-
4a also yielded in a reduction of HCC/A uptake (Harper et al., 2011). In addition, their 
experiments also show a decrease of endocytosis after treatment with Dynasore. However, their 
observed reduction was more pronounced and the experimental conditions were different, as 
these experiments were done under depolarising conditions (Harper et al., 2011), which is 
known to alter HCC/A trafficking (Wang et al., 2015). BoNT/A-treated mice died of botulism 
in a short time in absence or presence of Dyngo-4a (Harper et al., 2011). However, Dyngo-4a 
did delay the onset of and death by botulism. This could be explained because only a partial 
reduction of SNAP-25 cleavage was achieved with dynamin blockade by Dyngo-4a. Since 
BoNT/A(0) does not cleave SNAP-25, I was unable to test this. 
Interestingly, Fgfr3 is able to undergo dynamin-independent endocytosis (Haugsten et al., 
2011) and BoNT/A could exploit this endocytic pathway as its ligand (Jacky et al., 2013; 
Figure 5-6).  
BoNT/A uses cholesterol to enter neurons 
Additionally, I tested the effect of MCD, a cyclodextrin capable of extracting cholesterol from 
the membrane (Mahammad and Parmryd, 2015). Due to the importance of cholesterol in 
membrane fluidity, this molecule plays an important role in the formation of lipid rafts 
(Kinoshita and Kato, 2008). MCD does not interfere with other mechanisms of endocytosis 
at the concentrations used (Rodal et al., 1999). Lipid rafts have been implicated in various 
processes relevant for BoNT biology. For example, forming, maintenance and function of 
cholinergic synapses are dependent on cholesterol and lipid rafts (Stetzkowski-Marden et al., 
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2006; Zamir et al., 2006; Cuddy et al., 2014). Consistent with these data, MCD drastically 
reduced BoNT/A(0) uptake by mature neurons (Figure 5-9).  
HCC/A binds to lipid rafts in neurons (Herreros et al., 2001). In differentiated neuron-like 
NG108-15 cells, MCD reduced HCC/A binding to the cell membrane (Couesnon et al., 2009), 
supporting my result. I have highlighted the importance of the differentiation status of the cell, 
as recent investigations indicate that neonatal mice are resistant to BoNT/A and can be 
sensitised using MCD (Thyagarajan et al., 2017). This finding is supported by other studies, 
which show that BoNT/A activity can be enhanced by MCD in undifferentiated Neuro2A 
cells (Petro et al., 2006). This can be explained by an increased binding of HCN/A to 
gangliosides in Neuro2A cells treated with MCD (Ayyar and Atassi, 2016). However, HCC/A 
binding to the membrane was unaffected. Therefore, it is likely that the activity increase seen 
is a consequence in channel-forming properties of HCN/A and a more efficient release of the 
LC. In addition, it must be considered that babies suffer infant botulism (see section 1.4.1.1) 
and the neonatal resistance in mice (Thyagarajan et al., 2017) could be restricted to the model 
used. Nonetheless, MCD effect on HCC/A entry varies from intestinal to non-intestinal cell 
lines (Couesnon et al., 2009). 
TeNT is able to enter cells independently of synaptic vesicle recycling (Herreros et al., 2001), 
as well as BoNT/A (Pellett et al., 2015a) and undergoes retrograde axon like HCC/A (Restani 
et al., 2012a). Moreover, BoNT/A and TeNT share endocytic routes (Blum et al., 2012). In 
differentiated PC-12 cells and spinal cord motor neurons, TeNT uses lipid rafts to enter cells 
(Munro et al., 2001, Herreros et al., 2001, Deinhardt et al, 2006).  
Furthermore, other toxins previously introduced (section 1.3.1.2) also depend on lipid rafts to 
enter their target cells. Botulinum toxin C2 binding and action is inhibited by MCD 
(Nagahama et al., 2009), while Botulinum toxin C3 (a non-binary toxin) appears to use a single 
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endocytic route, being this of cholesterol-independent (Rohrbeck et al., 2015). Botulinum toxin 
C16S, a complex formed with BoNT/C and several NAPs, undergoes endocytosis via clathrin-
coated pits and caveolae, which are dependent on cholesterol (Simons and Toomre, 2000; 
Uotsu et al., 2006). Endocytosis of Cholera toxin (produced by Vibrio cholera), which has been 
shown to be similar to an extent to that of TeNT and BoNT/A (Montesano et al., 1982; Harper 
et al., 2016), is also dependant on lipid rafts and dynamin-independent endocytosis (Torgersen 
et al., 2001; Massol et al., 2004). This was suggested to be caused by a reduction in the binding 
between gangliosides and the toxin at the membrane (Ermolinsky et al., 2013). Interestingly, 
Cholera toxin has been demonstrated to modify its preferred entry mechanisms during 
development (Torgersen et al., 2001; Lu et al., 2005).  
In conclusion, BoNT/A has multiple entry routes in to cells (Harper et al., 2011; Restani et al., 
2012a; Pellett et al., 2016, section 5.4.2), it can be enter into non-neuronal cell lines such as 
HEK293T or Caco-2 cells (Jacky et al., 2013, Couesnon et al., 2009) and intestinal cells 
(Maksyowych et al., 1999; Couesnon et al., 2008). Moreover, the relative importance of the 
multiple BoNT/A endocytic routes varies depending on the cell type being intoxicated 
(Couesnon et al., 2009). Therefore, as for Cholera toxin, I suggest a developmentally regulated 
mechanism for BoNT/A(0) endocytosis depending on cholesterol, in an analogous way as it 
occurs with Cholera toxin (Torgersen et al., 2001; Lu et al., 2005).  
Clearly, this is not the sole mechanism of BoNT/A entry, but may play an important role for 
investigating future therapeutic used of BoNT-type delivery mechanisms. Collectively, my 
data and published work indicate that one of the routes of entry for BoNT/A is cholesterol-
sensitive and developmentally regulated and different across cell types. 
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BoNT/A(0) enters the endocytic pathway 
BoNT/A(0) traffics through early endosomes 
Although BoNT/A is thought to enter recycling synaptic vesicles, it also enters non-recycling 
synaptic vesicles (Restani et al, 2012a; Harper et al., 2016). Synaptic vesicles recycle through 
early endosomes (Johnston et al., 1989; Holrdoyd et al., 1999) and HCC/A-containing non-
recycling vesicles enter autophagosomes (Wang et al., 2015). As BoNT/A requires a decrease 
of pH to release LC/A to the cytoplasm (Donovan and Middlebrook, 1986; Galloux et al., 
2008), I studied how BoNT/A trafficked through the endocytic pathway.  
Our antibody was validated for immunofluorescence studies, as non-treated cells lacked 
staining present in BoNT-treated cells (Figure 5-2). Moreover, this staining was punctate but 
in clusters distributed across all the processes in treated neurons. Similar distributions have 
been observed previously reinforces the idea of BoNT/A being endocytosis by multiple 
mechanisms in neurons and not solely at presynaptic terminals (Harper et al., 2011; Restani et 
al., 2012a; Wang et al., 2015; Harper et al., 2016). Furthermore, not all cells showed 
internalised toxin (Figure 5-2, Figure 5-3, Figure 5-8), suggesting the toxin has a preference 
for certain neuronal types. Some research suggested that BoNT/A susceptibility is dependent 
on the neuron type intoxicated as GABAergic and glutamatergic neurons have different SNAP-
25 expression profiles and BoNT/A action depends on specific calcium dynamics within the 
cell (Verderio et al., 2004, Tafoya et al., 2006; Tafoya et al., 2008; Grumelli et al., 2011). 
However, BoNT/A is able to be endocytosed and silence both populations (Beske et al., 2015).  
Fascinatingly, BoNT/A silencing of GABAergic neurons occurs before silencing of 
glutamatergic neurons, resulting in an increased activity of the circuit, and increased BoNT/A 
uptake (Beske et al., 2015). I have seen that blocking inhibitory GABAA receptors increases 
BoNT/A uptake (Figure 5-5). However, unlike BoNT/B or /F, BoNT/A cannot be endocytosed 
by glia (Verderio et al., 1999; Vazquez-Cintron et al., 2014). Non-labelled cells were present 
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in my cultures which could correspond to glial cells and all the effects observed regarding 
endocytosis would be restricted to the neuronal population, although this possibility was not 
tested.  
I detected limited colocalisation of BoNT/A(0) with EEA1 after endocytosis, and a fraction of 
BoNT/A(0) exited this organelle and trafficked further (Figure 5-10). Fgfr3 localises to early 
endosomes at times similar to the values I have presented (Haugsten et al. 2011). However, 
another study suggests that the initial level of colocalisation is larger and stable over a longer 
period of time (Harper et al., 2011). A fraction of HCC/A also stays stable at presynaptic 
terminals (Restani et al., 2012a). In these experiments, HCC/A entry occurred under 
depolarising conditions induced by high potassium concentrations, and trafficking of BoNT/A 
through the endocytic pathway has been shown to be different between normal conditions and 
under depolarisation (Wang et al., 2015). Furthermore, potassium depolarisation promotes the 
generation of autophagosomes, involved in BoNT/A trafficking (Wang et al., 2015). Therefore, 
it is possible that potassium depolarisation promoted a route which stabilised HCC/A at the 
early endosome. I have also seen a stabilisation of BoNT/A(0) over time, which could 
correspond to the pathway potentiated by potassium depolarisation. 
Nevertheless, I propose that, in normal conditions, the totality of endocytosed BoNT/A would 
not stay static in the early endosome but move further in the endocytic pathway. During this 
process, acidity increases until the lysosome is reached. Early endosomes are at the top of the 
route and are only lightly acidic organelles with pH ≈ 6.0 (Forgac et al., 1982; McNeil et al., 
1983). BoNT/A, like other BoNTs, theoretically needs a lower pH value for LC/A to be 
dissociated (Puhar et al., 2004), although LC/A release occurs from the moment in which 
BoNT/A is endocytosed at synaptic vesicles (Pirazzini et al., 2014).  
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BoNT/A(0) fate after endocytosis 
A fraction of BoNT/A(0) is resistant to degradation 
BoNT/A(0) entered and exited early endosomes in my experimental conditions (Figure 5-10) 
and I proposed the toxin to follow the endocytic route and get degraded by the lysosome. Full-
length BoNT/A(0) levels decreased during first 24 h after treatment, while no HC/A was 
detected (Figure 5-11). One possibility is the dissociation and immediate degradation of the 
HC. However, no HC/A was observed when protein degradation was blocked (Figure 5-12), 
indicating a much slower release of LC by BoNT/A(0) than by BoNT/A (Pirazzini et al., 2013). 
This could be due to the lack of autocatalytic activity in BoNT/A(0), known to contribute to 
LC release (see section 1.7). When looking at further points, surprisingly, full-length 
BoNT/A(0) levels remained stable over time, without no major degradation or dissociation 
occurring after 3 days. 
BoNT/A can persist for days in the blood stream after infection (Sheth et al., 2008; Fagan et 
al., 2009). This is interesting because my antibody recognises the full-length toxin of 150 kDa 
and my data indicate that a fraction of the intact toxin, as well as the previously reported LC/A 
fragment (see section 1.7.3) are persistent in neurons.  
For me to see this effect, the toxin needs to evade degradation at the lysosome. Four 
possibilities have been considered that can explain this phenomenon:  
1. Protection from lysosomal degradation. 
2. Arrest of maturation of the endocytic organelle.  
3. Escape from the endocytic pathway.  
4. Different combinations of all of the above. 
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Protection from lysosomal degradation 
First, BoNT/A(0) reached the lysosome but protected itself from degradation by an unknown 
mechanism. Nevertheless, an increase in acidity would result in dissociation of the LC from 
the HC (Puhar et al., 2004) and if the two components dissociated, I would be able to see a 
shift in the molecular weight of the observed band, from 150 kDa to 100 kDa. This is under the 
condition of HC/A not getting degraded by the lysosome. However, HCC/A can traffic to 
lysosomes in normal conditions and BoNT/A molecules that trafficked to the lysosome would 
undergo the conformational changes induced by low pH (Restani et al., 2012a; Wang et al., 
2015). I considered this option to be unlikely and favour a model in which full-length 
BoNT/A(0) stayed intact and escaped degradation by the lysosome at some point during the 
endocytic route, leaving two other options.  
Arrest of maturation of the endocytic organelle 
Second, a fraction of BoNT/A(0) could have stayed in the endosomal pathway without further 
progressing by blocking endosome maturation. This is supported by my results and by other 
research which show a fraction of the toxin remaining stable in early endosomes over time 
(Figure 5-10; Harper et al., 2011) or at the presynaptic terminal (Restani et al., 2012a). Such 
behaviour would require a blockade of the fusion between the phagosome and the lysosome. 
Some intracellular bacteria such as Brucella suis, Mycobacterium tuberculosis or Salmonella 
are internalised in vesicles whose maturation is arrested before fusion with the lysosome, 
avoiding degradation (Sun et al., 2013; Kohler and Roy, 2017; Rajaram et al., 2017). These 
have mechanisms which appear may relate to BoNT/A. For example, Brucella suis requires 
gangliosides to enter cells and is dependent on cholesterol (Naroeni et al., 2002). Salmonella
enters cells by modulating Ras-related Botulinum toxin C3 substrate 1 (Rac1) activity (Friebel 
et al., 2001; Stebbins et al., 2005). As its name suggests, this is the natural target of a toxin 
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produced by C. botulinum (Didsbury et al., 1989). Nonetheless, these mechanisms lack any 
experimental evidence regarding BoNT/A. These are treated further in section 7.3.2 
Escape from the endocytic pathway 
The third explanation consists of BoNT/A(0) escaping the pathway before reaching lysosomes 
and being exocytosed making it available to be  re-endocytosed. Other toxins, including TeNT 
and Cholera toxin, undergo retrograde trafficking and avoid lysosomes before reaching their 
target (Price et al., 1975, Sandvig et al., 1994). BoNT also undergoes retrograde transport 
(Restani et al., 2012a; Wang et al., 2015) and its effects are observed in sites away from the 
site of injection (Restani et al., 2012b). Furthermore, a fraction of HCC/A avoids lysosomes 
(Restani et al., 2012a; Wang et al., 2015). For this hypothesis to be true, BoNT/A(0) must 
undergo repeated cycles of endocytosis and exocytosis with a very high efficiency. In addition, 
a threshold for this pathway would be necessary, as the BoNT/A(0) levels remained constant 
from day 1 to day 3 (Figure 5-11). Under this threshold, degradation mechanisms would not 
detect BoNT/A(0) and it would constantly be recycled. In this scenario, mechanisms relying 
on high affinity would be reserved for recycling BoNT, whereas non-recycling BoNT would 
traffic to degradation with low affinity mechanisms, as only a limited fraction of BoNT/A(0) 
presented this effect. In addition, it would be necessary that the totality of the toxin remaining 
after the initial degradation had to be exocytosed, re-endocytosed for, at least, 48 h. This 
potential mechanism will be discussed later. 
Combination of the previous explanations 
In the blood stream, intact BoNT/A has been detected up to 25 days after intoxication, 
indicating protein stability (Sheth et al., 2008; Fagan et al., 2009). This is supportive on the 
existence of BoNT/A protection mechanisms beyond those of the LC.  
Combinations of the above pathways are also possible, even though protection from 
degradation within the lysosome seems an unlikely option. In addition, while I acknowledge 
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that none of the three explanations are fully supported by our or other data, they remain 
intriguing possibilities that are the focus of active research.   
BoNT/A(0) escapes degradation by the lysosome but gets degraded by the proteasome 
It has been discussed in the previous section that BoNT/A(0) can evade lysosomal degradation 
and my data, under not stimulated conditions, suggest it is degraded by the proteasome (Figure 
5-12). In normal conditions, a minority of HCC/A molecules retrogradely traffic in acidic 
organelles (Restani et al., 2012a). Potassium-induced depolarisation of neurons promoted 
HCC/A trafficking to the lysosome, likely targeting it for degradation (Wang et al., 2011). I 
considered effects of MG132 on endocytosis, but although it can affect endocytosis by altering 
the degradation state of BoNT/A(0) receptors, MG132 does not alter the endocytic pathway 
(Pilecka et al., 2011; Degnin et al., 2011). 
It has been shown that inhibition of the proteasome attenuates BoNT/A-induced muscle 
atrophy (Houston et al., 2018). However, this effect may be indirect as a result of an arrest of 
general protein degradation and not directly linked to BoNT/A (Fanin et al., 2014; Milan et al., 
2015). Similar treatments in a different model of muscle inactivity support this idea (Smuder 
et al., 2014).  
Potential BoNT/A(0) ubiquitination 
As explained in the introduction, LC/A can be targeted by the ubiquitin-proteasome system 
(section 1.7.3.2). This indicates that LC/A, and therefore BoNT/A(0), presents an 
ubiquitination site. I have observed bands that appeared to be specific for BoNT/A(0)-treated 
samples with a molecular weight higher than that of BoNT/A(0) (Figure 5-5, Figure 5-6, 
Figure 5-7, Figure 5-9, Figure 5-11, Figure 5-12). These were absent in samples run in 
presence of Me (Figure 5-4). Also, similar bands have been observed before on BoNT/A-
treated samples but not on HCC/A-treated ones (Coffield and Yan, 2009). These could suggest 
posttranslational modifications, specially ubiquitination, of BoNT/A on the LC before 
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dissociation that would lead to degradation by the proteasome (Figure 5-12). Nonetheless, 
more research needs to be done to confirm that BoNT/A is ubiquitinated.  
Full-length BoNT/A(0) is thought to be either at the lumen of a vesicle or inserted at membrane 
before HC-LC dissociation occurs (Montecucco and Schiavo, 1994; Koriazova and Montal, 
2003). Assuming that the proteasome does not translocate to the lumen of the organelle 
containing the toxin, BoNT/A(0) could be degraded  as a membrane-bound protein, like Fgfr3 
(Degnin et al., 2011). If so, this must occur after HCN/A is inserted into the membrane and 
before LC/A(0) dissociation. 
I consider that LC/A is exposed to ubiquitination and degradation before it reaches its target, 
as it lacks the protective effect of septins (Vagin et al., 2014) and possibly of deubiquitinating 
enzymes (Tsai et al., 2017). This would lead to degradation by the proteasome. In contrast, 
HC/A molecules which have successfully released their corresponding LC/A would not be 
recognised by the ubiquitin-proteasome system and would get degraded at the lysosome, as 
some research suggests (Harper et al., 2011; Wang et al., 2015).  
Degradation by the proteasome 
When focusing on proteins which BoNT/A(0) co-traffics with, degradation of SV2 has not 
been studied whereas degradation of Fgfr3 has been suggested to occur through the lysosome 
(Haugsten et al., 2005; Ota et al., 2016) and the proteasome (Degnin et al., 2011, Laederich et 
al., 2011). Interestingly, not Fgfr3 but Fgfr1 was shown to better escape lysosomal degradation 
(Haugsten et al., 2005). Phosphorylation of Fgfr3 is necessary for this process to occur, and in 
concordance with my results (Figure 5-6) and published data (Jacky et al., 2013), BoNT/A 
triggers activation and endocytosis dependant on phosphorylation. This can lead to degradation 
of the receptor (Degnin et al., 2011). Very interestingly, Fgfr3 is ubiquitinated by Carboxyl 
terminus of Hsp70-Interacting Protein (CHIP) but also interacts with this protein and Hsp90 
(Laederich et al., 2011). Hsp70 and Hsp90 are involved in the translocation of Botulinum toxin 
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C2 (Haug et al., 2003; Ernst et al., 2017), but only Hsp90 has been described to be involved in 
the translocation of BoNT/A (Azarnia Tehran et al., 2017) without ruling out the possibility of 
Hsp70 being involved. Therefore, similar mechanisms as the ones involved in Fgfr3 
degradation could exist for BoNT/A. 
Finally, promoting BoNT/A degradation by the proteasome could be used as a preventive 
treatment for botulism before disease onset. 
BoNT/A(0) is exocytosed and re-endocytosed as a full-length toxin 
I have discussed previously (section 5.5.4.2) how BoNT/A(0) escaped degradation by the 
lysosome could be explained by exocytosis and endocytosis of the molecule. If, as these data 
indicate, a fraction of full-length BoNT/A is not degraded I explored a more likely possibility. 
In my model, BoNT/A(0) is able to enter cells for then being released into the medium and re-
endocytosed as a single polypeptide (Figure 5-13). 
HCC/A is retrogradely transported in neurons in autophagosomes (Wang et al., 2015) and 
BoNT/A effects are found away from the injection site (Antonucci et al., 2008; Restani et al., 
2012b). Blocking HC/A with antibodies also result in a reduction of SNAP-25 cleavage 
(Bomba-Warcza et al., 2016).  
However, heterologous expression of a LC/A construct in culture resulted in total SNAP-25 
cleavage, despite transfection efficiency not being total (Arsenault et al., 2014b). My results 
suggest that it is the full-length toxin the molecule which would undergo transcytosis. 
Conclusion 
I have validated BoNT/A(0) as a tool and a specific antibody suitable for its detection by 
western blotting and immunofluorescence, although LC/A specific detection was not possible. 
Regarding endocytic processes BoNT/A(0) behaved similarly to HCC/A, indicating minimal 
contribution of the channel-forming domain (HCN/A) or the protease domain (LC/A). 
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BoNT/A(0) enters cultured neurons through multiple mechanisms. One of them occurs at the 
presynaptic terminal. Another mechanism is mediated by Fgfr3, whose activation is necessary 
for internalisation of the toxin. In addition, I have highlighted the importance of cholesterol for 
BoNT/A(0) uptake in cultured neurons. Finally, BoNT/A(0) endocytosis occurs through both 
dynamin-dependent and dynamin-independent pathways. 
Our results suggest that BoNT/A traffics to early endosomes at least partially, where it can 
follow three routes:  
1. The catalytic route, where LC/A would be released and cleave SNAP-25,  
2. The degradation route, where the proteasome detects and degrades the toxin  
3. The transcytosis route, by which BoNT/A would be able to exit neurons and enter 
neighbouring cells.  
Other fates are also possible, as imaging studies may also suggest that BoNT/A is able to 
remain in early endosomes without further trafficking, potentially caused by an arrest of 
endosomal maturation. A model integrating the nature of the multiple vesicles BoNT/A visits 
and their inter-relationships, the causes of lysosomal escape, the agents involved in degradation 
by the proteasome, other possible endocytosis routes and or other fates within the cell is 
depicted below (Figure 5-14). 
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Figure 5-14. BoNT/A fate after endocytosis. 
An integrated view of BoNT/A trafficking. In the synapse (peach colour background), 
BoNT/A can enter both via recycling and non-recycling vesicles, including structures 
dependent on lipid rafts such as caveolae. At this point, LC/A release starts. A fraction of 
BoNT/A is retrogradely transported by autophagosomes to the cell soma body (blue 
background), whereas another fraction stops in early endosomes. BoNT/A can also use Fgfr3 
to enter the endocytic pathway. LC/A dissociation expose ubiquitination sites and forces 
degradation of BoNT/A by the proteasome. Little or none toxin gets degraded at the lysosome.
170 
Chapter 6 HCC/A-mediated Neurotrophic Effects of BoNT/A(0)  
171 
Aims 
The aim of this chapter was to explore the effect of BoNT/A on neurite outgrowth and the 
signalling pathways behind it. After initial positive results, I then broadened this aim to 
investigate other potential neurotrophic effects and whether they shared the same causal 
mechanisms with the effects seen on neurite outgrowth. More specifically, I examined; 
1. The possible activation by BoNT/A of known pathways involved in neurite formation 
and outgrowth.  
2. Other neurotrophic effects (filopodia formation, neurogenesis, synaptic vesicle 
release) and their underlying signalling pathways.  
3. The functional consequences of these effects on BoNT/A endocytosis. 
Introduction 
BoNT/A effects beyond synaptic silencing 
A wide range of actions have been proposed for BoNT/A in addition to its effects on 
presynaptic release via cleavage of SNAP25. Some of them are reviewed at Matak et al., 2015, 
while here the most relevant will be outlined. Importantly, these effects suggest that BoNTs 
could have valuable therapeutic potential in diverse pathways. 
Effect on phospholipids 
BoNT/A has been shown to affect the physiology of arachidonic acid (AA) and 
lysophosphatidic acid (LPA), both produced by phospholipase A2 (PLA2) (Farooqui et al., 
1997). AA is a signalling molecule messenger with functions in Ca2+ mobilisation, ion channel 
modulation and neurotransmitter transport and uptake (Katsuki et al., 1995). BoNT/A inhibits 
its release and AA-mediated effects on neurotransmitter release in PC-12 cells, an effect which 
is proposed to be independent of SNAP-25 (Ray et al., 1993; Zhang et al., 2017). LPA, and 
similarly AA, signals through a G-protein coupled receptor (GPCR) to induce neurite 
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outgrowth via a Ras superfamily member, Ras homolog B (RhoB) and Rac1 (Kim et al., 1997; 
Gohla et al., 1998; Nakashima et al., 2003). Interestingly, BoNT/A promotes RhoB degradation 
at the proteasome interfering therefore with induced cytoskeletal rearrangements by it (Ishida 
et al., 2004) and induces Rac1 transcript expression (Park et al., 2016). 
Apoptosis and cell proliferation 
BoNT/A has been shown to inhibit growth of the prostate cancer cell line LNCaP (Karsenty et 
al., 2009). In T47D cells, a breast cancer cell line, BoNT/A induced apoptosis (Bandala et al., 
2013). On the other hand, has been reported to inhibit apoptosis in neuron-like SY-SH5Y cells 
(Kumar et al., 2012). 
In addition, BoNT/A has been shown not to alter fibroblasts proliferation (Oh et al., 2012), 
whereas other studies suggest that BoNT/A inhibits it (Zhibo et al., 2008). Fibroblasts do not 
express SNAP-25, and these effects could possibly due to Fgfr3 activation by BoNT/A (Jacky 
et al., 2013) or by an effect of muscle distension derived from flaccid paralysis induced by 
BoNT/A (Sobel, 2005).  
Gene expression 
Many studies have linked BoNT/A treatment with regulation of gene expression (summarised 
in Table 6-1). Two interesting ‘brute-force’ studies have been conducted for BoNT/A. One of 
them compared the expression profiles of epithelium-type cell and neuronal-type cell lines after 
BoNT/A intoxication, and the other compared the effects of treatment with BoNT/A and 
BoNT/A(0). 
In the first study, two cell lines (HT-29 and SH-SY5Y) were compared. Proteins involved in 
proteasomal degradation were upregulated in both cell lines (Thirunavukkarasu et al., 2011). 
In the previous chapter, proteasomal degradation was identified as the mechanism responsible 
for BoNT/A(0) clearance (section 5.4.4.2). In HT-29 colon-derived clonal cells, the level of 
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many proteins with functions on cell adhesion was altered (Thirunavukkarasu et al., 2011), 
while in neuron-like SH-SY5Y cells, there was an upregulation of immune and inflammatory 
processes.  
The second study compared BoNT/A to BoNT/A(0) and non-treated cells in human Induced 
Pluripotent Stem Cells (hIPSCs). Between BoNT/A and BoNT/A(0), only a heat shock protein,  
Heat Shock Protein family A member 6 (HSPA6), protein was regulated differentially between 
cells exposed these groups (Scherf et al., 2014). When comparing both groups to a non-treated 
control, upregulated proteins were positive regulators of neuronal function, including many 
proteins involved in neurite outgrowth. Among them, FGF-2 (an endogenous ligand of Fgfr3, 
see section 1.6.1.2), was particularly noteworthy. Retinol dehydrogenase 10, involved in 
retinoic acid biosynthesis and therefore neurogenesis was also upregulated. Additionally, other 
proteins related to Ca2+ signalling were upregulated, for example the muscarinic acetylcholine 
receptor 3 (CHRM3). 
Other specific studies have reported changes in the expression profile of different genes, 
summarised in the following lines. 
BoNT/A has been proposed to upregulate the mRNA expression of several small GTPases, 
including Rac1, cell division control protein 42 (Cdc42) and RhoA at the transcript level in 
human dermal fibroblasts (Park et al., 2016) and also related to neurite outgrowth (for their 
regulation, see 6.2.2.2). Interestingly, however, RhoB degradation by the proteasome is 
enhanced by BoNT/A in PC-12 cells (Ishida et al., 2012). 
Importantly, the expression of NGF, tyropomyosin kinase receptor A (TrkA) and p75NTR at the 
mRNA level is promoted bladder biopsies after injection of BoNT/A into the detrusor muscle, 
which controls urination (Giannantoni et al., 2013). TrkA and p75NTR act as receptors of NGF 
(see section 6.2.2.1). In this study, the mRNA expression of Transient Receptor Potential 
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Vanilloid type 1 (TRPV1), which is involved in nociception derived from heat or molecules 
such as capsaicin (Darré and Domene, 2015), was also upregulated (Giannantoni et al., 2103). 
These proteins have a major impact on neurite outgrowth and therefore will be treated 
separately (section 6.2.2). 
In the trigeminal system, BoNT/A does not alter TRPV1 mRNA expression but inhibits TRPV1 
trafficking to the membrane and promotes its degradation at the proteasome (Shimizu et al., 
2012). Similarly, in Dorsal Root Ganglion (DRG) neurons, BoNT/A reduces TRPV1 
expression at the protein level (Xiao et al., 2013; Fan et al., 2017). DRG neurons positive for 
P2X purinoceptor 3 (P2X3), a purinergic receptor with functions in nociception and urinary 
reflexes (Ford and Undem, 2013), were also reduced after BoNT/A injection (Xiao et al., 2013). 
Paradoxically, in T47D cells BoNT/A also reduces SV2 expression at the protein level 
(Bandala et al., 2015). 
From its use in cosmetics, BoNT/A has encountered a new application in skin surgery. In this 
context, human dermal fibroblasts incubated with BoNT/A present increased collagen 
expression and reduced expression of certain metalloproteases at the protein level (Oh et al., 
2012; Roh et al., 2013).  
BoNT/A has also angiogenic properties as it induces endothelial cell proliferation and an 
increase in Vascular Endothelial Growth Factor (VEGF) protein levels (Tang et al., 2017; 
Botzenhart et al., 2017). The same study also reported an increase in caveolin-1 and caveolin-
3 expression. BoNT/A angiogenic effect could be causing the protection conferred by BoNT/A 
against cutaneous ischemia-reperfusion injury (Uchiyama et al., 2015). BoNT/A also shows 
anti-inflammatory properties by reducing the number of immunoactive cells expressing 
interleukins in arthritic articulations (Yoo et al., 2014), while in macrophages it induces the 
expression of pro-inflammatory genes such as Toll-like receptor 2 (TLR2), interleukin-6 (IL-
6) and Tumour Necrosis Factor  (TNF-) at the mRNA level in vitro and leads to 
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inflammatory responses (Kim et al., 2015).  Axon regeneration can be promoted with an agonist 
of this receptor (Hauk et al., 2010).  
Table 6-1: Effects of BoNT/A on gene expression.
Comparison Model Gene/gene function Level Reference 













HSPA6 mRNA Scherf et al., 2014 




Neurite outgrowth mRNA Scherf et al., 2014 




Neurogenesis mRNA Scherf et al., 2014 




Calcium signalling mRNA Scherf et al., 2014 
BoNT/A to control 
Dermal 
fibroblasts 
Rac1, Cdc42, RhoA mRNA Park et al., 2016 
BoNT/A to control PC­12 cells RhoB Protein Ishida et al., 2014 
BoNT/A to control Bladder 
NGF, TrkA, p75NTR, 
TRPV1 
mRNA 
Giannantoni et al., 
2013 
BoNT/A to control Trigeminal system TRPV1 Protein Shimizu et al., 2012 
BoNT/A to control DRG neurons TRPV1, P2X3  Protein Xiao et al., 2013 
BoNT/A to control 
Dermal 
fibroblasts 
Collagen Protein Oh et al., 2012 
BoNT/A to control 
Dermal 
fibroblasts 
Metalloproteases mRNA Roh et al., 2013 
BoNT/A to control T47D cells SV2 Protein Bandala et al., 2015 
BoNT/A to control 
Adipose stem 
cells 
VEGF mRNA Tang et al., 2013 
BoNT/A to control Masseter muscle VEGF Protein 
Botzenhart et al., 
2017 
BoNT/A to control Masseter muscle Caveolins Protein 
Botzenhart et al., 
2017 
BoNT/A to control Macrophages TLR2, IL­6, TNF­a mRNA Kim et al., 2013 
Green and red colours indicate increase and decrease in expression 
Nevertheless, the mechanism used by BoNT/A to induce changes in expression is unknown 




Axons from neurons innervating muscles treated with BoNT/A undergo strpouting, an effect 
which was thought to be caused by the blockade of synaptic transmission (Brown et al., 1977; 
Holland et al., 1980). These sprouts innervate the same targets and intoxication-induced 
terminals had the same properties as terminals in non-intoxicated control neuron, with normal 
calcium influx, impulse propagation and clustering of receptors at the adjacent NMJ (Angaut-
Petit et al., 1990). 
BoNT/A induces neurite branching in co-cultures of neurons and muscle. It was also suggested 
that the effect was independent of presynaptic blockade, as a post-synaptic blocker did not 
prevent the sprouting of silenced nerve terminals (Bonner et al., 1994).  
In preclinical models, regeneration of a nerve after a mechanical injury is enhanced by a 
BoNT/A pre-treatment. Moreover, human stem cell-derived motor neurons also develop longer 
neurites when exposed to BoNT/A (Franz et al., 2018). 
There are arguments to support SNARE cleavage as the cause for neurite outgrowth. Once the 
effect of SNAP-25 cleavage by BoNT/A disappears, redundant branches are eliminated (de 
Paiva et al., 1999). In addition, BoNT/D and BoNT/F treatment also induces the development 
of sprouts to innervate the disconnected NMJ (Comella et al., 1993, Meunier et al., 2003). 
However, TeNT and BoNT/B were shown not to affect neurite outgrowth, while BoNT/A was 
reported to inhibit axonal outgrowth in the same study (Osen-Sand et al., 1996). Other studies 
show BoNT/A-induced inhibition of neurite outgrowth in immature neurons (Grosse et al., 
1999), but this could be a consequence of synaptic silencing. BoNT/C blocks axonal outgrowth 
and this is thought to be directly caused by syntaxin cleavage (Igarashi et al., 1996).  
The domain of BoNT/A responsible for inducing neurite outgrowth was mapped to be its 
binding domain, HCC/A. Consistently, abolition of its interaction with the ganglioside GT1b 
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and therefore blocking endocytosis, the neuritogenic effect of BoNT/A are abolished (Coffield 
and Yan, 2009). 
Neurite outgrowth regulation 
Neurotrophins and their receptors 
As neurites develop, they are attracted or repulsed by external signalling molecules 
(Gundersen, 1985; Yaginuma et al., 1993; Stoeckli, 2018). It has been shown that neurite 
outgrowth is not the only mechanism to increase neurite area, as axon production can continue 
with microtubule stabilisation and arrest of neurite outgrowth by thickening. However, neurite 
outgrowth is the preferred mechanism to increase neurite surface area. (Rochlin et al., 1996).  
One of the most studied signalling pathways that drive outgrowth are neurotrophins and their 
receptors.  
Neurotrophins are traditionally considered a group of four proteins. These are Brain-Derived 
Neurotrophic Factor (BDNF), NGF, Neurotrophin-3 and Neurotrophin-4. After being secreted, 
they act on their cognate receptors at the cell surface (Mitre et al., 2017). 
TrkA, TrkB and TrkC, are tyrosine kinase receptors which form dimers and then cross-
phosphorylate to start a signalling cascade (Friedman et al., 1999). The fourth neurotrophin 
receptor, p75 neurotrophin receptor (p75NTR), lacks catalytic activity and its effects are 
mediated by protein adaptors (Dechant and Barde, 2002). Although there are four main 
neurotrophins and four neurotrophin receptors, these are not necessarily paired with a single 
receptor. For example, NGF binds and signals though any of the receptors and p75NTR binds 
and signals after binding any of the neurotrophins, as well as influencing the properties of other 
neurotrophin receptors (Friedman et al., 1999). After receptor binding, neurotrophins can there 
are multiple pathways to transduce the signal into the interior of the neuron. The specific 
mechanisms behind them are not fully understood. 
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In addition to neurotrophin signalling, other receptors can promote neurite outgrowth. As an 
example, VEGF, whose expression is upregulated by BoNT/A (see section 6.2.1.2), induces 
neurite outgrowth through its receptor (Nowroozi et al., 2005). Fgfr3, receptor for BoNT/A in 
cell lines (Jacky et al., 2013) and neurons (Figure 5-6), is also involved in neurite outgrowth 
(Raffioni et al., 1998; Hart et al., 2000; Nowroozi et al., 2005). 
Signalling cascades 
The Rho family of proteins is one of the key regulators of neurite outgrowth. Rho proteins are 
one of the five families of the Ras superfamily of small GTPases, together with Ras, Ras-like 
proteins in nucleus (Ran), Rab and Arf proteins. These two last families where introduced 
previously for their functions in endocytosis and vesicle recycling (1.2.2.1 and 1.2.3.2). The 
activity of small GTPases depends on guanine nucleotide binding, being coupled Guanosine 
Diphosphate (GDP) when inactive and GTP when active (Narumiya, 1996; Wennerberg et al., 
2005; Um et al., 2014). This process is regulated by two main players. A Guanine nucleotide 
Exchange Factor (GEF) promotes GDP dissociation and GTP binding, allowing Rac1 to 
interact and activate other proteins. Then, a GTPase-Activating Protein (GAP) stimulates the 
GTPase activity of its target and GTP is hydrolysed to GDP, finally inactivating the GTPase 
and completing the cycle (see Figure 6-1 for a schematic and Wennerberg et al., 2005 for a 
review).  
179 
Figure 6-1. The Ras superfamily.
A) Mechanism of activation and inactivation of Ras GTPases. Inactive Ras is bound to 
GDP. A Guanine nucleotide Exchange Factor promotes GDP dissociationg and GTP 
binding, activating Ras and allowing signalling. A GTPase Activating Protein 
stimulates the catalytic activity of Ras, which hydrolises GTP returning to the inactive 
state. 
B) The five families within the Ras superfamily, their most relevant members and the 
roles of the family. 
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Nevertheless, many other pathways contribute to the regulation of neurite outgrowth. For 
instance, neurite outgrowth is also influenced by Phospho-Inositide 3-Kinase (PI3K) (Lavie et 
al., 1997). It targets Ak thymoma (Akt), another kinase related to neurite function. However, 
Akt function, does not exclusively depend on PI3K activation since it can independently 
promote neurite outgrowth (Virdee et al., 1999). In addition, Phosphatase and Tensin homolog 
(PTEN) inhibits Akt, leading to an impairment in neurite outgrowth (Musatov et al., 2004; 
Christie et al., 2010). After this cascade, mammalian Target Of Rapamycin (mTOR) is 
activated and promotes neurite outgrowth (Zeng et al., 2008).  
Extracellular signal–Regulated Kinases (ERK) are suggested to be a signalling node for neurite 
outgrowth in response to different stimuli (Caceres et al., 1992; Perron et al., 1999). TrkA 
induces neurite outgrowth through ERK after binding NGF (Peng et al., 1995). Fgfr3-mediated 
neurite outgrowth in PC-12 cells occurs by activation of the ERK pathway, as well as others 
(Hart et al., 2000; Nowroozi et al., 2005). Even though it is a signalling node, ERK activation 
is not compulsory for neurite outgrowth (Aglah et al., 2008; Mullen et al., 2012).  
It is important to note that these are all inter-linked signalling molecules and the activation of 
individual pathways can be simultaneous (Christie et al., 2010; Mendoza et al., 2011; Xiao et 
al., 2013; Tong et al., 2013; Gordon et al., 2014; Speranza et al., 2015; Liu et al., 2018).  
These regulators are shown in Figure 6-2. 
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In summary, as it has been stated during the first section of this introduction, BoNT/A affects 
different pathways through unknown mechanisms (section 6.2.1), with many examples of 
molecules regulating neurite outgrowth (section 6.2.1.4). Their relationships are summarised 
in Figure 6-3. This chapter will explore the nature of neurite outgrowth induced by BoNT/A 
as well as its underlying pathways. 
Figure 6-2. Pathways controlling neurite outgrowth
Neurite outgrowth is regulated through different pathways, including the Rho (RhoA, RhoB, 
Rac1), mTOR (PI3K-Akt-mTOR) and ERK pathways. Relation between signalling molecules 
are shown in green (activating) or negative (inactivating) lines directed in the direction of 
signalling. Grey symbols represent receptors and their ligands. GTPases are represented in red, 
kinases in purple and phosphatases in yellow. 
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Figure 6-3. BoNT/A effects on pathways controlling neurite outgrowth
BoNT/A affects the expression or function of different agents involved in neurite outgrowth. 
Changes in expression induced by BoNT/A are shown with green (upregulation) or red 
(downregulation) arrows next to the affected protein. Relation between signalling molecules 
are shown in green (activating) or negative (inactivating) lines directed in the direction of 
signalling. Grey symbols represent receptors and their ligands (except for BoNT/A, shown in 
green). GTPases are represented in red, kinases in purple and phosphatases in yellow. 
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Materials and Methods 
Materials 
Rac1 activation 
To measure Rac1 activation, Active Rac1 Detection Kit by Cell Signalling Technologies (CST) 
(Cat. No. 8815) was used. 
Live imaging 
IncuCyte technology was used for live imaging and the process was fully automated, including 
neurite length quantification. 
Synaptic vesicle release measurement 
MASTER 8 pulse stimulator obtained from A.M.P.I. was used to generate pulses. The slotted 
bath chamber was from Warner Instruments (Cat. No. RC-21BRFS). 
Dow Corning High Vacuum Grease was purchased to Univar (Cat. No. HVGR50). 
NSC media 
NSC growth medium consisted of DMEM/F-12 (Thermo Fisher Scientific, Cat. No. 31330-
095) supplemented with 100 U/mL penicillin and 100 g/mL streptomycin (Sigma Cat. No. 
P4333), Insulin-Transferrin-Selenium (Thermo Fisher Scientific Cat. No. 41400045), 1X Non-
Essential Aminoacids (NEAA) (Thermo Fisher Scientific Cat. No. 11140-035), 20 ng/mL 
Epidermal Growth Factor (EGF) (Preprotech Cat. No. AF-100-15) and 20 ng/mL FGF 
(Preprotech Cat. No. AF-100-18) 




Rac1 activation assay was done following the recommendations by the manufacturer, with the 
exception of Rac1 antibody probing, where the supplier advices using BSA for blocking and 
3% milk in TBS-T was used instead. A schematic of the assay is provided in Figure 6-4.  
Figure 6-4. Rac1 activation assay.
An aliquot is taken from the total lysate as a total Rac1 control. The rest of the sample is loaded 
onto the column. Rac1 binds to an interacting protein (PAK1) and is retained in the column. 
Inactive Rac1 and other proteins are discarded. Finally, active Rac1 is eluted and incorporated 
to the total lysate for probing by western blot. 
185 
Live imaging 
Relative total neurite outgrowth values were calculated by referring each time point value of 
total neurite length to the total neurite length of the first image taken after cells were plated on 
DIV0 (i.e. the initial value is 1 for all the conditions and the value when neurite length 
duplicates is 2). 
Synaptic vesicle release measurement 
These experiments were performed by Vanilla Shi. 
Neurons were transfected (see section 2.2.2.4) with pcDNA3-SypHy and a knockdown-rescue 
construct co-expressing mCherry. Cells expressing only SypHy or mCherry were discarded. 
BoNT/A(0) and HCC/A were applied to the culture after transfection. 
MASTER 8 pulse stimulator was programmed and connected to a field stimulation imaging 
chamber with a slotted bath. Coverslips were mounted on the chamber and sealed with grease. 
The chamber was fitted into a compatible holder, connected to a gravity flow perfusion system 
and placed on the microscope stage. Buffers were pre-warmed to 37° C before the experiment.  
Experiments were performed as described in the literature (Burrone et al., 2006; Fernández-
Alfonso et al., 2006; Craig et al., 2015).  
Baseline recordings were measured when cells were stimulated at 2 Hz for 30 s. Then, a 
stimulation of 40 APs at 20 Hz was applied to release RRP. 10 s after this, a stimulation of 600 
APs at 20 Hz was applied so that RP release could be recorded. 120 s after the start of the 
experiment, NH4Cl was perfused onto neurons for 120 s to reveal the total levels of SypHy 
loading in neurons. Recording was stopped 60 s after NH4Cl addition. 25 µM CNQX and 50 
µM D-AP5 were perfused throughout the experiment. BoNT/A(0) and HCC/A were not present 
in the solutions perfused. 
186 
For each cell, 15 ROIs were analysed with non-responsive ROIs being discounted. Data were 
first normalised to background levels (ΔF/F0) and then expressed as a percentage of 
fluorescence obtained after NH4Cl perfusion (Fmax).  
NSC culture and subculture 
E14 rat embryos were obtained as referred before for E18 embryos (2.2.2.1). Forebrains were 
dissected out, and remaining skull and meninges removed. Brain tissue was dissociated using 
Accutase protease solution, washed and inoculated into flasks to be grown at 37° C and 5% 
CO2 in growth medium.  
NSC cultures were sub-cultured every 3-4 days using the following protocol. Cells were 
pelleted by centrifugation at 1000 g for 2.5 min, supernatant was removed by aspiration and 
pelleted cells were dissociated by resuspension in Accutase protease solution and incubation at 
37° C for 3 min. 1X DPBS (prepared from 10X DPBS) was added and cells were again pelleted 
by centrifugation under the same conditions. Supernatant medium was aspirated and cells were 
resuspended in growth medium from which they were plated or passed into a new flask. Cells 
were used only from passages 3 to 25 and plated at a density of 500,000 cells/well for 
biochemistry and 200,000 cells/well for imaging. NSCs were differentiated by removal of 
growth medium and addition with differentiation medium on DIV1.  
Results 
BoNT/A(0) activates Rac1 and ERK through HCC/A 
BoNT/A(0) and HCC/A activate Rac1 in neurons 
Small GTPases are a major target for pathogens acting intracellularly (reviewed at Stein et al., 
2012; Quintero et al., 2015; Spanò et al., 2018). 
I chose to investigate Rac1 (see sections 6.2.1.2 and  6.2.2.2) since BoNT/A can modulate the 
transcript expression of Rac1 (Park et al., 2016). Rac1 is a small GTPase ‘switch’ that is 
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expressed in neurons and is heavily involved in cytoskeleton dynamics (Ridley et al., 1992a; 
Ridley et al., 1992b; Nobes et al., 1995).  
Rac1 is the target of Botulinum toxin C3, secreted by some strains of C. botulinum (Didsbury 
et al., 1989). Previous comparisons between Botulinum toxin C3 and BoNT/A (outlined in 1.3.1 
and 5.5.2.4) lead me to study the involvement of Rac1 as an effector for BoNT/A-induced 
neurite outgrowth. To test the impact of Rac1 signalling, I used a specific inhibitor of Rac1, 
NSC23766, which targets activation by GEFs (Gao et al., 2004). Ipsen provided HCC/A to 
verify that this is the domain responsible for neurite outgrowth caused by BoNT/A(0). 
First, Rac1 activation by BoNT/A(0) and HCC/A was examined. 
Cells were treated for 30 min with 25 nM BoNT/A(0) or HCC/A. This concentration was chosen 
because it was that used in the previous chapter, and similar concentrations have been shown 
to induce neurite outgrowth in vitro (Coffield and Yan, 2009). In addition, ny conclusions from 
Chapter 5 regarding BoNT/A(0) trafficking could be applied to the current chapter. After toxin 
treatment, GTP-bound (active) Rac1 was isolated from the lysate as described (section 6.3.2.1) 
and a fraction of the total lysate was used to calculate total Rac1 levels. Then, samples were 
run in parallel to determine the proportion of active Rac1 (Figure 6-5). The ratio of Rac1 bound 
to GTP over total Rac1 was 1.69 ± 0.18 times higher for BoNT/A(0)-treated cells and 1.49 ± 
0.07 for cells treated with HCC/A, indicating Rac1 activation.  
I concluded that BoNT/A(0) can activate Rac1 through HCC/A. 
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Figure 6-5. BoNT/A(0) and HCC/A induce Rac1 activation.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
with 25 nM BoNT/A(0) or 25 nM HCC/A for 30 min, plus a non-treated control. 
Activated Rac1 was isolated using Active Rac1 Detection Kit by CST and compared 
to total Rac1. Membranes were probed with anti-Rac1 antibodies. 
B) Quantification of the results, represented by mean values ± SEM. ANOVA followed 
by Tukey post hoc test. p* < 0.05. N = 3. 
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BoNT/A(0) and HCC/A induce ERK phosphorylation 
I also investigated the effects of BoNT/A(0) and HCC/A on intracellular signalling downstream 
of Rac1 by testing activation of the extracellular signal-regulated kinase (ERK). This pathway 
has been shown to be one of the main nodes signalling leading to neurite outgrowth (Perron et 
al., 1999; Tsuda et al., 2011) and it is involved in nerve regeneration (Agthong et al., 2006; 
Agthong et al., 2009; Tsuda et al., 2011). 
Cells were treated for 30 min with either BoNT/A(0) or HCC/A at 25 nM and lysed. Samples 
were run in a western blot and ERK activation assessed with specific antibodies targeting 
phosphorylated (active) ERK (Figure 6-6). Membranes were stripped and re-probed (see 
section 2.2.4.5) to blot for total ERK as a control. In my samples, the proportion of 
phosphorylated ERK over total ERK was 2.20 ± 0.31 times higher than the control for 
BoNT/A(0) and 2.52 ± 0.27 times higher for HCC/A. This suggested that ERK pathway is 
activated by BoNT/A(0) via its binding domain. 
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BoNT/A(0) or HCC/A do not promote total neurite outgrowth in cortical or 
hippocampal neurons 
IncuCyte recognises neurites in developing neurons 
To measure neurite outgrowth, I used an automated system for neurite length detection and 
total neurite (i.e. axons and dendrites) outgrowth calculation (see section 6.3.2.2). Figure 6-7
shows the validation of the IncuCyte system in recognising neurites. 
Figure 6-6. BoNT/A(0) and HCC/A induce phosphorylation of ERK.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
with 25 nM BoNT/A(0) or 25 nM HCC/A for 30 min, plus a non-treated control. 
Membranes were probed with anti-pERK and then stripped and re-probed with anti-
ERK antibodies. 
B) Quantification of the results, represented by mean values ± SEM. ANOVA followed 
by Tukey post hoc test.  p* < 0.05, p** < 0.01. N = 4. 
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Rac1 inhibition of total neurite outgrowth is not rescued by BoNT/A(0) or HCC/A 
DIV1 hippocampal neurons were plated and treated with 25 nM BoNT/A(0) or HCC/A in 
absence or presence of NSC23766 (Figure 6-8) and maintained for 140 h in the IncuCyte.  
In absence of NSC23766, relative total (dendrites + axons) neurite outgrowth values were 16.9 
± 1.5 for the control, 17.1 ± 1.3 for BoNT/A(0)-treated cells and 18.0 ± 1.2 HCC/A-treated 
cells, with no statistical differences between groups. This suggest that BoNT/A(0) or HCC/A 
do not affect neurite outgrowth in my model.  
On the other hand, the presence of NSC23766 reduced neurite outgrowth values to 0.75 ± 0.15 
for the control, 0.60 ± 0.3 for BoNT/A(0)-treated cells and 0.56 ± 0.09 for HCC/A-treated cells. 
Figure 6-7. IncuCyte technology recognition of neurites. 
In the left panel, a representative image of cultured hippocampal neurons on DIV7 grown in 
neuronal feeding medium and observed by IncuCyte using bright field imaging. In the left 
panel, an image of growing cells. In the right panel, an overlapping mask highlights in purple 
neurites detected by the system in neurons from the left panel image. Scale bars represent 300 
m. 
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Groups treated with NSC23766 and the groups without this treatment were statistically 
different (p** < 0.01).  
This confirmed that Rac1 plays a major role in neurite outgrowth but since there were no 
differences between the control and BoNT/A(0) or HCC/A-treated groups. BoNT/A 
neuritogenic action was questioned. 
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Figure 6-8. BoNT/A (0) and HCC/A do not rescue total neurite outgrowth inhibition 
induced by NSC2736.
A) Representative images of DIV7 hippocampal neurons grown in absence or presence of 
25 nM BoNT/A(0) and HCC/A and absence or presence of 100 M NSC23766. Scale 
bar is 10 m. 
B) Quantification of the relative neurite outgrowth over time, represented as mean values 
± SEM. N = 4.  
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BoNT/A(0) and HCC/A do not induce neurite total outgrowth 
As shown in Figure 6-8, I did not detect any clear effects by BoNT/A(0) and HCC/A in neurite 
outgrowth. As feeding medium contains several factors, such as retinol acid in B27 supplement 
(section 2.1.6.2), that could confound the results (Clagett-Dame et al., 2006; Chen et al., 2008), 
I decided to perform the same experiments in plain Neurobasal medium. Furthermore, 
published effects of BoNTs on outgrowth refer to DRG neurons and not to hippocampal 
neurons (Coffield and Yan, 2009). To test the possibility that hippocampal neurons are 
insensitive to BoNT/A neuritogenic effects I also tested cortical neurons (I did not have ready 
access to DRGs) (quantification is shown in Figure 6-9).  
Growth in Neurobasal medium reduced neuronal viability, especially after 48 h. Therefore, the 
following results correspond to total neurite outgrowth after 24 h.  
For control hippocampal neurons, these values were 2.22 ± 0.17 times higher than the value 
at the beginning of the experiment. For BoNT/A(0)-treated group, this was 2.25 ± 0.27 and 
for the HCC/A-treated group, 1.99 ± 0.07. For NSC23766-treated cells, these values were 
0.63 + 0.21 for the control, 0.56 ± 0.17 and 0.67 ± 0.33. 
For cortical cells (Figure 6-9B), total neurite outgrowth values were 1.64 ± 0.20 for the control, 
1.41 ± 0.04 for the group treated with BoNT/A(0) and 1.56 ± 0.31 for the group treated with 
HCC/A. In presence of NSC23766, these values were 0.58 ± 0.13, 0.56 ± 0.14, 0.49 ± 0.12.  
There were statistically significant differences between NSC23766-treated and non-treated 
groups (p** < 0.01), but not between toxin-treated groups and their controls. Again, this 
indicated that Rac1 regulates neurite outgrowth and suggested that BoNT/A(0) and HCC/A do 
not induce neurite outgrowth in hippocampal or cortical neurons. 
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Figure 6-9. BoNT/A(0) and HCC/A do not promote total neurite outgrowth.
A) Quantification of the relative neurite outgrowth over time for hippocampal neurons 
grown in Neurobasal medium in absence or presence of 25 nM BoNT/A(0) and HCC/A, 
with or without 100 M NSC23766, represented as mean values ± SEM. ANOVA 
followed by Tukey post hoc test, p** < 0.01. N = 3. 
B) Quantification of the relative neurite outgrowth over time for cortical neurons in the 
same conditions. Values are represented as mean values ± SEM. ANOVA followed by 
Tukey post hoc test, p** < 0.01. N = 3. 
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Fgfr3 inhibition does not significantly alter total neurite outgrowth 
I tested the Fgfr3 inhibitor SU5402 to test the possibility of Fgfr3 activation by HCCA (Jacky 
et al. 2013) being responsible for any effect on neuritogenesis. Fgfr3 has been previously linked 
to neurite outgrowth previously (Raffioni et al., 1998; Hart et al., 2000; Nowroozi et al., 2005). 
Hippocampal neurons treated on DIV1 with 25 nM BoNT/A(0) or HCC/A and maintained for 
140 h. The result of the experiment was as follows.  
In absence of the Fgfr3 inhibitor SU5402, the control group had 19.7 ± 0.63 times more neurite 
length than at the beginning at of the experiment. The BoNT/A(0)-treated group had 20.9 ± 1.0 
and the HCC/A-treated group 20.8 ± 2.1 (Figure 6-10). No significant differences were 
detected between any of the conditions, confirming that BoNT/A(0) and HCC/A do not affect 
neurite outgrowth under my settings.   
In presence of the Fgfr3 inhibitor SU5402, these values were 16.0 ± 0.9 for the control, 19.0 ± 
1.4 for BoNT/A(0)-treated cells, 19.2  ± 1.36 for HCC/A-treated cells. Although Fgfr3 
inhibition resulted in an apparent decrease of neurite outgrowth and this was rescued by 
BoNT/A(0) and HCC/A, none of these differences were statistically significant.  
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Figure 6-10. Effects of BoNT/A(0) and HCC/A on neurite outgrowth in the presence and 
absence of the Fgfr3 inhibitor SU5402. 
A) Representative images of DIV7 hippocampal neurons grown in absence or presence of 
25 nM BoNT/A(0) and HCC/A and absence or presence of 20 M SU5402. Scale bar 
represents 10 m. 
B) Quantification of the relative neurite outgrowth (measured as total neurite length at a 
certain point over total neurite length at t = 0) over time. N = 4. 
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BoNT/A(0) and HCC/A selectively promotes axonal outgrowth via Rac1 
Our models failed to replicate the reported increase in total neurite outgrowth (Figure 6-8, 
Figure 6-9, Figure 6-10). Careful examination of the published images (Coffield and Yan, 
2009) showing an increase in neurite outgrowth induced by HCC/A made me reconsider my 
approach. The images provided suggest that the process with most difference in outgrowth 
corresponds to a thin neurite with a conical structure at the end. I interpreted this to be an axon. 
Furthermore, I was puzzled by the potential biological impact of total neurite outgrowth. Given 
that increasing neurite outgrowth could enhance the efficiency of BoNT/A entry by increasing 
membrane surface area. However, in vivo BoNT/A enters neurons through the NMJ (Colasante 
et al., 2013). Therefore, an increase in dendrite length would have a minimal effect on total 
uptake. However, promoting axonal growth and presynaptic terminal strength could have a 
positive impact in the uptake of BoNT/A. 
To directly address these issues, I selectively measured axonal outgrowth. In mature neurons, 
AnkyrinG (AnkG) is expressed at the initial segment of the axon as well as the nodes of 
Ranvier, and it acts as a key regulation of axonal differentiation from other neurites (Bouzidi 
et al., 2002; Fréal et al., 2016; Saifetiarova et al., 2017). In developing neurons, AnkG can be 
stained as early as DIV1 and can be used as an axonal marker (Fréal et al., 2016; Kuijpers et 
al., 2017).  
DIV1 hippocampal neurons were treated with BoNT/A(0) HCC/A in absence or presence of 
NSC23766. On DIV2, cells were fixed and stained with the axonal marker (AnkG) (Figure 
6-11).  
199 
Figure 6-11. BoNT/A(0) and HCC/A induce axon outgrowth via Rac1.
A) Representative images of DIV2 hippocampal neurons grown with 25 nM BoNT/A(0) 
and HCC/A and absence or presence of 100 M NSC2736. Scale bar is 10 m. 
B) Quantification of axonal outgrowth, shown as mean values ± SEM. ANOVA followed 
by Tukey post hoc test, p* < 0.05,  **p < 0.01. N = 3. 
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In absence of NSC23766, axonal length values were 53.9 ± 12.8 m for the control. For toxin-
treated cells, these values were 153.3 ± 25.0m for the BoNT/A(0) group and 139.3 ± 13.3 for 
the HCC/A group. Thus, there is a statistically significant increase in axonal outgrowth 
compared to control (p** < 0.01 and p* < 0.05, respectively).  
In presence of NSC23766, these values were reduced to 52.6 ± 7.4m for the control, 57.7 ± 
11.0m for BoNT/A(0)-treated cells and 55.6 ± 8.34 m for HCC/A-treated cells.  
These data reveal that:   
1. Inhibition of Rac1 does not block basal axonal outgrowth since as axonal length was 
not altered in presence of NSC23766.  
2. BoNT/A(0) induces axonal outgrowth through HCC/A.  
3. The promotion of axonal outgrowth by BoNT/A(0) involves Rac1. 
BoNT/A(0) and HCC/A induce filopodia formation via Rac1 
Filopodia are protrusions from the cell membrane with functions related to sensing, cell 
migration and cell adhesion (Heckman et al., 2013). In neurons, cell adhesion constitutes the 
basis of synapse formation (Purves et al., 2012). That is, neurite branching and spine formation 
are initiated with the formation of filopodia that can then mature into structures including 
presynaptic termini in the NMJ or dendritic spines in the brain (Niell et al., 2004; Yoshihara et 
al., 2009).  
After observing BoNT/A(0)-induced axonal outgrowth, the same mechanism could also affect 
filopodia formation. Filopodia identification was defined in section 2.2.6.3. To test this, 
hippocampal neurons were treated with BoNT/A(0) and HCC/A in absence or presence of 
NSC23766. DIV12-15 hippocampal neurons were transfected with an eGFP-expressing vector 
for visualisation. In control neurons, 3.31 ± 0.86 filopodia/100 m were observed. For toxin-
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treated cells these values were significantly higher (p* < 0.05) with 7.42 ± 0.55 filopodia/100 
m for BoNT/A(0)-treated cells and 7.40 ± 0.72 filopodia/100 m for HCC/A-treated cells. No 
filopodia were observed for NSC23766-treated cells.  
This indicates that Rac1 is involved in the formation and/or stabilisation of filopodia. In 
addition, BoNT/A(0) uses HCC/A to activate Rac1 and manipulate this system. 
Figure 6-12. BoNT/A(0) and HCC/A promotes the formation of filopodia via Rac1.
A) Representative images of neurites from DIV14-17 hippocampal neurons transfected 
with a plasmid encoding for eGFP and treated for 3 days with 25 nM BoNT/A(0) or 
25 nM HCC/A in absence or presence of 100 M NSC23766. 
B) Quantification of the number of filopodia per unit of length. Quantification of the 
results, represented by mean values ± SEM. ANOVA followed by Tukey post hoc test. 
p* < 0.05. N = 3 
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HCC/A enhances synaptic vesicle release 
Measurement of vesicle release 
Given the neurotrophic effect on axonal outgrowth and filopodia formation, I next investigated 
the effects of BoNT/A(0) and HCC/A on presynaptic release. To test this, I used SypHy, a probe 
consisting of synaptophysin fused to a pH-sensitive GFP, pHluorin, exposed to the luminal side 
of the vesicle (see Figure 6-13). The basis of the protocol are the processes of endocytosis and 
exocytosis that synaptic vesicles follow, as described in the Introduction (section 1.2.1 and 
1.2.2.2). Within the synaptic vesicle, low pH stops pHluorin from fluorescing. Then upon 
vesicle release, pHluorin is exposed to the extracellular neutral medium which enables 
fluorescence emission. Therefore, at a single presynaptic button, an increase in fluorescence 
indicates higher levels of release (Burrone et al., 2006; Craig et al., 2015).  
Figure 6-13. Measurement of synaptic vesicle exocytosis.
A first stimulus triggers the fusion of the Readily Realisable Pool (RRP) with the membrane. 
Acidity of the vesicle is reduced and pHluorin fluoresces. When vesicles are re-internalised 
are re-acidified and the fluorescence of the probe is quenched. A second stimulus can trigger 
the release of the Reserve Pool (RP), whose vesicles follow the same principle. 
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Hippocampal neurons were treated with 25 nM BoNT/A(0) and HCC/A for 3 days. Figure 6-14
shows the fluorescence values obtained during the experiment (6.3.2.3).  
Figure 6-14. Effect of BoNT/A(0) and HCC/A on synaptic vesicle release.
A) Representative images of synapses from DIV14-16 hippocampal neurons transfected 
with SypHy and mCherry-expressing plasmids. Cells were treated for 3 days with 25 
nM BoNT/A(0) or HCC/A and stimulated after 30 s from recording at 66 APs at 33 Hz 
and 10 s after at 900 APs at 20 Hz. Signal was taken directly as fluorescence intensity. 
The experiment was conducted by Vanilla Shi. 
B) Quantification of the SypHy signal, represented by mean values ± SEM. Red arrows 
point towards stimulation points described in A. ANOVA followed by Tukey post hoc 
test. N = at least 3 cells from independent dissections. 
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BoNT/A(0) and HCC/A do not significantly enhance RRP release 
After the first depolarisation, the RRP is released, with a subsequent increase in fluorescence 
at the presynaptic terminal. These values were calculated using values corresponding to 2.5 s 
after depolarisation and 2.5 s before the second stimulus (a total of 5 s), where the release starts 
decaying.  
The fluorescence values were 4.79 ± 0.68 for control cells, 7.92 ± 1.20 for cells treated with 
BoNT/A(0) and 7.07 ± 1.89 for cells treated with HCC/A. Quantification of this results is shown 
in Figure 6-15. 
Figure 6-15. BoNT/A(0) and HCC/A do not significantly increase the release of the RRP.
Quantification of the SypHy signal 2.5 s after a first stimulation for a total of 5 s, represented 
by mean values ± SEM. Cells were treated for 3 days with 25 nM BoNT/A(0) or 25 nM HCC/A 
and stimulated after 30 s from recording at 66 APs at 33 Hz and 10 s after at 900 APs at 20 Hz. 
Signal was taken directly as fluorescence intensity. Signal was taken directly as fluorescence 
intensity. Quantification of the SypHy signal, represented by mean values ± SEM. ANOVA 
followed by Tukey post hoc test. N = at least 3 cells from independent dissections. The 
experiment was conducted by Vanilla Shi. 
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Due to the limited sensitivity of the method to detect the RRP, these differences were not 
statistically significant, although a similar increase for both BoNT/A(0) and HCC/A could be 
observed. 
HCC/A, but not BoNT/A(0), significantly enhances the release of the RP  
The traces suggested that both BoNT/A and HCC/A increased RP vesicle release (Figure 6-14).  
RP release values from 10 s after the second stimulation peak until decay started at t = 70 s 
were included in the calculation (Figure 6-16A). The average values at the peak were 38.5 ± 
3.7 for control neurons, 46.7 ± 3.3 for BoNT/A(0)-treated neurons, and 60.0 ± 3.6 for HCC/A-
treated neurons. This increase in synaptic vesicle release was significantly different between 
control and HCC/A groups (p** < 0.01), but there was no statistical difference when comparing 
control to BoNT/A(0) or BoNT/A(0) to HCC/A groups.  
This indicates that HCC/A treatment increases the release of neurotransmitter at glutamatergic 
synapses. It is intriguing that treatment with BoNT/A(0) failed to generate statistical 
significance. Possible reasons for this are discussed later (section 6.5.3.2). 
The time point values when the maximum value occurred were unaltered among conditions, 
although HCC/A showed a trend suggesting a more rapid onset of release. These values were 
68.9 ± 1.8 s for the control, 70.0 ± 1.79 s for BoNT/A(0)-treated cells and 64.5 ± 4.1 s for 
HCC/A-treated cells (Figure 6-16B). 
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BoNT/A(0) and HCC/A do not significantly increase the rate of endocytosis 
In addition, the rate of endocytosis was also analysed by measuring the rate of decrease in 
fluorescence on curves normalised to the peak value of exocytosis. The loss of fluorescence 
correlates with endocytosed molecules as vesicles are re-acidified and their fluorescence is 
Figure 6-16. HCC/A, but not BoNT/A(0), significantly potentiates RP release.
A) Quantification of the SypHy signal 10 s after a second stimulation for a total of 20 s, 
represented by mean values ± SEM. Cells were treated for 3 days with 25 nM 
BoNT/A(0) or 25 nM HCC/A and stimulated after 30 s from recording at 66 APs at 
33 Hz and 10 s after at 900 APs at 20 Hz. Signal was taken directly as fluorescence 
intensity. ANOVA followed by Tukey post hoc test. N = at least 3 cells from 
independent dissections, p** < 0.01. The experiment was conducted by Vanilla Shi. 
B) Quantification of the time at which the absolute maximum value of fluorescence 
occurred, expressed as mean values ± SEM. ANOVA followed by Tukey post hoc test. 
N = at least 3 cells from independent dissections. 
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quenched (Burrone et al., 2006; Craig et al., 2015).  The rate of endocytosis, therefore, 
corresponds to the rate of change in fluorescence with respect to time, that is, the slope of the 
normalised trace. This trace is shown in (Figure 6-17A). 
Although values for BoNT/A(0) and HCC/A were similar, and both higher than the control, the 
results were not statistically different. Numerical values for the endocytosis rate were 5.06·10-
3 ± 1.05·10-3 AU/s for the control, 8.13·10-3 ± 0.69·10-3 AU/s for BoNT/A(0)-treated cells and  
9.40·10-3 ± 3.5·10-3 AU/s for HCC/A-treated cells.  
Figure 6-17. BoNT/A(0) and HCC/A do not significantly increase the rate of endocytosis.
A) Quantification of the SypHy signal normalised to the peak value. Data corresponds to 
signal recorded 30 s after a second stimulation for a total of 50 s, represented by mean 
values ± SEM. N = at least 3 cells from independent dissections Cells were treated for 
3 days with 25 nM BoNT/A(0) or 25 nM HCC/A and stimulated after 30 s from 
recording at 66 APs at 33 Hz and 10 s after at 900 APs at 20 Hz. Signal was taken 
directly as fluorescence intensity. The experiment was conducted by Vanilla Shi. 
B) Quantification of the rate of endocytosis as the slope derived from A). ANOVA 
followed by Tukey post hoc test. N = at least 3 cells from independent dissections. 
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Effect of HCC/A pre-treatment on BoNT/A(0) uptake 
The results in this chapter so far were interpreted as BoNT//A(0) having a neurotrophin-like 
behaviour through HCC/A-mediated Rac1 activation.  
This has a series of implications since BoNT/A enters neurons via synapses (section 5.4.2.1, 
Colasante et al., 2013) and upon entry, it silences them without affecting its own endocytosis 
(Montecucco and Schiavo, 1994; Neale et al., 1999). Therefore, I explored the impact of HCC/A 
neurotrophic effects on BoNT/A(0) entry. To do this, neurons were pre-treated with 
BoNT/A(0) and HCC/A(0) in absence or presence of NSC23766 for 3 days. Finally, they were 
exposed to BoNT/A(0) for 10 min and lysed. Results are shown in Figure 6-18. Neurons pre-
treated with HCC samples internalised 1.69 ± 0.82 times the amount of toxin internalised by 
the control. NSC23766-treated cells internalised 1.04 ± 0.33 times the amount of the control, 
and cells pre-treated with HCC/A internalised 0.88 ± 0.27 times the amount of the control. None 
of these differences was statistically significant. 
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Figure 6-18. Effect of Rac1 activation by pre-treatment with HCC/A on BoNT/A(0) 
uptake.
A) Representative western blot results of samples from DIV14-17 cortical neurons treated 
with 25 nM BoNT/A(0) (B) or HCC/A (H) for 3 days followed by a short treatment of 
10 min, plus non-treated controls (C), in absence or presence of 100 M NSC23766. 
Cells were treated on different days and lysed at the same time. Membranes were 
probed with anti-BoNT/A and anti-GAPDH antibodies. 
B) Quantification of the results, represented by mean values ± SEM. ANOVA followed 
by Tukey post hoc test. N = 3. 
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BoNT/A(0) and HCC/A promote NSC differentiation via Rac1 
BoNT/A(0) is endocytosed by NSC 
Results shown in this chapter indicate that functions BoNT/A(0) and HCC/A can positively 
modulate neuronal function, both structurally and functionally. It also has been suggested that 
BoNT/A can alter cell cycle progression (section 6.2.1.2) so I next investigated the effects on 
neurogenesis.  
Neural Stem Cells (NSC) are multipotent cells with the ability to differentiate into neurons or 
glial cells (Yuan et al., 2011; Song et al., 2012). These can be maintained in an undifferentiated 
state by stimulating proliferation with growth factors such as FGF-2 and EGF and removal of 
these factors or the addition of external agents can modify this behaviour (see section 6.3.2.4 
for the protocol). 
In Chapter 5, it was shown that BoNT/A(0) is internalised by cultured primary neurons under 
my experimental settings. I therefore initially tested if NSCs also internalise BoNT/A(0). NSCs 
were plated and treated on DIV10 with 25 nM BoNT/A(0) for 10 min. Probing with -BoNT/A 
antibodies revealed a BoNT/A(0) band at 150 kDa in lanes corresponding to treated samples, 
while absent in non-treated ones (Figure 6-19). This confirmed binding or endocytosis of 
BoNT/A(0) by NSCs. 
Figure 6-19. BoNT/A(0) is internalised by Neural Stem Cells.
Representative western blot results of samples from DIV10 NSC treated 10 min with 25 nM 
BoNT/A(0). Membranes were probed with anti-BoNT/A and anti-GAPDH antibodies as a 
loading control. 
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BoNT/A(0) promotes NSC differentiation via HCC/A-mediated activation of Rac1 
NSC differentiation into neurons was assessed by measuring the expression of neuron-specific 
markers such as III-tubulin (TuJ1) (Lööv et al., 2012; Zhu et al., 2018). Cells were plated 
after neurosphere dissociation and treated with 25 nM BoNT/A(0) or HCC/A in absence or 
presence of NSC23766. On DIV10, cells were fixed and stained with an antibody targeting 
TuJ1. 
The percentage of TuJ1-positive cells was 7.70 ± 6.34 % for the control, indicating minimal 
spontaneous differentiation. Both BoNT/A(0) and HCC/A dramatically promoted 
differentiation, with values of 55.2 + 3.2% (p** < 0.01) and 42.7 + 3.7% (p* < 0.05), 
respectively. However, for NSC23766-treated conditions, the percentage of differentiated cells 
went up to 90.5 ± 9.5% for the control, 87.8 ± 6.2% for BoNT/A(0)-treated cells and 86.3 ± 
3.2% for HCC/A-treated cells. These values are significantly higher than the respective 
conditions without NSC2733 treatment. These surprising results could be interpreted to suggest 
that either inhibition by NSC23766, or activation of Rac1 by BoNT/A(0) and HCC/A of Rac1, 
or both induce NSC differentiation (Figure 6-20).  
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Figure 6-20. BoNT/A(0), HCC/A and NSC23766 increase the percentage of differentiated 
cells.
A) Representative images of DIV10 NSCs grown in non-differentiated conditions absence 
or presence of 25 nM BoNT/A(0) or 25 nM HCC/A in absence or presence of 100 M 
NSC23766, and stained with anti-Tuj1 antibodies (green) as a marker for 
differentiation and DAPI (blue) to stain nuclei. 
B) Quantification of the proportion of Tuj1-positive cells represented as mean values ± 
SEM. ANOVA followed by Tukey post hoc test. * = p < 0.05, ** = p < 0.01. N = 3 
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However, it is important to note that other parameters must be considered. It particular, there 
was an anti-proliferative effect of NSC23766. The cell count per 10000 m2 (100x100 m) 
was 11.6 ± 0.4 for the control and 16.8 ± 4 for the group treated with BoNT/A(0) and 18.5 ± 
3.8 for the group treated with HCC/A. On the other hand, in presence of NSC23766, the number 
of cells per field was significantly reduced 2.77 ± 0.86 (p* < 0.05 to the corresponding 
NSC23766-lacking group), 1.65 ± 0.14 (p** < 0.01) and 1.28 ± 0.24 (p** < 0.01). Thus, 
NSC23766-induced block of proliferation is lilely to be responsible for the abnormal increase 
in the percentage of differentiation, since most of surviving cells were differentiated.  
Since the percentage of differentiated cells was misleading, the number of Tuj1-positive cells 
per 10000 m2 was calculated. For the control, 0.85 ± 0.70 cells were TuJ1-positive. For 
BoNT/A(0), these values were 6.40 ± 0.24, and significantly higher than control values (p** < 
0.01). HCC/A-treated group presented similar values, with 7.63 ± 1.1 TuJ1-positive cells per 
field (p** < 0.01 to the control). For NSC23766-treated groups, these values were 2.34 ± 0.44, 
1.39 ± 0.14 and 1.01 ± 0.19 for the control, BoNT/A(0)-treated and HCC/A-treated conditions. 
These quantifications are shown in Figure 6-21. 
Overall, these results indicate that BoNT/A(0) and HCC/A are able to induce NSC 
differentiation into neurons via Rac1 without affecting cell proliferation. In addition, Rac1 is 
fundamental for NSC growth in vitro and its inhibition results a total arrest of the cell cycle or 
cell death. 
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Figure 6-21. BoNT/A(0) and HCC/A promote stem cell differentiation via Rac1.
A) Quantification of NSC density grown in non-differentiated conditions absence or 
presence of 25 nM BoNT/A(0) or 25 nM HCC/A in absence or presence of 100 M 
NSC23766, represented as mean values ± SEM. ANOVA followed by Tukey post hoc 
test. ** = p < 0.01. N = 3. 
B) Quantification of the total number of Tuj1-positive cells per unit of area from the same 
experiment, represented as mean values ± SEM. ANOVA followed by Tukey post hoc 
test. N = 3. ** = p < 0.01. N = 3. 
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Discussion 
BoNT/A(0) and HCC/A promote activation of Rac1 and ERK 
BoNT/A(0) and HCC/A cause Rac1 activation  
I first tested for Rac1 activation itself. Both BoNT/A(0) and HCC/A increased the proportion 
of Rac1 bound to GTP over total Rac1 (Figure 6-5).  
These effects are suroprising, since the HCC/A domain is unable to translocate into the cytosol 
(Ho et al., 2011; Surana et al., 2018). While several bacterial toxins are known to interfere with 
the normal functioning of Rho GTPases, all these act intracellularly (Sakurai et al., 2009; 
Sakaguchi et al., 2015; Di Bella et al., 2016; Takehara et al., 2017). 
Therefore, the mechanism of Rac1 activation by BoNT/A remains unclear. I speculate that 
some of the same processes involved in BoNT/A trafficking could also be involved in Rac1 
activation, and this is discussed in the general discussion (section 7.3.3). 
BoNT/A(0) and HCC/A promote ERK phosphorylation 
Phosphorylation of ERK was also enhanced by BoNT/A(0) and its binding domain (Figure 
6-6). It has been reported that ERK phosphorylation is positively regulated by BoNT/A as a 
result of an overexpression of TLR2 in macrophages (Kim et al., 2015). TLR2 promotes 
phosphorylation of ERK in neurons (Paulino et al., 2011) but TLR2 and Rac1 are uncoupled 
in Rac1-mediated spinal cord regeneration (Dong et al., 2013).  
The relationship between Rac1 and ERK is contingent, being one an upstream regulator of the 
other and vice versa, as well as being independent. Rac1 can modulate ERK activity and 
inhibition of Rac1 leads to inactivation of the ERK pathway, which impairs axonal regeneration 
(Xiao et al., 2013; Liu et al., 2018). ERK can phosphorylate Rac1 (Tong et al., 2013). In PC-
12 cells, these pathways can also be independent from each other in the regulation of neurite 
outgrowth (Goto et al., 2013). Interestingly, apoptosis observed after deletion of Rac1 in 
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fibroblasts can be rescued by overexpression of ERK whereas cytoskeleton function cannot 
(Guo et al., 2006). Therefore, I cannot conclude that ERK activation is due to Rac1 activation 
or independent from it. 
In conclusion, I have proved that BoNT/A(0) activates not only Rac1, but also ERK in neurons. 
As ERK constitutes a signalling node for neurite outgrowth (Perron et al., 1999; Caceres et al., 
2010), it could constitute a downstream effector of Rac1 but this remains as a question to be 
addressed by future research.  
BoNT/A effects on neurite outgrowth 
BoNT/A(0) and HCC/A failed to induce neurite outgrowth 
In my hands, neither BoNT/A(0) or HCC/A elicited a significant net increase in total neurite 
outgrowth (Figure 6-8, Figure 6-9, Figure 6-10). My data differ from the work of Coffield 
and Yan (2009) in several ways. The maximum concentration tested in that study was 10 nM, 
while my working concentration was 25 nM. Although 10 nM was at the declining phase of 
the effect curve, I considered that a concentration in the same order of magnitude would cause 
a reduced but similar effect. However, neither BoNT/A(0) or HCC/A induced an increase in 
total neurite outgrowth. My experiments had a similar but not a simila rmodel, as Coffield and 
Yan (2009) used DRG neurons and I used mainly hippocampal neurons. 
BoNT/A affects preferentially axonal outgrowth 
I did find, however, that BoNT/A(0) selectively induced axonal outgrowth (Figure 6-11). Axon 
differentiation from neurites occurs from DIV1 and is a gradual process (Davare et al., 2009; 
Yamamoto et al., 2012). The marker I used, AnkG, is expressed both neurites destined to be 
axons and in differentiated axons (Fréal et al., 2016 Kuijpers et al., 2016). This offers an 
explanation on why my molecules failed at inducing total neurite outgrowth. Axons only 
accounts for a small fraction of the total neurites found in young neurons cultured in vitro (Fréal 
et al., 2016 Kuijpers et al., 2016), while their diameter is smaller than the diameter of dendrites 
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(Banker et al., 1979). In vivo, the length of single axons can equal the length of the dendritic 
arbour of a single neuron, although axonal diameter remains smaller (Stepanyants et al., 2002). 
Since IncuCyte is not able to discriminate axons and dendrites, it is possible that this system is 
biased towards the detection of dendrites because of their thickness, as they are harder to detect.  
Another possibility is that BoNT/A(0), through HCC/A, accelerated the differentiation process 
from neurites into axons rather than increase axonal length. However, I did not detect this 
(Figure 6-11) and there are not reports in the literature to suggest this occurs. Rather, the 
consensus is that BoNT/A induces neurite outgrowth (see section 6.2.1.4). 
Fgfr3 inhibition does not impair neurite outgrowth 
Our data also suggested that Fgfr3 inhibition did not cause a significant decrease in neurite 
outgrowth (Figure 6-10). In the previous chapter, I showed how SU5402 acted on Fgfr3 to 
prevent BoNT/A(0) endocytosis (section 5.4.2.2). Knockout mice for Fgfr3 presented reduced 
axonal diameter, but not length (Jungnickel et al., 2004) and Fgfr3 is directly involved in 
dendritic outgrowth in vivo (Huang et al., 2017) and non-axonal neurite outgrowth in vitro
(Raffioni et al., 1998). Therefore, this rescuing effect could be caused by a decrease in dendrite 
length and a simultaneous increase of axonal length. However, mork work has to be done to 
solve this question. 
BoNT/A(0) and HCC/A induction of axonal outgrowth is mediated by Rac1 
Rac1 and other Rho GTPases are regulators of actin function (Ridley et al., 1992a; Ridley et 
al., 1992b; Nobes et al., 1995). I found that Rac1 inhibition of axonal or total neurite outgrowth 
was not rescued by BoNT/A(0) or HCC/A (Figure 6-8, Figure 6-9, Figure 6-11).  
Rac1 inhibition did not have any effect on axonal growth after 24 h but blocked any toxin-
induced increase (Figure 6-11). It has been proposed that Preoptic regulatory factor-2 (Porf-2) 
inhibits Rac1 to stop axonal formation, but not growth (Huang et al., 2018). Rac1 also regulates 
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neuronal polarisation (Tahirovic et al., 2010). Once a neurite has differentiated as an axon, 
Rac1 is generally regarded as a positive regulator of axonal outgrowth (Tanabe et al., 2003; 
Miyamoto et al., 2006, Hua et al., 2015; Liu et al., 2018). However, overexpression of both 
constitutively active or dominant-negative forms of Drac1, the homolog of Rac1 in Drosophila 
melanogaster, impairs exclusively axonal outgrowth without affecting dendritic outgrowth 
(Luo et al., 1994). In cortical neurons, knock-out of Rho GAP 15 (ArhGAP15) (a Rac-speficic 
GAP) generated similar results (Zamboni et al., 2018). In addition, while dominant-negative 
mutations on the RAC1 gene lead to diseases with microcephaly, some mutations can lead to 
macrocephaly (Reijnders et al., 2017). Similarly, Rac1 inactivation by C3 toxin can lead to 
neurite outgrowth but it does not affect axonal regeneration in vivo (Rohrbeck et al., 2015). 
Rac1 is, therefore, not a binary switch but a signalling modulator of neurite outgrowth regulated 
spatiotemporally by many factors (Um et al., 2014; Das et al., 2015; Bai et al., 2018).  
Interestingly, however, overexpression of a human Rac1 in mouse Purkinje cells induces 
axonal outgrowth, but not dendritic outgrowth (Luo et al., 1996). These observations support 
my findings, since BoNT/A(0)- or HCC/A-induced outgrowth was restricted to axons and did 
not extend to dendrites (discussed in section 6.5.2.2).  
I also observed that Rac1 inhibition did not result in a decrease in axonal outgrowth. This is 
supported by Rac1 knock-down experiments, where axonal outgrowth was not impaired 
(Gualdoni et al., 2007). Therefore, Rac1 effect on axonal outgrowth could be restricted to a 
window of activity. 
Moreover, viability of neurons was compromised after 48 h of treatment with the Rac1 inhibitor 
NSC23766. Consistent with this, Rac1 inactivation either by knock-out or NSC23766 
treatment is known to cause apoptosis while its activation promotes cell survival (Guo et al., 
2006; Lorenzetto et al., 2013; Stankiewicz et al., 2014; Hua et al., 2015). These processes are 
particularly important in neurodevelopment (Corbetta et al., 2009; Leone et al., 2010, Haditsch 
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et al., 2013). Furthermore, I found that NSC proliferation was abolished by NSC23766 (Figure 
6-20, Figure 6-21). 
Interestingly, BoNT/C and E, which cleave SNAP-25, induce cell death through the products 
derived from SNAP-25 cleavage in vitro, while BoNT/A does not (Peng et al., 2013; Arsenault 
et al., 2014a). Although these effects are derived from LCs and not HCs, it is consistent that 
both LC/A and HCC/A evolved to avoid inducing cell cytotoxicity. Therefore, SNAP-25 
cleavage caused by LC/A would not interfere with the neurotrophic action of HCC/A. 
Rac1-mediated effects are not restricted to axonal outgrowth 
BoNT/A(0) and HCC/A affect filopodia density via Rac1 
In addition to an increase in axonal outgrowth, BoNT/A(0) and HCC/A induced an increase in 
the density of filopodia (Figure 6-12), uncoupled from an increase in dendrite length (Figure 
6-8, Figure 6-9, Figure 6-10). These data are consistent with a previous report where an 
increase dendritic protrusion density was observed together with Rac1-mediated axonal 
outgrowth (Luo et al., 1996).  
NSC23766 treatment fully abolished filopodia formation in my cultures, and this was not 
rescued by BoNT/A(0) or HCC/A. Formation of filopodia in neurites is a process regulated by 
Rac1, whose loss of function leads to a decrease in filopodia formation (Spillane et al., 2012; 
Galic et al., 2014; Álvarez Juliá et al., 2016) in an already highly dynamic scenario where 
filopodia are formed and removed in short periods of time (Varnum-Finney et al., 1994). The 
elimination of dendritic protrusions and the maturation of filopodia into functional spines is 
also governed by Rac1 (Tashiro et al., 2004; Fiuza et al., 2013). Again, this appears to be a 
process with differential regulation across cell types. For example, in glial cells, inhibition of 
RhoA, another small GTPase, eliminated filopodia, while Rac1 inhibition only reduced their 
motility (Sild et al., 2016). 
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As mentioned, an alternative explanation could be related to neuronal survival since Rac1 
inhibition induces apoptosis (Lorenzetto et al., 2013; Hua et al., 2015; Stankiewicz et al., 2015). 
Since neurite protrusion pruning and apoptosis share signalling pathways (Meng et al., 2015a), 
the observed effect could be related to apoptosis rather than a being direct effect on filopodia 
formation.  
HCC/A potentiates synaptic vesicle 
I next tested whether BoNT/A(0) affected synaptic vesicle release. Intriguingly, contrary to the 
silencing effect of BoNT/A, HCC/A caused an increase in synaptic vesicle release (Figure 6-15, 
Figure 6-16). For technical reasons it was not possible to include NSC23766 in these 
experiments because of loss of cell viability and synaptic dysfunction. 
I interpret this seemingly counterintuitive effect of increased synaptic release by HCC/A to be 
the consequence of the synaptic activity-dependent mechanisms of entry of BoNT/A. This was 
explained in the introduction (section 1.6.1.4) and corroborated by my results (Figure 5-5) 
indicate that HCC/A enhances neurotransmitter release by affecting the RP (Figure 6-16), 
although by an unknown mechanism.  
A topic to be addressed were the implications for these functional changes. I consider that they 
most likely relate to enhancing the efficiency of BoNT delivery.  
Nonetheless, BoNT/A(0) did not significantly promoted synaptic vesicle release. BoNT/A(0), 
unlike HCC/A, can deliver LC/A(0) to the presynaptic terminal (Vazquez-Cintron et al., 2014). 
Despite being catalytically inactive, LC/A(0) binds to SNAP-25, and co-localises with it at the 
synapse, probably caused by the same interaction (Pellett et al., 2011; Vazquez-Cintron et al., 
2014). In addition, LC/A action occurs SNAP-25 in a space close to the neuronal membrane 
(Fernández-Salas et al., 2004a; Chen and Barbieri, 2011; Vazquez-Cintron et al., 2014; Cai et 
al., 2017). LC/A binds and cleaves SNAP-25 before forming the SNARE complex competing 
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with Synatxin-1a (Hayashi et al., 1994). SNAP-25 is thought to form the SNARE complex at 
primed vesicles (Sørensen et al, 2003; Nofal et al., 2006; Südhof, 2013 Zhou et al., 2017), 
which are released during the first stimulation (Burrone et al., 2006). 
BoNT/A has been shown to preferentially target the RRP (Yang et al., 2002; Sørensen et al, 
2003; Stigliani et al., 2003; Kitamura et al., 2009). However, LC/A binds SNAP-25 and 
produces SNAP-25197 (Binz et al., 1994), while LC/A(0) only binds SNAP-25 and its effects 
must be restricted to SNAP-25 sequestration (Pellett et al., 2011). LC/E, which cleaves SNAP-
25 forming a SNAP-25180 (Binz et al., 1994), which is unable to support a SNARE complex 
(Meunier et al., 2003; Bajohrs et al., 2004; Rickman et al., 2004), block both the RRP and the 
RP release (Xu et al., 1999). 
Therefore, primed vesicles at the RRP would be released normally, whereas non-primed 
vesicles at the RP would release less efficiently because of SNAP-25 sequestration by LC/A(0). 
This model is shown in Figure 6-22. 
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On the other hand, SNAP-25 is a negative modulator of voltage-gated Ca2+ channels via SNAP-
25 phosphorylation at Ser187 and recruitment of syntaxin (Pozzi et al., 2008; Toft-Bertelsen et 
al., 2016). This modulation is mediated by residues 180-197 of SNAP-25 (Verderio et al., 
2004). SNAP-25 sequestration by LC/A(0) this inhibitory action on these channels. 
Alternatively, SNAP-25 association with LC/A(0) could occlude the phosphorylation site to 
kinases or phosphatases, since the phosphorylatable residue (Ser187) faces to LC/A when 
associated with it (Breidenbach and Brunger, 2004; Pozzi et al., 2008). Nonetheless, these two 
hypothesis are not supported alone by the obtained data as the impact of the inhibition of 
SNARE complex formation by SNAP-25 sequestration seems to be greater.  
Figure 6-22. LC/A(0) effect on synaptic vesicle release
On the left, LC/A(0) cannot bind SNAP-25 from an already formed SNARE complex of a 
primed vesicle and only binds free SNAP-25. On the right, LC/A(0) binds free SNAP-25, 
therefore impeding the formation of new SNARE complexes necessary for vesicle priming. 
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The rate of endocytosis was not significantly increased for BoNT/A(0) and HCC/A, suggesting 
that effects in the endocytosis rate of the reserve pool are not affected by LC/A(0). Although 
variable depending the method used to induce depolarisation, SNAP-25 plays a role in 
endocytosis. This is likely supported by SNAP-25 molecules which formed part of the SNARE 
complex during exocytosis (Bronk et al., 2007; Xu et al., 2013). Therefore, the rate of 
endocytosis of exocytosed vesicles would not be altered by LC/A(0) sequestration of SNAP-
25. Consistent with this idea, BoNT/A does not block endocytosis at the presynaptic terminal 
(Neale et al., 1999). 
Although I was unable to test this directly, Rac1 could be the mediator used by HCC/A to 
potentiate the synapse. Rac1 elimination impairs synaptic plasticity and impairs spatial learning 
(Haditsch et al., 2013) and it also facilitates Ca2+-dependent exocytosis (Li et al., 2003). 
However, this action is regulated and has been proposed that excessive Rac1 activity negatively 
affects synaptic functions (Oh et al., 2010), similarly as it occurs with axonal outgrowth (Luo 
et al., 1994). Similarly, C3 toxin, which inactivates Rac1, enhances glutamate uptake and 
release by astrocytes (Höltje et al., 2008). Finally, activation of Rac1 (but not over-activation) 
promotes the clustering of ACh receptors at the NMJ (Bai et al., 2018).  
In summary, HCC/A promotes synaptic vesicle release. The mechanism underlying it could be 
Rac1, which would be consistent with the literature (Li et al., 2003; Haditsch et al., 2013), but 
this could not be tested in my system because of problems regarding cell viability. 
Impact of HCC/A neurotrophic actions on BoNT/A(0) endocytosis 
Our experiments show that BoNT/A has neurotrophin-like actions. What then is the 
evolutionary significance of this action? Based on the increase in synaptic vesicle release, I 
hypothesised that this action would have an evolutionary advantage for either BoNT/A as a 
potentiation of its entry or a compensation by intoxicated neurons as a response to the loss of 
function caused by SNAP-25 cleavage. 
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The variability of the results did not allow me to define the consequences of the effect, although 
an increase in BoNT/A(0) uptake in cell pre-treated with HCC/A which was abolished by 
NSC23766 suggested that BoNT/A(0) could manipulate the system for its own purposes. Two 
possibilities were considered. 
1. It could be a mechanism by which BoNT/A potentiates its entry. BoNT/A, using 
HCC/A, would induce neurotrophic effects to strengthen one of its mechanisms of entry, 
the synapse (Figure 5-5).  
2. The enhancement of neuronal function would correspond to a defence mechanism, 
by which neurons recognise HCC/A and try to compensate SNAP-25 cleavage and 
synapse blockade by increasing their activity.  
In nature, SNAP-25 cleavage by LC/A follows HCC/A interaction with neurons (Montecucco 
and Schiavo, 1994) and in my model, missing SNAP-25 cleavage is a limiting factor. An 
increase of internalised BoNT/A would be a sign of BoNT/A manipulating neurons to promote 
its own uptake. Since BoNT/A has multiple mechanisms of entry into neurons (see Chapter 5), 
it is possible that potentiation of one of these routes could be limited by my experimental 
settings. Shared discussion from these findings and the results shown in the previous chapter 
regarding the mechanism of entry of BoNT/A(0) will be treated in the general discussion 
(sections 7.3.2 and 7.3.3). 
BoNT/A treatments could be self-enhancing. Supporting this hypothesis, the duration of the 
effect has been found to be longer for the last treatment than for the first one (Lecouflet et al., 
2014; Abeywickrama et al., 2014; Şen et al., 2015). Efficacy was total for both treatments. 
Duration of action could be related to increased BoNT/A uptake and increased delivery of 
LC/A, which is resistant to degradation and the interval for its clearance would be longer. If 
these results hold true and were connected, this could represent a method to optimise BoNT/A 
treatments, as HCC/A could potentiate the efficiency of the drug. 
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BoNT/A(0) and HCC/A promote NSC differentiation 
In addition to structural and functional changes in neurons, I addressed the question of the 
potential influence of BoNT/A(0) on neurogenesis. My experiments indicate that BoNT/A(0) 
and HCC/A promote NSC differentiation (Figure 6-20, Figure 6-21). This effect could be due 
to binding or internalisation of the molecule, as BoNT/A(0) is internalised by NSCs (Figure 
6-19). Moreover, this process was controlled by Rac1 (Figure 6-20, Figure 6-21). 
Rac1 activity regulates hippocampal plasticity and memory (Haditsch et al., 2009; Martinez et 
al., 2011) and is required for neurogenesis evoked by learning (Haditsch et al., 2013). Rac1 
activation is also necessary for neurogenesis through NGF (Suzukawa et al., 2000). 
On the other hand, some authors have suggested that Rac1 inhibition induces differentiation 
(Meng et al., 2015). The observed effect corresponded, however, to an arrest of cell 
proliferation and not necessarily neurogenesis. This is consistent with my results, where Rac1 
inhibition arrested proliferation by induced differentiation of surviving cells (Figure 6-20). 
Rac1 inhibition is known to cause apoptosis in neurons (Lorenzetto et al., 2013; Hua et al., 
2015; Stankiewicz et al., 2015) and regulates the cell cycle by promoting proliferation of 
quiescent fibroblasts (Olson et al., 2015). In addition, the density of culture is an important 
factor in NSC proliferation; low density leads to spontaneous differentiation (Pastrana et al., 
2011; Cha et al., 2017,). Therefore, I suggest that the observed differentiation corresponds to 
an apoptotic effect followed by spontaneous differentiation caused by the low density of culture 
and should be seen as a technical artifact. 
Conclusion 
In this chapter, the neurotrophic behaviour of BoNT/A(0) was explored. I demonstrated that 
BoNT/A(0) induced the activation of the small GTPase Rac1 via HCC/A as well as the 
activation of ERK by phosphorylation. Neurotrophic actions caused by BoNT/A(0) via HCC/A 
were multiple. The mechanism is, however, unknown to us. 
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In my model, HCC/A-induced neurite outgrowth was mediated by activation of the small 
GTPase Rac1. This effect was restricted to axonal outgrowth and did not extend to dendrite 
outgrowth. Structural changes were also present in other compartments, as I observed an 
increase in filopodia density, which also appeared to be mediated by Rac1.  
Functional changes were by HCC/A, as I observed an increase in synaptic vesicle release, which 
was surprisingly not significant for BoNT/A(0).  
Neurodevelopment also appeared to be affected by BoNT/A(0) and HCC/A as both promoted 
NSC differentiation into neurons while maintained cell viability. This process was mediated 
by Rac1, whose inhibition caused cell death. 
Finally, I tested whether the observed neurotrophic effects could be a strategy used by BoNT/A 
to promote its internalisation in neurons. However, I was unable to give a reliable answer to 
this question. Nonetheless, it proposes HCC/A as a candidate tool for future therapeutic 
development. While BoNT/A is used in disorders where a reduction of firing is needed, 
selectively targeted HCC/A could potentially be used in disorders requiring increased neuronal 
function such as Parkinson’s Disease (PD) or Amyotrophic Lateral Sclerosis (ALS) (Casas et 
al., 2016; Eira et al., 2016; Paul et al., 2018). HCC/T has been recently shown to protect against 
parkinsonism in rodents when administrated peripherally (Moreno-Galarza et al., 2018). 
HCC/A could be used similarly thanks to the Rac1-mediated neurotrophic effects here 
demonstrated. Following the comparison between BoNTs and the painting The Garden of 
Death (Figure 1-10), this is a step forward towards knowing the face of the third skeleton. 
However, the mechanism of activation of Rac1 by HCC/A are discussed in the next chapter. 
These ideas are graphically summarised in Figure 6-23.  
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Figure 6-23. Diagram showing the neurotrophic effects of BoNT/A(0) via Rac1. 
BoNT/A binding or internalisation, mediated by HC
C
/A, promotes Rac1 binding to GTP by 
an unknown mechanism. This leads to Rac1-mediated potentiation of axonal outgrowth, 
filopodia formation and neuronal differentiation, as well as other possible effects. In addition, 
BoNT/A could potentiate synaptic release by Rac1-dependent or independent mechanisms.
Together, these actions result in a potentiation of neuronal function. 
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Chapter 7 General Discussion 
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Tool development for BoNT/A and BoNT/E comparisons 
As outlined in the Introduction, BoNT/A and BoNT/E have many similarities, including the 
receptor(s) mediating their internalisation and the target of their enzymatic activity. 
Due to the extremely high lethality of BoNTs, most studies do not use the native proteins. For 
trafficking studies, their HCC binding domains are used, which are mostly thought to bind and 
traffic into neurons in the same way as their respective full-length toxins. Endocytosis and 
release studies predominantly use the LC as detection of the cleaved products indicates 
cytoplasmic presence of the catalytic domain.  
I studied LC/A location by eGFP-tagging and determined that the factors that have been 
suggested to target LC/A to the membrane are not sufficient to target LC/E to the membrane 
(Figure 3-3). Unfortunately, the low efficiency of transfection and the toxicity of the LC 
constructs prevented an investigation on the causes of these differences. In addition, because 
of safety concerns I was unable to make LC viruses so I was unable to pursue these aspects of 
my studies. 
I also tagged full-length, inactive toxins with GFP. I purified BoNT/A(0)-GFP-10HT (Figure 
4-12) and BoNT/E(0)-GFP-10HT (Figure 4-19) to a high level. However, when I tested the 
usability of the proteins  they were inadequate for my purposes, as internalisation of 
BoNT/A(0)-GFP-10HT in resting conditions or under depolarisation was not detectable 
(Figure 4-20). Subsequently, this project was also ended.
BoNT/A(0) trafficking 
After discarding GFP-tagged molecules, I worked with non-tagged BoNT/A(0). First, the 
specificity of the antibody was validated by demonstrating that the non-tagged BoNT/A(0) 
entered neurons (Figure 5-1) as previously reported for HCC/A (Harper et al., 2011; Restani et 
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al., 2012a; Wang et al., 2015). In addition, I studied specific aspects of BoNT/A(0) endocytosis. 
I showed that  
1. Synaptic activity has a limited impact in BoNT/A(0) uptake (Figure 5-5).  
2. Fgfr3 is a functional BoNT/A(0) receptor in neurons (Figure 5-6).  
3. BoNT/A(0) uses dynamin-dependent endocytosis under resting conditions (Figure 5-9).  
4. BoNT/A(0) relies heavily on cholesterol to enter mature neurons (Figure 5-9).  
After endocytosis, BoNT/A(0) trafficked through early endosomes, with most of the toxin 
colocalising with this organelle and exiting it after a short period of time (Figure 5-10). After 
transit through early endosomes, BoNT/A(0) did not follow canonically the endocytic pathway 
towards lysosomal degradation. Rather, most of the toxin was degraded by the proteasome and 
remained very stable over time, lasting for days after initial internalisation (Figure 5-12). In 
addition, a fraction of BoNT/A(0) was able to escape this degradation and enter surrounding 
cells by being released into the extracellular medium as a full-length toxin (Figure 5-13).
BoNT/A(0) acts as a neurotrophin via HCC/A-mediated activation of Rac1 
Selective increase of axonal outgrowth 
In Chapter 6, I investigated the neuritogenic actions of BoNT/A(0). Initially, I examined total
neurite (i.e. axons and dendrites) outgrowth but there were no detectable changes following 
application of the full-length toxin or its binding domain (Figure 6-8). To reconstruct the 
signalling pathway used by BoNT/A, I specifically tested the possible involvement of 
BoNT/A(0) - Fgfr3 interactions (Jacky et al., 2013). Fgfr3 inhibition only caused a small 
impairment of total neurite outgrowth, which was rescued by BoNT/A(0) and HCC/A (Figure 
6-10). I therefore concluded that the effect of BoNT/A effect on total neurite outgrowth was 
limited but that the toxin could rescue outgrowth impairment caused by Fgfr3 inhibition.  
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I investigated a possible involvement of the signalling molecule Rac1, which is known to 
promote neurite outgrowth (Tanabe et al., 2003; Miyamoto et al., 2006, Hua et al., 2015; Liu 
et al., 2018).  Surprisingly, given that it has not reported to have a direct connection with any 
BoNT, it was strongly implicated in neurite outgrowth. Consistent with the literature, in my 
experiments Rac1 inhibition resulted in a pronounced inhibition of total neurite outgrowth 
(Figure 6-8, Figure 6-9). Neither BoNT/A(0) nor HCC/A rescued the effects of Rac1 inhibition 
on total neurite outgrowth in of the different culture conditions and different neuronal types 
tested. 
Intriguingly, however, when I looked at axonal morphology and dynamics I observed robust 
effects of BoNT/A(0) and HCC/A, which were blocked by Rac1 inhibition (Figure 6-11). The 
causes of this specificity were discussed in section 6.5.2.2. 
Pathogenic sabotage of the Rho family proteins 
HCC/A was also effective at potentiating synaptic vesicle release. BoNT/A(0) presented a 
similar effect, but reduced in size and affecting only the RP (Figure 6-14, Figure 6-15, Figure 
6-16). I argued that this effect could be through an sequestration of SNAP-25 by LC/A(0) (for 
a schematic, see Figure 6-22). HCC/A and BoNT/A(0)-treated terminals also showed a non-
significant increase in the rate of endocytosis (Figure 6-17). 
Consequently, I examined the possibility of BoNT/A using its binding domain to activate Rac1 
(Figure 6-11) to potentiate its own mechanism of entry at the synapse. However, the results of 
this experiment were very variable and no conclusions could be made, although they pointed 
towards confirmation of my hypothesis (Figure 6-18). Nonetheless, the observed effect could 
be due to a mechanism other than potentiation of synaptic release and endocytosis at the 
presynaptic terminal: caveolae.  
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Rac1 activation occurs mainly when it is targeted to cholesterol-rich membrane domains 
(Michaely et al., 1999; Moissoglu et al., 2014) and it is particularly involved in endocytosis by 
caveolae, a mechanism which includes ERK-induced cytoskeleton rearrangements (Kawamura 
et al., 2003; Prieto-Sánchez et al., 2006). Remarkably, BoNT/A can induce expression of 
caveolins after injection (Botzenhart et al., 2017) and I have demonstrated that BoNT/A(0) 
entry depends on cholesterol in neurons (Figure 5-9). However, Rac1 is involved in other 
clathrin-independent, caveolae-independent endocytosis mechanisms, as evidenced by 
interleukim-2 receptor endocytosis (Grassart and 2008). 
Rac1 and other Rho proteins are located at the top of different signalling cascades causing 
cytoskeleton rearrangements (Ridley et al., 1992a; Ridley et al., 1992b; Nobes et al., 1995). 
Consequently, many toxins secreted by bacteria sabotage them for their own purposes (Stein 
et al., 2012; Quintero et al., 2015; Spanò et al., 2018). However, HCC/A does not enter cells by 
using Rac1 or Cdc42-dependent endocytosis in cell line models (Couesnon et al., 2009). 
Toxins acting on Rho signalling cascades 
As outlined, many bacteria act on Rac1 for their own purposes, and among these is endocytosis. 
Uropathogenic E. coli, Salmonella, V. parahaemolyticus, a close relative of V. cholera, are 
examples of bacteria that manipulate Rac1 to enter cells (Visvikis et al., 2011; and reviewed at 
de Souza Santos and Orth, 2015). B. anthracis spores use Cdc42 for the same purpose (Xue et 
al., 2010). 
Uropathogenic E. coli produces Cytotoxic Necrotizing Factor 1 (CNF1) that inactivates Rho 
by deamidation on a glutamine residue of the GTPase (Flatau et al., 1997; Schmidt et al., 1997), 
but it activates Rac1 and leads to endocytosis (Visvikis et al., 2011). 
Salmonella bacteria are an intracellular pathogen which promote its internalisation through 
caveolae by activating Rac1 (Lim et al., 2014). They achieve this by injection of Salmonella 
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Outer Protein E (SopE), which acts as a GEF on Rac1 and activates it, and Secreted effector 
Protein P (SptP), which acts as a GAP (Fu et al., 1999; Friebel et al., 2001; Stebbins et al., 
2005). Negative modulation of Rac1 by SptP helps Salmonella to evade the immune system 
(Fu et al., 1999). This gives it control of the cytoskeleton (Figure 7-1). It also produces SopE2 
to act as a GEF on Cdc42 (Friebel et al., 2001). Moreover, Salmonella modulates action Rac1 
to arrest endosomal maturation and avoid lysosomal degradation. Then, bacteria replicates in 
the interior of the arrested endosome (Kohler and Roy, 2017). 
Mycobacterium tuberculosis has also been suggested to manipulate Rac1 to promote its own 
endocytosis and arrest endosome maturation (Sun et al., 2013; Rajaram et al., 2017). In Chapter 
5 (section 5.5.4.2), it was discussed how a proportion of endocytosed BoNT/A(0) did not 
Figure 7-1. Rac1 manipulation by Salmonella. 
Salmonella injects two different toxins acting as a GEF (SopE) and as a GAP (SptP). These 
modulate Rac1 activity to promote its own endocytosis through caveolae and block endosome 
maturation, avoiding lysosomal degradation.  
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progress to the lysosome and escaped degradation at this compartment. Therefore, pathways 
between BoNT/A, Salmonella and M. tuberculosis could be linked. 
Moreover, bacteria of the genus Clostridium (C. botulinum and C. difficile) also modulate Rho 
proteins to cause enteric disease. C3 toxin acts on Rac1 and inactivates it by ADP-ribosylation 
(Didsbury et al., 1989). On the other hand, C. difficile produces TcdB, which delivers TcdA to 
the cytosol to activate Rho by ADP-ribosylation (Di Bella et al., 2016). These are direct 
enzymatic actions on Rho proteins. However, other bacteria use different mechanisms to 
manipulate Rho proteins. For example, Pasteurella multocida toxin (PMT) does not interact 
with Rho GTPases to alter their activity, and instead it activates by deamidation G proteins 
signalling proteins coupled to certain receptors, called G protein-coupled receptors), which 
activate GEFs (Orth et al., 2009). These are summarised in Figure 7-2. 
Figure 7-2. Strategies of manipulation of Rho family members by toxins produced by 
extracellular bacteria. 
C. botulinum–produced C3 toxin ADP-ribosylates and inactivates Rac1. Toxin A produced by 
Clostridium difficile (TcdA), activates Rho by ADP-ribosylation. Pasteurella multocida toxin 
(PMT) deamidates and activates G proteins, which are positive upstream regulators of GEFs.
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Other proteins acting on members of the Rho family 
Manipulating Rho proteins to promote endocytosis is a strategy exploited not exclusively by 
cells and, for example, Superoxide Dismutase 1 (SOD1) aggregates can activate Rac1 to 
promote their own endocytosis and spread (Zeineddine et al., 2015). In intestinal cells, BoNT/A 
and /B are also internalised through a Cdc42-dependent pathway (Couenson et al., 2009; 
Connan et al., 2017). HCC/T has a neuroprotective effect against oxidative stress through Akt 
phosphorylation (Cubí et al., 2013), Akt activation by Rac1 in regulatory T (Treg) cells (a 
subtype of lymphocyte) has been shown to be protest against damage induced by the neurotoxic 
compound 1-methyl-4-phenylpyridinium (MPP+) (Huang et al., 2017) and TeNT itself has been 
shown to improve axon regeneration (Gunay et al., 2014). HCC/T can prevent toxicity by this 
compound (Moreno-Galarza et al., 2018). 
Rac1 exploitation by the BoNT/A could potentially have analogous effects in neurons and 
affect endocytosis. Nevertheless, HCC/A does not undergo Rac1-mediated endocytosis in cell 
line models (Couesnon et al., 2009) and effects could be restricted to the neurotrophic action 
of the toxin. Moreover, The toxins mentioned in section 7.3.2.1 act intracellularly and interact 
with their target and. The domain of BoNT/A responsible for Rac1 activation, HCC/A, is 
supposedly retained in a vesicle lumen during its lifetime and therefore, my results do not show 
a shared mechanism between these bacteria and BoNT/A. However, they show that BoNT/A 
can use Rac1 for its own purpose. Thus, I consider that direct interaction of the toxin with Rac1 
is unlikely and an intermediate step needs to be added.  Based on data from this thesis and 
unconnected evidence from the literature, BoNT/A could use neurotrophin receptors to activate 
Rac1.  
Rac1 mechanism of activation by BoNT/A 
Although I have demonstrated that BoNT/A(0) can activate Rac1 using HCC/A (Figure 6-5), 
the mechanism underlying this action is completely unknown. My results suggest that Rac1 
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activation by BoNT/A is independent from Fgfr3 binding and activation, as Fgfr3 inhibition 
effects were negligible compared to those observed when Rac1 was inhibited (Figure 6-8, 
Figure 6-10). There is no evidence regarding SV2-mediated activation of Rac1. 
BoNT/A traffics to endosomes (Figure 5-10; Harper et al., 2011) and its signalling mechanism 
could be generated at these organelles. Rac1 activation could, therefore, be triggered from a 
signalling endosome, an organelle which has been specifically confirmed to be able to activate 
Rac1 and ERK pathways (Delcroix et al., 2003; Harrington et al., 2011). 
For the coupling of signalling endosomes and BoNT/A, I propose two non-exclusive and 
intimately related pathways focusing on TrkB receptors and p75NTR. 
TrkB receptors 
Axonal retrograde transport of signalling endosomes is modulated by TrkB (Wang et al., 2016). 
Signalling endosomes have been also described for TrkA (Howe et al., 2001), and potentially 
exist for TrkC (Meabon et al., 2016).  
TrkA, TrkB and TrkC activate by phosphorylation, T-lymphoma Invasion And Metastasis-
inducing protein 1 (Tiam1), a GEF for Rac1, promoting neurite outgrowth, in a process related 
to ERK activation (Miyamoto et al., 2006; Esteban et al., 2006; Shirazi Fard et al., 2010, Yan 
et al., 2016). Rac1 is also necessary for the generation of these signalling endosomes (Valdez 
et al., 2007). 
Moreover, TeNT enters neurons colocalising with TrkB in signalling endosomes (Deinhardt et 
al., 2006; Terenzio et al., 2014; Bercsenyi et al., 2014). BoNT/A could use a similar 
mechanism, represented in Figure 7-3, as they do indeed co-traffic. 
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p75NTR
More intriguing could be the relation of BoNT/A with p75NTR. This neurotrophin receptor can 
bind neurotoxic molecules, such as A (Ovsepian et al., 2014; Dechant and Barde, 2002). 
p75NTR has been related to its clearance and interestingly, this process is enhanced by 
potassium-induced depolarisation and not affected by BoNT/A or TTX, being independent of 
synaptic activity (Ovsepian et al., 2014). I have also demonstrated that BoNT/A(0) endocytosis 
can be promoted by potassium-induced depolarisation and can independent from synaptic 
Figure 7-3. BoNT/A activation of Rac1 through TrkB. 
According to this hypothesis, BoNT/A would activate TrkB during endocytosis. This would 
activate GEFs by phosphorylation and consequently activate Rac1, which would produce the 
observed neurotrophic effects. 
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activity (Figure 5-4, Figure 5-5). Therefore, p75NTR and BoNT/A would share at least one 
endocytosis mechanism. 
It has been shown that p75NTR can switch from clathrin-independent to clathrin-mediated 
endocytosis upon ligand binding, and this process would redirect the receptor to a signalling 
endosome (Deinhard et al., 2007). Similarly, BoNT/A is also able to enter through clathrin-
mediated endocytosis and clathrin-independent endocytosis (Harper et al., 2011). 
In addition, p75NTR interacts with caveolins and is actually endocytosed by caveolae (Hibbert 
et al., 2006). My data demonstrated that BoNT/A depends on cholesterol to enter neurons 
(Figure 5-9). Even more interestingly, caveolins are upregulated by both BoNT/A treatment 
and p75NTR overexpression (Tan et al., 2003; Botzenhart et al., 2017). 
After endocytosis, HCC/A undergoes axonal retrograde transport and co-traffics with p75
NTR, 
although this colocalisation is not complete (Restani et al., 2012a). Importantly, p75NTR
retrogradely traffics in signalling endosomes which activate Rac1 (Harrington et al., 2002; 
Bronfman et al., 2003; Tian et al., 2014). Nonetheless, unlike TrkB, p75NTR needs intermediate 
steps to activate Rac1, these including receptor cleavage and adaptor proteins (Zeinieh et al., 
2015; Yan et al., 2016). 
Finally, neurotrophin binding to p75NTR can delay lysosomal degradation of the receptor and 
redirected trafficking towards transcytosis (Deinhard et al., 2007; Butowt et al., 2009). Co-
expression of p75NTR in TrkB-expressing cells delays TrkB degradation (Makkerh et al., 2005). 
I have shown that BoNT/A(0) escaped lysosomal degradation and is transcytosed as a full-
length toxin (Figure 5-12, Figure 5-13) and this could be caused by p75NTR too. Therefore, 
TrkB association is also possible in this model. 
In summary, binding between HCC/A and p75
NTR -or an indirect activation through another 
molecule co-trafficking within the signalling endosome- could be related to many aspects of 
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BoNT/A biology which were investigated separately in this thesis. First, endosome trafficking 
followed by retrograde trafficking and escape from lysosomal degradation; second, Rac1 
activation and the neurotrophic effects derived from it; third, caveolae-dependent endocytosis.  
A graphic model for this hypothesis is shown by Figure 7-4. 
Figure 7-4. BoNT/A activation of Rac1 through p75NTR. 
According to this hypothesis, BoNT/A would activate p75NTR during endocytosis. This would 
trigger receptor cleavage and signalling. This could include changes in gene expression and 
activation of Rac1 by unknown means. Rac1 activity would be responsible for the arrest of 
endosomal maturation, a potentiation of BoNT/A endocytosis and neurotrophic effects. 
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Future work 
Endocytosis, degradation and exocytosis 
Endocytosis 
Our results showed that BoNT/A(0) can enter independently of synaptic activity (Figure 5-5), 
while other mechanisms of entry could correspond to Fgfr3-mediated endocytosis (Jacky et al., 
2013; Figure 5-6), as well as other possible receptors that remain to be identified. As outlined 
in the preceding sections (5.5.4.2), differences between the results I obtained and previous 
reports may largely be due to the precise conditions used. For example, potassium 
depolarisation promotes HCC/A trafficking to the lysosome (Wang et al., 2015). In addition, a 
small fraction of BoNT/A(0) stayed in early endosomes longer than the rest of the toxin, while 
other fraction progressed to a different compartment. This could constitute a different 
mechanism of protection for BoNT/A against degradation. My work (Figure 5-10) and 
previous research (Harper et al., 2011) also showing maintained BoNT/A-early endosome 
colocalisation were done in fixed cells. Therefore, life imaging studies of BoNT/A in neurons 
expressing fluorescently tagged endosomal markers such as Rab5 or EEA1 (Wilson et al., 
2000; Vonderheit and Helenius, 2005; Barysch et al., 2009; Poteryaev et al., 2010) are 
necessary to clarify the question. 
Our results also indicated that BoNT/A(0) relied on cholesterol to enter neurons. However, 
immature neurons have been reported to have an inverse correlation between BoNT/A action 
and cholesterol (Petro et al., 2006; Thyagarajan et al., 2017) and whether the effect I observed 
is an artefact of my system or this is a developmentally regulated process are questions that it 
would be informative to address in the future. Since HCN/A binding to the membrane is 
enhanced by MCD (Ayyar and Atassi, 2016), it is necessary to blot for SNAP-25 cleavage 
and BoNT/A internalisation within a single experiment with neurons at different stages of 
maturation to confirm if both hypothesises are true.  
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Previously (section 7.3.2.1), I discussed how different toxins manipulated different GTPases 
for a range of purposes, including Rac1-regulated endocytosis in caveolae (Lim et al., 2014). 
This could be the case for BoNT/A and would represent a third mechanism together with the 
synapse and Fgfr3. To test the putative involvement of Rac1-controlled caveolae in BoNT/A 
endocytosis, several approaches can be taken, including tools used in this thesis (MCD and 
NSC23766). In addition, knock-down of caveolins has been shown to fully eliminate the 
formation of caveolae and provides a more delicate alternative than MCD (Griffoni et al., 
2000). Simultaneous and independent inhibition of Rac1 activation and caveolae formation 
would answer to this hypothesis. 
Another interesting experiment to be done is a simultaneous inhibition of all the known 
endocytosis mechanisms for BoNT/A, which could result only in a partial inhibition of 
BoNT/A uptake, indicating the presence of unidentified pathways. Once all of them are 
discovered, individual selection of these (i.e. inhibition of all the other mechanisms) followed 
by colocalisation experiments with different organelles would generate a useful model for 
BoNT/A trafficking. 
Finally, due to variability I was unable to conclude if BoNT/A actually promoted its own 
endocytosis through its Rac1-mediated neurotrophic effect. Due to the multiple pathways 
followed by BoNT, a specific experimental design focusing on a possible Rac1-dependent 
pathway is necessary. For example, downregulation of Fgfr3 would exclude the contribution 
of this pathway from the overall BoNT/A uptake signal and make my assay more sensitive to 
detect synapse-mediated BoNT/A internalisation. Different time courses of endocytosis should 
also be considered. 
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Degradation  
Full-length BoNT/A(0) avoids degradation at the lysosome (Figure 5-12). Rac1 is potentially 
involved as other pathogens use this mechanism to circumvent lysosomal degradation. Future 
experiments are needed to text this hypothesis.   
Full-length BoNT/A(0) and LC/A are degraded by the proteasome (Figure 5-12, Tsai et al., 
2010; Tsai et al., 2017). Because of the existence lysines that are potential ubiquitination sites 
in LC/A, targeting BoNT/A to the proteasome by direct ubiquitination is likely. However, it is 
not known if these lysine residues are actively ubiquitinated in BoNT/A or even if full-length 
BoNT/A gets ubiquitinated. My results (see 5.5.4.2 for a discussion), and previous findings 
(Coffield and Yan, 2009), indicate the presence of bands that could correspond to ubiquitinated 
forms of BoNT/A. A range of experiments including immunoprecipitation of BoNT/A and 
probing for ubiquitination or mass spectrometry would address this point. If direct 
ubiquitination was confirmed, the machinery targeting BoNT/A could be studied with the 
ligase acting on LC/A, HECTD2, as a possible candidate. 
From an industrial perspective, since most of full-length BoNT/A degradation occurred before 
the LC was released (Figure 5-11, Figure 5-12), elimination of these sites would result in a 
more efficient LC release and therefore enhance the potency of the toxin. Moreover, it could 
result in a longer action duration, as the LC/A would have an extra defence mechanism against 
degradation.  
This could generate more potent toxins with a lower therapeutically effective dose. 
Mechanism of exocytosis 
BoNT/A is released as a full-length toxin to the extracellular space and is able to enter other 
cells (Figure 5-13). Some of the results presented here enabled me to compare BoNT/A with 
different bacterial toxins, such as CNF1. This toxin is able also to exit cells and propagate 
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(Fabbri et al., 2015). To do this, the toxin is packed within exosomes and, after internalisation 
in second-generation intoxicated cells, promotes Rac1-mediated cytoskeleton rearrangements 
in those. B. anthracis-produced Lethal factor (LF) of Anthrax toxin (LC/A analogue) is 
released into the cytosol to then be included in exosomes, which release LF into surrounding 
medium (Abrami et al., 2013). TeNT binding domain also associates to exosomes and 
constitutes a mechanism of propagation (Lachenal et al., 2011; Chivet et al., 2014). However, 
this mechanism would not explain how there is 100% SNAP-25 cleavage in cultures where not 
all cells were transfected with GFP-LC/A (Arsenault et al., 2014b). In addition, antibodies 
targeting BoNT/A impairs transcytosis (Bomba-Warcza et al., 2016). Therefore, the main 
mechanism of BoNT/A release is not exosomes but release after its journey through the 
endocytic pathway. 
Studying the route followed by BoNT/A to intoxicate neurons after it has been released is 
important to understand the off-site effects of the toxin. This can be done through purification 
of exosomes and detection of BoNT/A and its components and also imaging these in exosomes 
prior to release. TeNT could be used as a control. 
BoNT signalling and its consequences 
BoNT/A signalling 
As explained in the discussion (section 7.3.3.2), I hypothesise a BoNT/A - p75NTR - Rac1 
signalling pathway. Knockdown by shRNA, downregulation with the recently developed 
inhibitor EVT901 (Delbary-Gossart et al., 2016) or the use of a knock-out mouse model of 
p75NTR activity followed by treatment with BoNT/A or HCC/A and examination of Rac1 
activation and its mediated effects would clarify this question. Experiments showing direct 
interaction between BoNT/A and p75NTR, such as co-immunoprecipitation would be highly 
valuable. It should be noted, however, that analysis of these experiments may be confounded 
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by the fact that p75NTR is a low affinity receptor for most of its ligands (Lee et al., 1998; Dechant 
and Barde, 2002). 
Although the presented research focused mainly on Rac1 activation, HCC/A also activates the 
ERK pathway (Figure 6-6). Future work investigating the mechanisms of activation and roles 
of this pathway would provide clearer understanding of the complex pharmacological cascades 
affected by BoNTs. This would include necessarily determine which protein (ERK or Rac1) is 
the upstream regulator by selective inhibition of both molecules. 
Consequences of Rac1 activation and application 
A key finding in this thesis work was that HCC/A is neurotrophic in vitro, eliciting axonal 
outgrowth (Figure 6-11), filopodia formation (Figure 6-12), enhancement of synaptic vesicle 
release (Figure 6-14) and neurogenesis (Figure 6-20, Figure 6-21). These observations are 
intriguing but, as yet, no studies have been conducted in vivo. Examination of the possible 
potentiating effects of HCC/A on learning-evoked neurogenesis in mice or rats could be hugely 
interesting, as Rac1 mediates this type of neurogenesis (Haditsch et al., 2013). If successful, 
these would constitute an interesting approach to treat conditions where neuronal function is 
negatively impaired such as PD. Neurotrophic factors have already been developed for 
therapeutic approaches to treat PD, with some candidates (glial cell line-derived growth factor, 
neurturin, platelet-derived growth factor and cerebral dopaminergic neurotrophic factor) 
entered into clinical trials (reviewed at Paul et al., 2018). Furthermore, in PD and ALS, 
BoNT/A is used to reduce drooling and has been shown to exert neurotrophic actions at the site 
of injection, which can compromise the intended selective paralysis effect derived from SNAP-
25 cleavage (Møller et al., 2011). HCC/A has the potential to be used as a neurotrophic agent 
in these diseases. 
These observations are interesting and relevant because they confirm that the doses used in 
those studies are safe and can potentially induce neurotrophic effects similar to those shown in 
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this thesis for in vitro systems. According to my model, pre-clinical research would show 
HCC/A-mediated axonal regeneration as well as BoNT/A (Franz et al., 2018), but could be 
different if delivered into other areas or if Rac1 action itself is impaired.  
Effects on the vascular system 
BoNT/A has been proposed to upregulate Rac1 transcript expression, as well as other proteins 
involved in Rac1 signalling (Park et al., 2016). This research was conducted in the field of 
wound repair, in which BoNT/A has a prominent potential due to its angiogenic properties 
inducing endothelial cell proliferation and increasing VEGF levels (Tang et al., 2013). In 
hIPSCs, alteration of expression by BoNT/A(0) is identical to that induced by BoNT/A, 
eliminating the possibility of the effect being dependent on SNAP-25 cleavage (Scherf et al., 
2014).  
Rac1 has been shown to promote angiogenesis by inducing proliferation of endothelial cells 
and upregulating VEGF levels (Xue et al., 2004; Sawada et al., 2008; Tan et al., 2008; Ma et 
al., 2013).  
BoNT/A protects against cutaneous ischemia-reperfusion injury (Uchiyama et al., 2012). On 
the other hand, Rac1 has been shown to negatively influence the injury caused by ischemia-
reperfusion after stroke (Li et al., 2017; Liang et al., 2018). Therefore, these protective actions 
could be independent of BoNT/A-mediated activation of Rac1, rather they may be related to 
the beneficial effects of muscle paralysis, as BoNT/B induces similar changes to those of 
BoNT/A (Schweizer et al., 2013, Sekiguchi et al., 2018). Nonetheless, the first experiment to 
be performed must determine whether HCC/A alone has angiogenic properties similar to 
BoNT/A. If it does, use of HCC/A could constitute a novel tool for possible therapeutic 
intervention. As mentioned above, although I have data indicating the involvement of Rac1 in 
mediating BoNT/A effects in neurons there are clearly other cell types in which cytotrophic 
actions exist. These make it a valuable candidate for research in other areas.   
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Conclusion 
BoNT/A is a prodigy of nature. After ingestion, the toxin crosses the intestinal epithelium to 
the blood stream, escapes and acts primarily on cholinergic nerve terminals at the 
neuromuscular junction. To achieve this the toxin binds to the neuronal surface and uses 
multiple mechanisms to get internalised, to ensure intoxication of the target cell when one of 
the pathways is blocked. Within the cell, it escapes lysosomal degradation and jumps from cell 
to cell. During its journey through the endocytic pathway, it refolds to forms a channel which 
is used by LC/A to translocate into the cytosol. Then, LC/A relocates to the plasma membrane 
where it gets protected from degradation and it cleaves SNAP-25 close to its C-terminus, 
generating a non-functional, inhibiting protein.  
The work presented in this thesis adds to this knowledge by describing aspects of BoNT/A 
endocytosis in neurons and a novel and fascinating action of BoNT/A. My data indicate that 
the toxin uses its entry to activate Rac1 and induce neurotrophic effects which could possibly 
lead to a potentiation of its own entry routes, to the improvement of already existing treatments 
and to the creation of new therapeutic applications for the toxin. 
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These sequences correspond to proteins used in this research. Start methionins are coloured in 
green to facilitate identification. Catalytic motifs are in red, and aminoacids mutated to generate 
catalytically inactive proteins are underlined. NA and CA are both in purple. Cysteine residues 








































































































































Translation of an excerpt of the Opera Omnia by Paracelsus  
This is a free translation into English of the translation done by E. Lluesma Uranga on the work 
by Paracelsus, published while exiled in Buenos Aires, 1945. 
How and when should foods be considered as poisons. 
Finished my dissertation on the Astral Entity, I shall occupy ourselves, following a 
logical order, on the Entity of the Poison, second cause of the afflictive disorders of my 
body. 
We shall remember first, one more time, that the organism can be damaged by five 
Entities, to which it is submitted for all suffering.  
In this speech, I will deal with the Entity of the Poison. It is known that all bodies need 
to live, for which they use certain vehicles that nourish and preserve them, resulting 
life impossible where these means are lacking. And equally, it must be remembered that 
the same who has formed my bodies has created foods, although his work has not been 
so perfect in this point. There is one true thing and that is that my body has been given 
exempt from poisons, which are found precisely in the food I eat. This means that the 
body has been created perfect and that imperfections, that is the poisons, are in the 
fruits and in the other animals that sustain us, although they, for themselves, do not 
contain imperfections, as it corresponds to equally perfect works by the Creator.  
This way, only when a thing is taken from outside as food, it acquires the property of 
poison, which is lacking in itself and for itself. 
